WO2007023507A2 - Oxazolidinones bearing antimicrobial activity composition and methods of preparation - Google Patents

Oxazolidinones bearing antimicrobial activity composition and methods of preparation Download PDF

Info

Publication number
WO2007023507A2
WO2007023507A2 PCT/IN2006/000208 IN2006000208W WO2007023507A2 WO 2007023507 A2 WO2007023507 A2 WO 2007023507A2 IN 2006000208 W IN2006000208 W IN 2006000208W WO 2007023507 A2 WO2007023507 A2 WO 2007023507A2
Authority
WO
WIPO (PCT)
Prior art keywords
oxazolidin
ylmethyl
oxo
fluorophenyl
acetamide
Prior art date
Application number
PCT/IN2006/000208
Other languages
French (fr)
Other versions
WO2007023507A3 (en
Inventor
Milind D. Sindkhedkar
Satish B. Bhavsar
Vijaykumar J. Patil
Prasad K. Deshpande
Mahesh V. Patel
Original Assignee
Wockhardt Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Limited filed Critical Wockhardt Limited
Priority to US11/922,239 priority Critical patent/US20090018123A1/en
Priority to EP06821680A priority patent/EP1912980A2/en
Publication of WO2007023507A2 publication Critical patent/WO2007023507A2/en
Publication of WO2007023507A3 publication Critical patent/WO2007023507A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Definitions

  • WO 2004/048350 A2 describes pyridyl and pyrimidyl moiety as one of constituents of biaryl oxazolidinone compounds. However oxazolidinone moiety bearing methyl acetamide, or methyl thioacetamide are not described. This application does not disclose halogen substituted biphenyl oxazolidinone compounds with methyl acetamide moiety.
  • S(O) NC(O)NHCH 35
  • S(O) NC(O)NHCH 2 CH 2 CI, with proviso that when X is CH, Y is CF, one of X' or Y' or both X', Y' are N, then Z is not NH.
  • X and Y may be same or different, represent, CH, CF, N;
  • R 4 is acetamido, [l,2,3]-triazol, methyl carbamate, t-butyl carbamate, OR 1 wherein Ri is hydrogen, P(O)(OM) 2 , wherein M is hydrogen, Na, methyl, ethyl, t-butyl, phenyl; or Ri is an amino acid residue derived from one of the 20 naturally occurring amino acids viz.
  • acetamido stands for NHC(O)CH 3 .
  • forrnamide stands for NH-CHO.
  • Ci-Ce alkylamido means an alkyl group attached to the carbonyl of the amide. Examples of alkyamido groups include acetamido, -NHC(O)-C 2 H 5 , -NHC(O)-C 3 H 7 and so on.
  • C 1 -C 6 haloalkylamido means alkyl group substituted with halogen, for example -NHC(O)-
  • Ci-C 6 aralkylsulfanyl refers to aralkyl group attached to sulfur for example PhCH 2 S-.
  • carbamate refers to NH-CO-O-alkyl, for example NH-CO-O-CH 3 (methyl carbamate), NHCO 2 C 2 H 5 (ethyl carbamate) .
  • pharmaceutically acceptable acid addition salts of the compounds of the invention include salts derived from nontoxic inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, hydrofluoric, phosphorous, and the like, as well as the salts derived from nontoxic organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc.
  • (2S,5R)-2- Amino-propionic acid 3- ⁇ 4-[6-(S,S-dioxo-thiomo ⁇ holin-4-yl)-pyrid in- 3-yl]-3-fluoro-phenyl ⁇ -2-oxo-oxazolidin-5-ylmethyl ester methanesulfonic acid salt; 283.
  • (2S,5R)-2-Amino-3-methyl-butyric acid 3- ⁇ 4-[6-(S,S-dioxo-thiomorpholin-4-yl)- pyridin-3-yl]-3-fluoro-phenyl ⁇ -2-oxo-oxazolidin-5-ylmethyl ester;
  • R2 H ; CH 3 ; F
  • the oxazolidinone 19 is optionally oxidized with sodium peroidate in solvent such as aqueous methanol or rectified spirit at a temperature between 0-80 °C for 1 to 48 hours to provide oxazolidinone compound 24 of the invention.
  • R5 heteroaryl
  • the oxazolidinone compound 21 (prepared as described above) is reacted with cyanoacetic acid and base such as pyridine or triethylamine or piperidine in presence of ammonium acetate in a solvent such as toleune or xylene at a temperature between 80-120 0 C for 1 to 12 hours to provide oxazolidinone compounds 30 of the invention.
  • cyanoacetic acid and base such as pyridine or triethylamine or piperidine
  • R16 alkyl, aryl
  • Z O, S 1 SO, SO 2 .
  • the compounds of this invention are useful antimicrobial agents, effective against various human and veterinary pathogens, including multiple-resistant staphylococci and streptococci, enteroccoci, as well as anaerobic organisms such bacteroides and Clostridia species, and acid resistant organisms such as Mycobacterium tuberculosis and Mycobacterium avium.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention provides compounds of Formula (I) having antimicrobial activity for preventing and treating diseases caused by microbial infections. Thus, the present invention provides novel oxazolidinone derivatives, processes for making compounds as well as antimicrobial pharmaceutical compositions containing said derivatives as active ingredients and methods of treating microbial infections with the said derivatives. Formula (I): wherein Q is formula (II): or formula (III).

Description

Oxazolidinones bearing Antimicrobial Activity Composition and Methods of Preparation
Field of Invention
The present invention relates to the field of oxazolidinones having antimicrobial activity. The invention also relates to processes for preparation of the compounds, to pharmaceutical compositions containing the compounds and to methods of treating microbial infections with the compounds.
Background of Invention
Oxazolidinones represent a novel chemical class of synthetic antimicrobial agents, with Linezolid, as a first representative, of this class1'2 This advance enabled the profiling of the unique properties of the members of this class, which is that they display activity against important Gram-positive human and veterinary pathogens including Methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant enterococci (VRE) and β-lactam resistant Streptococcus pneumoniae (PRSP). The oxazolidinones also show activity against Gram-negative aerobic bacteria and Gram-positive and Gram-negative anaerobes3.
Some deficiencies of oxazolidinones have also surfaced. They are inactive against Enterobacteriaceae4. Moreover their potency for atypical respiratory pathogens such as Mycoplasma pneumoniae, M. hominis, Ureaplasma urealyticium and Chlamydia species is of a borderline range which could result into unacceptable clinical efficacy for the treatment of respiratory tract infections3.
Other limitations that have appeared through the clinical development studies and use of Linezolid and its potential successors in development are that the class has a propensity to induce myelosuppression with consequent thrombocytopenia5. Inhibition of monoamine oxidase by oxazolidinones has prompted a recommendation made to clinicians that clinical use of members of this class be done with caution during concomitant usage of adrenergic or serotonergic agents and selective serotonin reuptake inhibitors6. Linezolid has been shown to have two targets in cells for its inhibitory effects. It binds to the 5OS subunit within domain Y of the 23S or RNA peptidyl transferase center near the interface with the 3OS subunit, thereby blocking the formation of the tMet-tRNA-ribosome-mRNA ternary complex. In addition, linezolid associates with the nascent 50S particle and stops the assembly process7.
The present invention the identification of novel oxazolidinone compounds with antimicrobial activity, which is an embodiment of this invention.
The following publications may be referred to with respect to the statements made in the above-described background information.
1 Slee AM, et al., Antimicrob. Agents Chemother (1987) 31:1791 -1797;
2 2nd European Congress of Chemotherapy and 7th Biennial Conference on Antiinfective Agents and Chemotherapy (Final Program), (1998): 93; 3Diekema D J et al., Lancet 2001; 358: 1975-82;
4 Zhanel GG et al., Canadian Journal of Infectious Diseases, 2001, 12: 379- 390;
5 Kuter D J et al., Pharmacotherapy, 2001: 21: 1010-1030;
6 Ament P W et al., Am Fam Physician 2002, 65: 663-70; 7Shinabarger D, Exp. Opin. Invest. Drugs (1999) 8:1195-1202; Champrey W S et al., Curr. Microb. 2002, 44: 350-356;
Information Disclosure
There are several patents cited in the literature, which refer to oxazolidinones having antibacterial activity. Piperidinylphenyl moiety bearing oxazolidinones are described in following patents;
WO95/25106 discloses substituted piperidino phenyloxazolidinones. This corresponds to US
5,668,286 and EP 0.750618. WO 96/13502 discloses phenyloxazolidinones having a multisubstituted azetidinyl or pyrrolidinyl moiety.
US application 10/475,735; 10/616,888 and 10/935,708 PCT application PCT/IN03/00237,
PCT/INO3/0O238 and PCT/IN04/00276 discloses piperidinyl phenyl oxazolidinones of antimicrobial use. Pyrrolidinyl/piperidinyl phenyl oxazolidinone antibacterial agents are also described in Kim
H Y et al, Bioorg. & Med. Chem. Lett., (2003), 13:2227-2230.
However in all above cited patents, substituted or unsubstituted heteroaryl bearing piperidinophenyl oxazolidinone compounds are not disclosed. Similarly, following citations pertain to oxazolidinones having biaryl moiety attached to oxazolidinone ring.
WO 2004/048350 A2 describes pyridyl and pyrimidyl moiety as one of constituents of biaryl oxazolidinone compounds. However oxazolidinone moiety bearing methyl acetamide, or methyl thioacetamide are not described. This application does not disclose halogen substituted biphenyl oxazolidinone compounds with methyl acetamide moiety.
US 2004/147760 Al and WO 2003/072553 Al describe some biaryl oxazolidinone compounds but oxazolidinones with methyl acetamide are not described.
WO 0194342 Al describes pyridinyl and pyrimidinyl moiety as one of constituents of biaryl oxazolidinone compounds. However oxazolidinone biaryl compounds bearing thiomorpholine are not described. This application does not disclose halogen substituted on both biphenyl rings of oxazolidinone compounds.
WO 04056819 Al also describes pyridinyl and pyrimidinyl moiety as one of constituents of biaryl oxazolidinone compounds. However examples of biaryl oxazolidinone compounds bearing methyl acetamide are not disclosed. This application does not describe halogen substituted on both rings of biphenyl moiety.
WO 2005/058886 Al describe heterocyclic ring attached to biaryl compounds. However examples of biaryl oxazolidinone compounds bearing morpholino derivatives are not disclosed.
WO 2005/ 012271 A2 describes a process for synthesis of biaryl compounds where one of the ring in biaryl moiety is either pyridine or desfluorophenyl ring however biaryl ring with both rings bearing fluorine atom are not described. WO 2005/ 012271 A2 does not describe thiomorpholine moiety as one of the substituent on biaryl moiety.
The present inventors have found that the novel piperidino substituted phenyloxazolidinones and biaryl oxazolidinones of the invention herein described have a favorable in vitro and in vivo efficacy advantages. US application 10/475,735; 10/616,888 and 10/935,708 and PCT application PCT/IN03/00237, PCT7INO3/O0238 and PCT/IN04/00276 discloses a novel series of oxazolidinones which display increased potency.
Summary of Invention:
The present invention relates to novel substituted phenylpiperidino and biaryl oxazolidinone compounds of Formula I.
Figure imgf000005_0001
Formula I wherein Q is
Figure imgf000005_0002
X and Y may be same or different, represent, CH, CF, N;
X' and Y' may be same or different, represent,
CH, CF, N, C-OCH3, C-CH2-Ra; wherein Ra is hydrogen, amino, halogen, hydroxyl, azido, carboxamido, NHCH2CONH2, N(CH2CONH2)2;
R2 and R2- may be same or different, represent, hydrogen, methyl, hydroxyl, C1-C6 alkoxy or halogen;
R4 is selected from the group comprising a) 0-R1, b) NRbRc; wherein Rb is selected from hydrogen, C1-C6 alkylcarbonyl;
Rc is selected from hydrogen, C(O)OCH2OC(O)Rd or CH(CH3)OC(O)R6; wherein Rd is hydrogen, C1-C6 alkyl, substituted Ci-C6 alkyl with substitutents selected from amino or Ci-C6 alkylamido
Re is selected from hydrogen, C1-C6 alkyl, substituted C1-C6 alkyl; c) formamide; d) carbamate; e) thiocarbamate; f) urea; g) C i -C6 alkylamido; h) C1-C6 haloalkylamido; i) Ci-C6 thioalkylamido; j) substituted Ci-C6 thioalkylamido, wherein the alkyl group is substituted with halo; Ic) unsubstituted or substituted heteroaryl, wherein substituents of the heteroaryl are selected from the group comprising Ci-C6 alkyl, nitro, cyano, hydroxyl, halo, amino, C1-C6 alkylcarbonyl, C1-C6 alkoxycarbonyl, carboxy; wherein R1 is selected from the group comprising hydrogen, C1-C6 alkylsulfonyl, C1-C6 alkylcarbonyl, -P(O)(OM)2, wherein M is hydrogen, methyl, ethyl, t-butyl, phenyl or an alkali metal ion such as Li, Na, K; or Ri is an amino acid residue derived from one of the 20 naturally occurring amino acids viz. alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine, attached to the oxygen via carbonyl of the amino acid to form a ester linkage;
When Q is
Figure imgf000006_0001
wherein n is 0, 1 or 2;
W represents 3-7 membered heterocyclyl bearing one or more heteroatom selected from N, O, S; optionally substituted with one or more substitutents selected from the group comprising Ci-C6 alkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxycarbonyl, carboxamide, cyano, hydroxyl, amino, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl or heteroaryl bearing one or more heteroatom selected from N, O S, optionally substituted with one or more substitutents selected from the group comprising i. substituted or unsubstituted C1-C6 alkyl with substituents selected from the group hydroxyl, halo, nitro, cyano, aryl or heteroaryl;
11. substituted or unsubstituted C2-C6 alkenyl with substituents selected from the group hydroxyl, halo, nitro, cyano, aryl or heteroaryl;
C1-C6 alkylcarbonyl;
IV. C1-C6 alkoxycarbonyl; V. C1-C6 alkoxycarbonylalkyl; vi. C1-C6 alkylcarbonylalkyl; vii. C1-C6 haloalkyl; viϋ. formyl; iX. carboxy; x. carboxamide; xi. cyano; xϋ. amino; xiϋ. nitro; xiv. hydroxyl; xv. halo; xvi. morpholinocarbonylalkyl; x vii. hydroxyiminoalkyl; xviϋ. alkylcarbonylaminoalkyl; xix. alkoxyiminoalkyl; XX. aralkyloxyiminoalkyl; xxi. hydroiminoaminoalkyl;
XXlI. aryl, substituted aryl, with substituents selected from C1-C6 alkyl, nitro, cyano, hydroxyl, halo, amino, heterocyclyl;
XXIU. substituted or unsubstituted heteroaryl, with substituents selected from C1-C6 alkyl, nitro, cyano, hydroxyl, halo, amino, heterocyclyl;
XXIV. substituted or unsubstituted heterocyclyl, with substituents selected from Cj-
C6 alkyl, Cj-C6 alkylcarbonyl, aralkyl, nitro, cyano, hydroxyl, halo, amino; xχv. Ci-C6 alkylthio; xxvi. Ci-C6 alkylsulfanylalkyl; xxvϋ. C1-C6 aralkylsulfanyl; xxviϋ. C1-C6 alkylsulfonylmethyl; xxix. C1-C6 alkylsulfonyloxy;
NRbRc; xxxi. -(C1-C6 alkyl)-NRr(CrC6 alkyl)-NRbRc; wherein Rf is hydrogen, Ci-C6 alkyl, substituted C1-C6 alkyl with substitutents selected from amino or Ci-C6 alkylamido; or
W is heteroaryloxy group optionally substituted with one or more substitutents such as Ci-C6 alkyl, C2-C6 alkenyl, Ci-C6 alkylcarbonyl, C1-C6 alkoxycarbonyl, formyl, carboxy, carboxamide, cyano, amino, hydroxyiminoalkyl, alkoxyiminoalkyl, aralkyloxyiminoalkyl, hydroxyiminoaminoalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl, substituted heterocyclyl; OR
when Q is
Figure imgf000008_0001
X' and Y' are as defined above;
T is hydrogen or
Figure imgf000008_0002
wherein
R2 and R2- are as defined above; "a" is optional double bond; R3 and R3- may be same or different, represent, hydrogen, methyl, hydroxyl, C1-C6 alkoxy or halogen; with the proviso that when T is hydrogen, R4 is not acetamido; Z represents group selected from CH, NH, O, S, CH2, C(R6)R6', C=O, NR7, C=C(R8)R8S SO,
SO2, S=NH1 S=NC(O)CH3, S=NC(O)NHCH3, S(O)=NH, S(O)=NCH3, S(O)NC(O)CH3,
S(O)=NC(O)NHCH35 S(O)=NC(O)NHCH2CH2CI, with proviso that when X is CH, Y is CF, one of X' or Y' or both X', Y' are N, then Z is not NH.
wherein R6 and R6' may be same or different, represent, hydrogen, hydroxyl, amino, azido, Ci-C6 alkoxy, C]-C6 alkylcarbonyloxy, Cj-C6 alkylsulfonyloxy, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, C1-C6 alkyl optionally substituted with one or more substituent selected from the group comprising azido, cyano, carboxamido, hydroxyl, Cj-C6 alkyloxy, C1-C6 alkylcarbonyloxy, C1-C6 alkylcarbonyl or C2-C6 alkenyl optionally substituted with one or more azido, cyano, carboxamido or hydroxyl; or R6 and R6' are combined together to provide 3-7 member heterocyclyl bearing one or more heteroatom selected from N, O, S optionally substituted with substituent selected from group comprising Ci-C6 alkyl, C2-C6 alkenyl, Ci-C6 alkylcarbonyl, C1-C6 alkoxycarbonyl, formyl, carboxy, carboxamide, cyano, amino, hydroxyiminoalkyl, alkoxyiminoalkyl, aralkyloxyiminoalkyl, hydroxyiminoaminoalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl, substituted heterocyclyl;
R7 represents hydrogen, cyano, aralkyl, CO-OCH2Ph, Q-Q-alkylcarbonyl, C1-C6 alkyl optionally substituted with one or more azido, cyano, heteroaryl, substituted heteroaryl, carboxamido or hydroxyl;
R8, R8' may be same or different, represent, hydrogen, C1-C6 alkyl, C2-C6 alkenyl, cyano, amino, C1-C6 alkylcarbonyl, C1-C6 alkoxycarbonyl, cyano, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl, substituted heterocyclyl;
and isomers, polymorphs, N-oxides thereof or pharmaceutical acceptable salts thereof. Detailed Description of the invention:
The present invention relates to novel substituted phenylpiperidino and biaryl oxazolidinone compounds of Formula I.
Figure imgf000010_0001
Formula I wherein Q is
Figure imgf000010_0002
X and Y may be same or different, represent, CH, CF, N;
■ X' and Y' may be same or different, represent,
CH, CF, N, C-OCH3, C-CH2-R1; wherein Ra is hydrogen, amino, halogen, hydroxyl, azido, carboxamido, NHCH2CONH2, N(CH2CONH2)2;
R2 and R2- may be same or different, represent, hydrogen, methyl, hydroxyl, C1-C6 alkoxy or halogen;
R4 is selected from the group comprising a) O-Ri, b) NRbRc; wherein Rb is selected from hydrogen, C1-C6 alkylcarbonyl; Rc is selected from hydrogen, C(O)OCH2OC(O)Rd or CH(CH3)OC(O)R6; wherein Rd is hydrogen, C1-C6 alkyl, substituted Cj-C6 alkyl with substitutents selected from amino or C1-C6 alkylamido
Re is selected from hydrogen, C1-C6 alkyl, substituted C1-C6 alkyl; c) formamide; d) carbamate; e) thiocarbamate; f) urea; g) Ci-C6 alkylamido; h) Ci-C6 haloalkylamido; i) Ci-C6 thioalkylamido; j) substituted C1-C6 thioalkylamido, wherein the alkyl group is substituted with halo; k) unsubstituted or substituted heteroaryl, wherein substituents of the heteroaryl are selected from the group comprising C1-C6 alkyl, nitro, cyano, hydroxyl, halo, amino, Cj-C6 alkylcarbonyl, C1-C6 alkoxycarbonyl, carboxy; wherein Ri is selected from the group comprising hydrogen, Ci-C6 alkylsulfonyl, C1-C6 alkylcarbonyl, -P(O)(OM)2, wherein M is hydrogen, methyl, ethyl, t-butyl, phenyl or an alkali metal ion such as Li, Na, K; or R1 is an amino acid residue derived from one of the 20 naturally occurring amino acids viz. alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine, attached to the oxygen via carbonyl of the amino acid to form a ester linkage;
When Q is
Figure imgf000011_0001
wherein n is 0, 1 or 2;
W represents 3-7 membered heterocyclyl bearing one or more heteroatom selected from N,
O, S, optionally substituted with one or more substitutents selected from the group comprising C1-C6 alkyl, Ci-C6 alkylcarbonyl, Ci-C6 alkoxycarbonyl, carboxamide, cyano, hydroxyl, amino, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl or heteroaryl bearing one or more heteroatom selected from N, O S, optionally substituted with one or more substitutents selected from the group comprising i. substituted or unsubstituted C1-C6 alkyl with substituents selected from the group hydroxyl, halo, nitro, cyano, aryl or heteroaryl; 11. substituted or unsubstituted C2-C6 alkenyl with substituents selected from the group hydroxyl, halo, nitro, cyano, aryl or heteroaryl;
111. Ci-C6 alkylcarbonyl; iv. C1-CO alkoxycarbonyl;
V. Ci-C6 alkoxycarbonylalkyl; vi. C1-C6 alkylcarbonylalkyl;
Ci-C6 haloalkyl; formyl; carboxy; carboxamide; cyano; amino; nitro; hydroxyl;
XV. halo; xvi. morpholinocarbonylalkyl; xvii. hydroxyiminoalkyl ; xviii. alkylcarbonylaminoalkyl; alkoxyiminoalkyl; aralkyloxyiminoalkyl ; hydroiminoaminoalkyl; aryl, substituted aryl, with substituents selected from C1-C6 alkyl, nitro, cyano, hydroxyl, halo, amino, heterocyclyl; substituted or unsubstituted heteroaryl, with substituents selected from CpC6 alkyl, nitro, cyano, hydroxyl, halo, amino, heterocyclyl; substituted or unsubstituted heterocyclyl, with substituents selected from C1-
C6 alkyl, C1-C6 alkylcarbonyl, aralkyl, nitro, cyano, hydroxyl, halo, amino; xxv. CpC6 alkylthio; xx vi. Ci-C6 alkylsulfanylalkyl; xxvii. Ci-C6 aralkyl sulfanyl; xxviii. CpC6 alkylsulfonylmethyl; xxix. Ci-C6 alkylsulfonyloxy; xxx. NRbRc; xxxi. -(Ci-C6 alkyl)-NRf (CI-C6 alkyl)-NRbRc; wherein Rf is hydrogen, C1-C6 alkyl, substituted C1-CO alkyl with substitutents selected from amino or C]τC6 alkylamido; or
W is heteroaryloxy group optionally substituted with one or more substitutents such as Ci-C6 alkyl, C2-C6 alkenyl, Ci-C6 alkylcarbonyl, C1-C6 alkoxycarbonyl, formyl, carboxy, carboxamide, cyano, amino, hydroxyiminoalkyl, alkoxyiminoalkyl, aralkyloxyiminoalkyl, hydroxyiminoaminoalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl, substituted heterocyclyl;
OR
when Q is
Figure imgf000013_0001
X' and Y' are as defined above;
T is hydrogen or
Figure imgf000013_0002
wherein
R2 and R2- are as defined above; "a" is optional double bond; R3 and R3> may be same or different, represent, hydrogen, methyl, hydroxyl, C1-C6 alkoxy or halogen; with the proviso that when T is hydrogen, R4 is not acetamido;
Z represents group selected from CH, NH, O, S, CH2, C(R6)R6', C=O, NR7, C=C(R8)R8-, SO, SO2, S=NH, S=NC(O)CH3, S=NC(O)NHCH3, S(O)=NH, S(O)=NCH3, S(O)NC(O)CH3, S(O)=NC(O)NHCH3, S(O)=NC(O)NHCH2CH2C1, with proviso that when X is CH, Y is CF, one of X' or Y' or both X', Y' are N, then Z is not NH. wherein R6 and R6' may be same or different, represent, hydrogen, hydroxyl, amino, azido, Ci-C6 alkoxy, Ci-C6 alkylcarbonyloxy, Ci-C6 alkylsulfonyloxy, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, Ci-C6 alkyl optionally substituted with one or more substituent selected from the group comprising azido, cyano, carboxarnido, hydroxyl, Ci-C6 alkyloxy, C1-C6 alkylcarbonyloxy, C1-C6 alkylcarbonyl or C2-C6 alkenyl optionally substituted with one or more azido, cyano, carboxamido or hydroxyl; or Re and R6' are combined together to provide 3-7 member heterocyclyl bearing one or more heteroatom selected from N, O, S optionally substituted with substituent selected from group comprising Ci-C6 alkyl, C2-C6 alkenyl, Ci-C6 alkylcarbonyl, C1-C6 alkoxycarbonyl, formyl, carboxy, carboxamide, cyano, amino, hydroxyiminoalkyl, alkoxyiminoalkyl, aralkyloxyiminoalkyl, hydroxyiminoaminoalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl, substituted heterocyclyl;
R7 represents hydrogen, cyano, aralkyl, CO-OCH2Ph, Q-Ce-alkylcarbonyl, C1-C6 alkyl optionally substituted with one or more azido, cyano, heteroaryl, substituted heteroaryl, carboxamido or hydroxyl;
R8, R8' may be same or different, represent, hydrogen, Ci-C6 alkyl, C2-C6 alkenyl, cyano, amino, Ci-C6 alkylcarbonyl, Ci-C6 alkoxycarbonyl, cyano, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl, substituted heterocyclyl;
and isomers, polymorphs, N-oxides thereof or pharmaceutical acceptable salts thereof.
The preferred compounds of the invention are
a) The compound of formula Ia,
Figure imgf000015_0001
Formula Ia wherein, n is O or 1;
R2 and R2> are each independently hydrogen, methyl, hydroxyl, halogen; X and Y each independently CH or CF; W is heteroaryl or substituted heteroaryl, wherein heteroaryl is [l,2,3]-triazol, [l,2,4]-triazol, pyrrol, pyrazol, tetrazol, imidazol, [l,3,4]-oxadiazol, [l,2,4]-thiadiazol, [l,3,4]-thiadiazol, oxazol, isoxazol, thiazol, benzotriazol; the substituents on heteroaryl are selected from group comprising methyl, cyano, amino, fluoro, difluoromethyl, formyl, hydroxyl methyl, carboxamide, acetyl, 1-methoxyimino- methyl, 4-pyridinyl, 3-pyridinyl, diethylamino, methylsulfonylmethyl;
R4 is Ci-C6 alkylamido, acetamide, difluoroacetamide, thioacetamide, difluoroacetamide, carbamate, thiocarbamate, urea, [l,2,3]-triazol, [l,2,4]-triazol.
b) The compound of formula Ib
Figure imgf000015_0002
Formula Ib wherein, a is optional double bond; X and Y each independently CH, CF or N; X' and Y' are each independently CH, CF, N, C-CH3; R2, R.2 1, R3 and R3. are each independently hydrogen, methyl, hydroxyl, halogen; Z is S, SO, SO2;
R4 is acetamido, [l,2,3]-triazol, methyl carbamate, t-butyl carbamate, OR1 wherein Ri is hydrogen, P(O)(OM)2, wherein M is hydrogen, Na, methyl, ethyl, t-butyl, phenyl; or Ri is an amino acid residue derived from one of the 20 naturally occurring amino acids viz. alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine, attached to the oxygen via carbonyl of amino acid to form an ester linkage.
Description of terms:
The following definitions are used, unless otherwise described.
The term "C1-C6 alkyl" refers to saturated, straight or branched chain hydrocarbon having C1-
Ce number of carbon atoms such as methyl, ethyl, propyl, isopropyl and so on.
"substituted Q-C6 alkyl" refers to one or more hydrogen atom of the alkyl group substituted with halogen, amino, hydroxy, carboaxldehyde, mercapto, nitro, carboxy, alkoxycarbonyl, carboxamide, aryl, heteroaryl, substituted aryl, substituted heteroaryl. "C2-C6 alkenyl' means straight or branched chain hydrocarbon comprising C1-C6 carbon atom containing one or more carbon-carbon double bonds for examples ethenyl, propenyl, butenyl, pentenyl, hexenyl.
"substituted Ci -Ce alkenyl" refers to one or more hydrogen atom of the alkenyl group substituted with halogen, amino, hydroxy, carboaxldehyde, mercapto, nitro, carboxy, alkoxycarbonyl, carboxamide, aryl, heteroaryl, substituted aryl, substituted heteroaryl.
"C2-Ce alkynyl' means straight or branched chain hydrocarbon comprising Ci-C6 carbon atom containing one or more carbon-carbon triple bonds for examples ethynyl, propynyl, butynyl, pentynyl, hexynyl.
"Ci-C6 alkylsulfonyloxy" means groups such as methanesulfonyloxy, ethanesulfonyloxy, propylsulfonyloxy and so on.
"Ci-Cfi-alkoxycarbonyl" means group such as methoxycarbonyl (CH3O-CO), ethoxycabonyl (C2H5O-CO), propoxycarbonyl (CsH7O-CO) and so on. "halogen" or "halo" means atom selected from atom such as fluorine, chlorine, bromine.
"Ci-C6 alkylcarbonyl" means groups such as acetyl, ethylcarbonyl, propylcarbonyl. "Ci-C6 alkylthio" means groups such as methylthio, ethylthio, propylthio.
"aryl" refers to a mono, fused bicyclic or fused tricyclic carbocyclic ring system having one or more aromatic rings including but not limited to phenyl, napthyl, indanyl, indenyl and so on. "substituted aryl" refers to an aryl group as defined herein substituted by independent replacement of one or more hydrogen atoms thereon with Cl, Br, F, I, OH, CN, Ci-C6 alkyl, Ci-C6 allcoxy, haloalkyl, amino, alkylamino, dialkylamino, mercapto, nitro, carboxaldehyde, carboxy, alkoxycarbonyl, carboxamide. "heteroaryl" refers to mono, fused bicyclic or tricyclic aromatic radical having 5-10 ring atoms of which one or more carbon atom of the ring is replaced by an atom selected from N, O, S, for example pyrrolyl, pyrazolyl, imidazolyl, [l,2,3]-triazolyl, [l,2,4]-triazolyl, tetrazolyl, [l,2,4]-oxadiazolyl, [l,3,4]-oxadiazolyl, furanyl, thiophenyl, [l,2,4]-thiadiazolyl, [l,3,4]-thiadiazolyl, thiazolyl, oxazolyl, isoxazolyl, pyridyl, pyrimidinyl, benzotriazolyl, quinolinyl, isoquinolinyl, and the like.
"substituted heteroaryl" refers to a heteroaryl group as defined herein substituted by independent replacement of one or more hydrogen atoms thereon with Cl, Br, F, I, OH, CN, C)-C6 alkyl, Ci-C6 alkoxy, haloalkyl, amino, alkylamino, dialkylamino, mercapto, nitro, carboxaldehyde, carboxy, alkoxycarbonyl, carboxamide. "heterocyclyl" means mono-, bi- or tri- cyclic ring systems which may be partially or fully saturated having 3-10 ring atoms. The individual rings may be 3-7 member bearing one or more heteroatom selected from N, O, S. This includes aryl and heteroaryl ring stems fused to non aromatic ring. For example aziridinyl, oxiranyl, piperidinyl, piperazinyl, morpholinyl, thiornorpholinyl, oxadiazolonyl, oxazolidinonyl, thiadiazolonyl, 5-thioxo-4,5- dihydro-[l,2,4]triazol-l-yl and so on.
"substituted heterocyclyl" refers to a heterocyclyl group as defined above substituted by independent replacement of one or more hydrogen atoms thereon with Cl, Br, F, I, OH, CN, Ci-C6 alkyl, Cj-C6 alkoxy, haloalkyl, amino, alkylamino, dialkylamino, mercapto, nitro, carboxaldehyde, carboxy, alkoxycarbonyl, carboxamide. "aralkyl" means groups like benzyl, benhydryl, trityl and so on.
"haloalkyl" refers to C1-C6 alkyl group substituted with one or more halogen for example chloromethyl, bromoethyl and the like.
"heteroaryloxy group' means heteroaryl linked via ether linkage for example group such as isooxazolyloxy, thiophenyloxy, pyridinyloxy. "Ci-Ce alkoxy" refers for the Ci-C6 alkyl group linked via ether linkage for example methoxy, ethoxy and so on.
"acetamido" stands for NHC(O)CH3. "forrnamide" stands for NH-CHO. "Ci-Ce alkylamido" means an alkyl group attached to the carbonyl of the amide. Examples of alkyamido groups include acetamido, -NHC(O)-C2H5, -NHC(O)-C3H7 and so on. "C1-C6 haloalkylamido" means alkyl group substituted with halogen, for example -NHC(O)-
CHCl2, -NHC(O)-CHF2, -NHC(O)-CH2CHCl2 and so on.
"thioacetarnido", stands for NHC(S)CH3.
"C1-C6 thioalkylamido" refers to alkylamido group wherein carbonyl group is replaced by C=S group; examples of alkyamido groups include thioacetarnido, -NHC(S)-C2H5, -NHC(S)-
C3H7 and so on.
"substituted Ci-Cβ thioalkylamido" refers to thioalkylamido group wherein alkyl group is substituted with halogen; for example -NHC(S)-CHCl2, -NHC(S)-CHF2, -NHC(S)-
CH2CHCl2 and so on. The term "carboxamide", refers to a group of the formula -CONH2, -C(O)NH(CrC6alkyl) or
-C(O)N(CrC6alkyl)(C1-C6alkyl).
"formyl", refers to the group -CHO. "cyanό" refers to the group -CN.
The term "amino" refers to NH2. "hydroxyl" refers to OH. "nitro" stands for NO2. "azido" stands for N3. The term "urea" stands for NH-CO-NH2. "substituted amino" refers to one or both hydrogen of amino substituted with optionally substituted Ci-C6 alkyl or optionally substituted C1-Cg alkenyl.
"carboxy", as used herein refers to a group of the formula -COOH.
"hydroxyiminoalkyl", refers to -C=N(OH)(C1-C6 alkyl).
"alkoxyiminoalkyl", stands for -C=N(O-(C1-C6 alkyl))(CrC6 alkyl). "aralkyloxyiminoalkyl", stands for -C=N(O-(aralkyl)(Ci-C6 alkyl) for example benzyloxyiminomethyl .
"hydroxyiminoaminoalkyl" refers to -C=N(OH)NH2.
"Ci-C6 alkoxycarbonylalkyl" refers to (C1-C6 alkyl)-O-CO-(C1-C6 alkyl) for example
CH3OCOCH2-. "Ci-C6 alkylcarbonylalkyl" refers to (C1-C6 alkyl)-CO-(C,-C6 alkyl) for example
CH3COCH2-.
"morpholinocarbonylalkyl" refers to morpholinocarbonyl-(Ci-C6 alkyl) for example morpholinocarbonylmethyl .
"alkylcarbonylaminoalkyl" refers to (C1-C6 alkyl)-CO-NH2-(Ci-C6 alkyl) for example CH3CONH2CH2-.
"C1-C6 alkylsulfanylalkyl" refers to (Ci-C6 alkyl)-S-(CrC6 alkyl) for example CH3SCH2.
"Ci-C6 alkylsulfonylmethyl" refers to (C1-C6 alkyl)-SO2-(d-C6 alkyl) for example
CH3SO2CH2-.
"Ci-C6 aralkylsulfanyl" refers to aralkyl group attached to sulfur for example PhCH2S-. "carbamate" refers to NH-CO-O-alkyl, for example NH-CO-O-CH3 (methyl carbamate), NHCO2C2H5 (ethyl carbamate).
"thiocarbamate" refers to NH-CS -O-alkyl, for example NH-CS-O-CH3 (methyl thiocarbamate), NHCS-OC2H5 (ethyl thiocarbamate) and the like.
"Mammal" refers to human or animals including livestock and companion animals. A "therapeutically effective amount" is an amount of a compound of the present invention that, when administered to a patient, provides the desired effect; i.e., lessening in the severity of the symptoms associated with a bacterial infection.
It will be appreciated by those skilled in the art that compounds of the invention having one or more chiral centers may exist in and be isolated in optically active and racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic, geometric, or stereoisomeric form, or mixtures thereof, of a compound of the invention, which possess the useful properties described herein, it being well known in the art how to prepare optically active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase) and how to determine activity or cytotoxicity using the standard tests described herein, or using other similar tests which are well known in the art.
Certain compounds of the invention are also useful as intermediates for preparing other compounds of the invention, a conversion which can occur both in vitro and in vivo.
Some of the compounds of the invention are capable of further forming pharmaceutically acceptable acid-addition and/or base salts. AU of these forms are within the scope of the present invention. Thus, pharmaceutically acceptable acid addition salts of the compounds of the invention include salts derived from nontoxic inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, hydrofluoric, phosphorous, and the like, as well as the salts derived from nontoxic organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinates suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzensoulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like. Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate (see, for example, Berge, S. M. et. al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 1977;66:1-19).
The acid addition salt of said basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner.
Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'- dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine.
Preferred salts are those of hydrochloride, hydrobromide, hydroiodide, sulphate, phosphate and salts of organic acids such as acetate, lactate, succinate, oxalate, maleate, fumarate, malate, tartrate, citrate, ascorbate, cinnamate, gluconate, benzoate, methane sulfonate and p- toluene sulfonate; lithium, sodium, magnesium, calcium and potassium salts, and amino acids salts such as alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan tyrosine or valine.
The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner.
Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention. A "prodrug" is an inactive derivative of a drag molecule that requires a chemical or an enzymatic biotransformation in order to release the active parent drug in the body. Some of the representative examples of oxazolidinone derivatives of the present invention represented by the general formula I are as follows:
1. (S)-N-{ 3-[4-(4-(2-Cyanoaziridin-l-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin- 5-ylmethyl }-acetamide;
2. (S)-N-{3-[4-(4-pyπOl-l-yl-piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl } -acetami de ; 3. (S)-N-{3-[3,5-Difluoro-4-(4-pyrrol-l-yl-piperidin-l-yl)-ρhenyl]-2-oxo-oxazolidin-5- ylmethyl } -acetamide ;
4. (S)-N-{3-[4-(4-(iH-imidazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethylj-acetamide;
5. (S)-N-{3-[4-(4-(lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
6. (S)-N-{3-[4-(4-(2H-[l,2,3]-triazol-2-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
7. (S)-N-{3-[4-(4-(lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide; 8. (S)-N-{3-[4-(4-(2H-[l,2,3]-triazol-2-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetarnide;
9. (S)-N-{3-[4-(4-(lH-[l,2,3]-triazol-l-yl)-3-fluoropiperidin-l-yl)-3,5-difluorophenyl]-2- oxo-oxazolidin-5-ylmethyl } -acetamide;
10. (S)-N-{ 3-[4-(4-(2H-[1 ,2,3]-triazol-2-yl)-3-fluoropiρeridin-l-yl)-3,5-difluorophenyl]-2- oxo-oxazolidin-5-ylmethyl } -acetamide;
11. (S)-N-{3-[4-(4-(lH-[l,2,3]-triazol-l-yl)-3-fluoroρiρeridin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
12. (S)-N-{ 3-[4-(4-(2H-[1 ,2,3]-triazol-2-yl)-3-fluoroρiperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide; 13. (S)-N-13-[4-(4-(2H-[1, 2,4]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
14. (S)-N-|3-[4-(4-(tetrazol-5-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl } -acetamide; 15. (S)-N-{3-[4-(4-(tetrazol-5-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo-oxazolidin-5- ylmethyl } - acetami de ;
16. (S)-N-{3-[4-(4-(lH-tetrazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl }-acetamide; 17. (S)-N-{ 3-[4-(4-(2H-tetrazol-2-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl } -acetami de ;
18. (S)-N-{3-[4-(4-(lΗ-tetrazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo-oxazolidin- 5-ylmethyl }-acetamide;
19. (S )-N- { 3- [4-(4-(2H-tetrazol-2-yl)-piperidin- 1 -yl)-3 ,5 -difluorophenyl]-2-oxo-oxazolidin- 5-ylmethyl }-acetamide;
20. (S)-N-{3-[4-(4-(lH-tetrazol-l-yl)-3-hydroxypiperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide and isomer thereof;
21. (S)-N-{3-[4-(4-(lH-tetrazol-l-yl)-3-hydroxypiperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide; 22. (S)-N-{ 3-[4-(4-(lH-tetrazol-l-yl)-3-fluoropiperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
23. (S)-N-{3-[4-(4-(4-formyl-lH-[l,2J3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
24. (S)-N-{3-[4-(4-(4-formyl-lΗ-[l,23]-triazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2- oxo-oxazolidin-5-ylmethyl } -acetamide;
25. (S)-N-{3-[4-(4-(4-foππyl-lΗ-[l;2,3]-triazol-l-yl)-3-fluoropiperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
26. (R)-{3-[4-(4-(4-formyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]- 5-(1H- [l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one; 27. (S)-N-{ 3-[4-(4-(4-difluoromethyl-lH-[l,2,3]-triazol-l-yl)-piperidm-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
28. (S)-N-{3-[4-(4-(4-difluoromethyl-iH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
29. (S)-N-{3-[4-(4-(4-[l,3]-Dioxolan-2-yl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-5-(lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
30. (S)-N-{3-[4-(4-(4-ethoxycarbonyl-lH-[l,2,3]-triazol-l-yl)-methyl-piperidin-l-yl)-3- fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
31. (S)-N-{ 3-[4-(4-(5-ethoxycarbonyl-lH-[l,2,3]-triazol-l-yl)-methyl-piperidin-l-yl)-3- fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide; 32. (S)-N-{3-[4-(4-(4-ethoxycarbonyl-lH-[l,2,3]-triazol-l-yl)-3-fluoroρiperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
33. (S)-N-{3-[4-(4-(4-ethoxycarbonyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide; 34. (R)-{3-[4-(4-(4-ethoxycarbonyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]- 5-(lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
35. (R)-{3-[4-(4-(4-ethoxycarbonyl-lH-[l,2,3]-triazol-l-yl)-ρiperidin-l-yl)-3,5- difluorophenyl]-5-( \H-[ l,2,3]-triazol-l -ylmethyl) }-oxazolidin-2-one;
36. (S)-N-{3-[4-(4-(4-hydroxymethyl-lΗ-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
37. (S)-N-{3-[4-(4-(5-hydroxymethyl-lΗ-[l,2,3]-triazol-l-yl)-ρiρeridin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
38. (S)-N- {3-[4-(4-(4-hydroxymethyl-lH-[l,2,3]-triazol- l-yl)-3-fluoropiperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; 39. (S)-N-{3-[4-(4-(4-hydroxymethyl-lH-[l,2,3]-triazol-l-yl)-piρeridin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
40. (R)-{3-[4-(4-(4-hydroxymethyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]- 5-(lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
41. (R)-{3-[4-(4-(4-hydroxymethyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3,5- difluorophenyl]-5-(lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
42. (S)-N-{3-[4-(4-((4-hydroxymethyl)-[i,2,3]-triazol-l-yl-methyl)-ρiperidin-l-yl)-3-fluoro- phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
43. (S)-N-{3-[4-(4-(4-cyano-lH-[l,2,3]-triazol-l-yl)-ρiρeridin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide; 44. (S)-N-{3-[4-(4-(4-carboxamido-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]- 2-oxo-oxazolidin-5-ylmethyl } -acetamide;
45. (R)-{3-[4-(4-(4-carboxamido-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluoroρhenyl]-5- (lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
46. (S)-N-{3-[4-(4-(4-carboxamido-lH-[l,2,3]-triazol-l-yl)-methyl-piperidin-l-yl)-3-fluoro- ρhenyl]-2-oxo-oxazolidin-5-ylmethyl }-acetamide;
47. (S)-N-{3-[4-(4-(5-carboxamido-lH-[l)2,3],-triazol-l-yl)-methyl-piperidin-l-yl)-3-fluoro- phenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
48. (S)-N-{3-[4-(4-(4-hydroxycarbonyl-lH-[l,2,3]-triazol-l-yl)-methyl-ρiρeridin-l-yl)-3- fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; 49. (S)-N-{3-[4-(4-(5-hydroxycarbonyl-lH-[l,2,3]-triazol-l-yl)-methyl-ρiperidin-l-yl)-3- fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
50. (S)-N-{3-[4-(4-(4-acetyl-lΗ-[l,2,3]-triazol-l-yl)-ρiperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide; 51. (S)-N-{3-[4-(4-(4-acetyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-acetamide;
52. (R)-{3-[4-(4-(4-acetyl-l//-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-5-(lH- [1 ,2,3]-triazol- 1-ylmethyl) }-oxazolidin-2-one;
53. (S)-N-{3-[4-(4-(4-acetyl-lH-[l,2,3]-trizol-l-ylmethyl)-lH-[l,2,3]-triazol-l-yl)-piperidin- l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl }-acetamide;
54. (S)-N-{3-[4-(4-(4-(l-hydroxyethyl)-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;'
55. (S)-N-{3-[4-(4-(4-(l-hydroxyethyl)-lH-[l,2,3]-triazol-l-yl)-piperidm-l-yl)-3,5- difluoropheiiyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide; 56. (R)-{3-[4-(4-(4-(2-hydroxyethyl)-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-5-(lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one; 57. (S)-N-{3-[4-(4-(4-(2-methyl-oxiranyl)-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
58. (R)-{3-[4-(4-(4-(2-methyl-oxiranyl)-lH-[l,2,3]-triazol-l-yl)-ρiperidin-l-yl)-3- fluorophenyl]-5-(lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
59. (S)-N-{3-[4-(4-((4-((E/Z)-2-cyano-vinyl)-lH-[l,2,3]-triazol-l-yl)-ρiρeridin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
60. (S)-N-{3-[4-(4-(4-hydroxyimino-methyl)-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; 61. (S)-N-{3-[4-(4-(l-methoxyimino-ethyl)-lΗ-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
62. (S)-N-{3-[4-(4-(4-(l-methoxyimino-ethyl)-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetaraide;
63. (R)-{3-[4-(4-(4-(l-methoxyimino-ethyl)-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-5-(lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
64. (R)-{3-[4-(4-(4-(l-methoxyimino-ethyl)-[l,2,3]-triazol-l-yl)-ρiperidin-l-yl)-3,5- difluorophenyl]-5-(lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
65. (S)-N-{3-[4-(4-(l-methoxyimino-methyl)-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide; 66. (S)-N-{3-[4-(4-(l-methoxyimino-methyl)-lH-[l>2,3]-triazol-l-yl)-piρeridin-l-yl)-3,5- difluorophenyI]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
67. (S)-N-{3-[4-(4-(l-benzyloxyimino-methyl)-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide; 68. (S)-N-{3-[4-(4-(4-hydxoxyiminoamino-methyl)-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
69. (S)-N-{3-[4-(4-(4-N,N-dimethylaminoethylaminomethyl)-lH-[l,2,3]-triazol-l-yl)- piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
70. (S)-N-{3-[4-(4-(2Η-benzotriazol-2-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
71. (S)-N-{3-[4-(4-(lH-benzotriazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
72. (S)-N-{3-[4-(4-Benzotriazol-2-yl-piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl }-acetamide; 73. (S)-N-{3-[4-(4-Benzotriazol-l-yl-piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl }-acetamide; 74. (S)-N-{3-[4-(4-(4-(l//-tetrazol-l-ylmethyl)-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
75. (S)-N-{3-[4-(4-(2Jf/-tetrazol-2-ylmethyl)-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl }-acetamide;
76. (S)-N-{3-[4-(4-(m-imidazol-l-ylmethyl)-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; 77. (R)-{3-[4-(4-(lH-[l,2,3]-triazol-l-yl)-3-fluoropiperidin-l-yl)-3-fluorophenyl]-5-(lH-
[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one; 78. (R)-{ 3-[4-(4-(lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-5-(lH-[l,2,3]- triazol-l-ylmethyl)}-oxazolidin-2-one;
79. (R)-{3-[4-(4-(lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]-5-(lH-[l,2,3]- triazol- 1-ylmethyl) } -oxazolidin-2-one;
80. (RXS-^^-ClH-tl^^l-triazol-l-yO-S-fluoropiperidin-l-yO-S^-difluorophenylj-S-ClH- [l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
81. (S)-N- {3-[4-(4-([l,2,3]-triazol-l-yl)-ρiperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazoIidin-5- ylmethyl } -thioacetamide;
82. (S)-N-{3-[4-(4-(5-methyl-2Η-tetrazol-2-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl }-acetamide; 83. (S)-N-{3-[4-(4-(5-methyl-lH-tetrazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
84. (S)-N- { 3 -[4-(4-(5-methyl- lH-tetrazol- 1 -yl)-piperidin- 1 -yl)-3 ,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide; 85. (S)-N-{3-[4-(4-(5-methyl-2H-tetrazol-2-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
86. (S)-N-{3-[4-(4-(2-methyl-2H-tetrazol-5-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
87. (S)-N- { 3 - [4-(4-( 1 -methyl- lH-tetrazol-5-yl)-ρiperidin- 1 -yl)-3-fluorophenyl] -2-oxo- oxazolidin-5-ylmethyl } -acetamide;
88. (S)-N- { 3-[4-(4-(2-methyl-2H-tetrazol-5-yl)-piperidin- l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
89. (S)-N-{3-[4-(4-(l-methyl-lH-tetrazol-5-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide; 90. (R)-{3-[4-(4-(2-methyl-2H-tetrazol-5-yl)-piperidin-l-yl)-3-fluorophenyl]-5-(lH-[l,2,3J- triazol-lylmethyl)-oxazolidin-2-one; 91. (R)-{3-[4-(4-(l-methyl-lH-tetrazol-5-yl)-piperidin-l-yl)-3-fluorophenyl]-5-(lH-[l,2,3]- triazol-l-ylmethyl)}-oxazolidin-2-one;
92. (S)-N-{3-[4-(4-(l-methyl)-lH-tetrazol-5-ylmethyl-piperidin-l-yl)-3,5-difluoro-phenyl]-2- oxo-oxazolidin-5-ylmethyl }-acetamide;
93. (S)-N-{3-[4-(4-(2-methyl)-2H-tetrazol-5-ylmethyl-piperidin-l-yl)-3,5-difluoro-phenyl]-2- oxo-oxazolidin-5-ylmethylJ-acetaniide; 94. (S)-N-{3-[4-(4-(l-methyl-lH-tetrazol-5-ylmethyl)-piperidin-l-yl)-3-fluoro-phenyl]-2- oxo-oxazolidin-5-ylmethyl }-acetamide; 95. (S)-N-{3-[4-(4-(2-methyl-2Η-tetrazol-5-ylmethyl)-piperidin-l-yl)-3-fluoro-phenyl]-2- oxo-oxazolidin-5-ylmethyl} -acetamide; 96. (S)-N-{3-[4-(4-(5-methylsulfanylmethyl-2H-tetrazol-2-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; 97. (S)-N-{3-[4-(4-(5-methylsulfanylmethyl-lH-tetrazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
98. (S)-N-{3-[4-(4-(5-methylsulfanylmethyl-2H-tetrazol-2-yl)-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide; 99. (S)-N- { 3-[4-(4-(5-methylsulf anylmethyl- lH-tetrazol- l-yl)-piperidin- 1 -yl)-3 ,5- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; 100. (S)-N-{3-[4-(4-(5-benzylsulfanyl-iH-tetrazol-l-yl)-ρiρeridin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
101. (S)-N-{3-[4-(4-(5-(benzylsulfanyl)-2H-tetrazol-2-yl)-ρiperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide; 102. (S)-N-{ 3-[4-(4-(5-(benzylsulfanyl)-2H-tetrazol-2-yl)-ρiρeridin-l-yl)-3-fluoroρhenyl]- 2-oxo-oxazolidin-5-ylmethyl}-acetamide;
103. (S)-N-{3-[4-(4-(5-(benzylsulfanyl)-2H-tetrazol-2-yl)-piρeridin-l-yl)-3-fluorophenyl]- 2-oxo-oxazolidin-5-ylmethyl}-acetamide;
104. (S)-N-{3-[4-(4-(5-methylsulfonylmethyl-lH-tetrazol-l-yl)-piρeridin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl} -acetamide;
105. (S)-N-{3-[4-(4-(5-methylsulfonylmethyl-lH-tetrazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
106. (S)-N-{3-[4-(4-(5-(thiophen-2-yl-methyl)-lH-tetrazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; 107. (S)-N-{3-[4-(4-(5-(thioρhen-2-yl-methyl)-lH-tetrazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
108. (S)-N-{3-[4-(4-(5-(thiophen-2-yl-methyl)-lH-tetrazol-l-yl)-ρiperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
109. (S)-N-{3-[4-(4-(5-(thiophen-2-yl-methyl)-2H-tetrazol-2-yl)-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
110. (S)-N-{ 3-[4-(4-(5-(morpholinocarbonylmethyl)-lH-tetrazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
111. (S)-N-{ 3-[4-(4-(5-(morpholinocarbonylmethyl)-lH-tetrazol-l-yl)-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; 112. (S)-N-{3-[4-(4-(5-(moφholin-4-yl)-2H-tetrazol-2-yl)-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
113. (S)-N-{ 3-[4-(4-(5-(moφholin-4-yl)-2H-tetrazol-2-yl)-piperidin-l-yl)-3-fluorophenyl]- 2-oxo-oxazolidin-5-ylmethyl}-acetamide;
114. (S)-N-{ 3-[4-(4-(5-phenyl-2H-tetrazol-2-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2- oxo-oxazolidin-5-ylmethyl} -acetamide;
115. (S)-N-{3-[4-(4-(5-phenyl-2H-tetrazol-2-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
116. (S)-N-{3-[4-(4-(5-(4-nitrophenyl)-2H-tetrazol-2-yl)-piperidin-l-yl)-3-fluorophenyl]- 2-oxo-oxazolidin-5-ylmethyl} -acetamide; 117. (S)-N- {3-[4-(4-(5-(4-nitrophenyl)-2H-tetrazol-2-yl)-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
118. (S)-N-{3-[4-(4-(5-(4-pyridinyl)-lH-tetrazol-l-yl)-piperidin-l-yl)-3-fluoroρhenyl]-2- oxo-oxazolidin-5-ylmethyl}-acetamide; 119. (S)-N-{3-[4-(4-(5-(3-pyridinyl)-2H-tetrazol-2-yl)-piperidin-l-yl)-3-fluoroρhenyl]-2- oxo-oxazolidin-5-ylmethyl}-acetamide;
120. (S)-N-{3-[4-(4-(5-(4-pyridinyl)-lH-tetrazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]- 2-oxo-oxazolidin-5-ylmethyl}-acetamide;
121. (S)-N-{3-[4-(4-(5-(3-pyridinyl)-2H-tetrazol-2-yl)-piperidin-l-yl)-3,5-difluorophenyl]- 2-oxo-oxazolidin-5-ylmethyl }-acetamide;
122. (S)-N-{3-[4-(4-(5-amino-2H-tetrazol-2-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
123. (S)-N-{3-[4-(4-(5-amino-2//-tetrazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylrnethyl } -acetamide; 124. (S)-N-{3-[4-(4-(5-(diethylamino)-2H-tetrazol-2-yl)-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl} -acetamide;
125. (S)-N-{3-[4-(4-(5-(piperazin-l-yl)-2Η-[l,2,3,4],-tetrazol-2-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
126. (S)-N-{3-[4-(4-(5-(piperazin-l-yl)-2H-tetrazol-2-yl)-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl }-acetamide;
127. (S)-N- { 3-[4-(4-(5-(4-methylpiρerazm- 1 -yl)-2H-tetrazol-2-yl)-piperidin- 1 -yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
128. (S)-N-{3-[4-(4-(5-(4-methylpiperazin-l-yl)-2H-tetrazol-2-yl)-ρiperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; 129. (S)-N- { 3-[4-(4-(5-(4-acetyl-piperazin- 1 -yl)-2/i-tetrazol-2-yl)-ρiperidin- 1 -yl)-3 - fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
130. (S)-N-{3-[4-(4-(5-(4-acetyI-ρiρerazin-l-yl)-2H-tetrazol-2-yl)-piρeridin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
131. (S)-N-{3-[4-(4-(5-(4-cyanopiperazin-l-yl)-2H-tetrazol-2-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl} -acetamide;
132. (S)-N-{3-[4-(4-(5-(4-cyanopiperazin-l-yl)-2H-tetrazol-2-yl)-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
133. (S)-N-{3-[4-(4-(5-(4-benzylpiρerazin-l-yl)-2Η-tetrazol-2-yl)-ρiperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; 134. (S)-N-{3-[4-(4-(5-(4-benzylpiρerazin-l-yl)-2H-tetrazol-2-yl)-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidm-5-ylmethyl} -acetamide;
135. (S)-N-{ 3-[4-(4-lH-tetrazol-5-ylmethyl-piperidin- l-yl)-3-fluoro-phenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide; 136. (S)-N-{ 3-[4-(4-lH-tetrazol-5-ylmethyl-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
137. (S)-N-{3-[4-(4-([l,2)3]-triazol-l-yl-methyl)-piperidin-l-yl)-3-fluoro-phenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
138. (R)-{3-[4-(4-(lH-tetrazol-l-yl)-piperidin-l-yl)-3-fluoroρhenyl]-5-(lH-[l,2,3]-triazol- l-ylmethyl)}-oxazolidin-2-one;
139. (R)-{3-[4-(4-(2H-tetrazol-2-yl)-piperidin-l-yl)-3-fluorophenyl]-5-(lH-[l,2,3]-triazol- 1-ylmethyl) }-oxazolidin-2-one;
140. (S)-{3-[4-(4-(tetrazol-5-yl)-piperidin-l-yl)-3-fluorophenyl]-5-(lH-[l,2,3]-triazol-l- ylmethyl) }-όxazolidin-2-one; 141. (S)-N-{ 3-[4-(4-(5-niethyl-[l,2,4]-oxadiazol-3-yl)-piperidin-l-yl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-acetamide;
142. (S)-N-{3-[4-(4-(5-methyl-[l,2,4]-oxadiazol-3-ylmethyl)-piperidin-l-yl)-3-fluoro- phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
143. (S)-N-{3-[4-(4-(5-methyl-[l,2,4]-oxadiazol-3-ylmethyl)-piρeridin-l-yl)-3,5-difluoro- phenyl]-2-oxo-oxazolidin-5-ylmethyl} -acetamide;
144. (S)-N-{3-[4-(4-(5-phenyl-[l,2,4]-oxadiazol-3-ylmethyl)-piperidin-l-yl)-3-fluoro- phenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
145. (S)-N-{3-[4-(4-(5-phenyl-[l,2,4]-oxadiazol-3-ylmethyl)-piperidin-l-yl)-3,5-difluoro- phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; 146. (S)-N-{ 3-[4-(4-((5-pyridm-3-yl)-[l,2,4]-oxadiazol-3-ylmethyl)-piperidin-l-yl)-3- fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
147. (S )-N- { 3- [4-(4-(5 -methyl-[ 1 ,3 ,4] -oxadiazol-2-ylmethyl)-piperidin- 1 -yl)-3-fluoro- phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
148. (S)-N-{3-[4-(4-(5-phenyl-[l,3,4]-oxadiazol-2-ylmethyl)-piperidin-l-yl)-3-fluoro- phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
149. (S)-N-{3-[4-(4-(5-Amino-2H-[l,3,4]-thiadiazol-2-yl)-piperidin-l-yl)-3-fluorophenyl]- 2-oxo-oxazolidin-5-ylmethyl}-acetamide;
150. (S)-N-{3-[4-(4-(5-Amino-[l,3,4]-thiadiazol-2-yl)-piperidin-l-yl)-3,5-difluoro- phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; 151. (S)-N-{3-[4-(4-(5-Amino-[l,3,4]-thiadiazol-2-ylmethyl)-piperidin-l-yl)-3,5-difluoro- phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
152. (S)-N-{3-[4-(4-(3-ethoxycarbonyl-imidazol-l-yl)-methyl-piperidin-l-yl)-3-fluoro- phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; 153. (S)-N-{ 3-[3,5-Difluoro-4-(4-2H-tetrazol-2-yl-piρeridin-l-yl)-ρhenyl]-2-oxo- oχazolidin-5-ylmethyl}-carbamic acid methyl ester;
154. (S)-N-{3-[3,5-Difluoro-4-(4-lH-tetrazol-l-yl-ρiρeridin-l-yl)-ρhenyl]-2-oxo- oxazolidin-5-ylmethyl}-carbamic acid methyl ester;
155. (S)-N-{3-[3,5-Difluoro-4-(4-[l,2,3]-triazol-l-yl-piperidin-l-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-carbamic acid methyl ester;
156. (S)-N-{3-[3-fluoro-4-(4-2H-tetrazol-2-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl }-carbamic acid methyl ester;
157. (S)-N-{3-[3-fluoro-4-(4-iH-tetrazol-l-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl }-carbamic acid methyl ester; 158. (S)-N-{3-[4-(4-2H-[l,2,3]-triazol-2-yl-piperidin-l-yl)-3,5-difluoro phenyl] -2-oxo- oxazolidin-5-ylmethyl}-carbamic acid methyl ester;
159. (S)-N-{3-[3,5-Difluoro-4-(4-[l,2,3]triazol-2-yl-piperidin-l-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-2,2-difluoro-acetamide;
160. (S)-N-{3-[3,5-Difluoro-4-(4-[l,2,3]-triazol-l-yl-ρiperidin-l-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl }-2,2-difluoro-acetamide;
161. (S)-N-{ 3-[3,5-Difluoro-4-(4-tetrazol-2-yl-piperidin-l-yl)-phenyl]-2-όxo-oxazolidm-5- ylmethyl}-2,2-difluoro-acetamide;
162. (S)-N-{3-[3,5-Difluoro-4-(4-[l,2,3,4]-triazol-l-yl-piperidin-l-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl }-2,2-difluoro-acetamide; 163. (S)-N-{ 3-[3,5-Difluoro-4-(4-2H-tetrazole-2-yl-piperidin-l-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-2,2-dichloro-acetamide;
164. (S)-N-{3-[3-fluoro-4-(4-2H-tetrazol-2-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl }-carbamic acid ethyl ester;
165. (S)-N-{3-[3,5-Difluoro-4-(4-lH-tetrazole-l-yl-piperidin-l-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl }-2,2-difluoro-thioacetamide;
166. (S)-N-{3-[3,5-Difluoro-4-(4-lH-tetrazole-l-yl-piperidin-l-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl } -cyclopropane carboxamide;
167. (S)-N-{3-[3,5-Difluoro-4-(4-[l,2,3]-triazol-l-yl-piperidin-l-yl)-ρhenyl]-2-oxo- oxazolidin-5-ylmethyl}-propionamide; 168. (S)-N-{3-[3,5-Difluoro-4-(4-[l,2,3]-triazol-2-yl-piperidin-l-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl } -propionamide;
169. (S)-N-{3-[3,5-Difluoro-4-(4-2H-tetrazol-2-yl-piperidin-l-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl } -propionamide; 170. (S)-N-{ 3-[3,5-Difluoro-4-(4-lH-tetrazol-l-yl-piρeridin-l-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-ρropionamide;
171. (S) N-{ 3-[3-Fluoro-4-(4-2H-tetrazol-2-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl } -propionamide;
172. (S) N- { 3-[3-Fluoro-4-(4-lH-tetrazol-l-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl}-propionamide;
173. (S)-N-{3-[3,5-Difluoro-4-(4-[l,2,3]triazol-2-yl-piperidin-l-yl)-ρhenyl]-2-oxo- oxazolidin-5-ylmethyl}-propionamide;
174. (S)-N-{3-[3,5-Difluoro-4-(4-[l,2,3]-triazol-l-yl-piperidin-l-yl)-phenyl]-2-oxo- oxazolidin-5'-ylmethyl}-propionamide; 175. (S)-N-{ 3-[3,5-Difluoro-4-(4-(5-methyl-tetrazol-2-yl)-piperidin-l-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-propionamide;
176. (S)-N-{ 3-[3,5-Difluoro-4-(4-(5-methyl-tetrazol- l-yl)-piperidin-l-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl } -propionamide;
177. (S)-N-{3-[3,5-Difluoro-4-(4-(4-methyl-5-thioxo-4,5-dihydro-tetrazol-l-yl)-piperidin- l-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
178. (S)-N-{3-[3,5-Difluoro-4-(4-(4-methyl-5-thioxo-4,5-dihydro-[l,2,4]triazol-l-yl)- piperidin- l-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetaraide;
179. (S)-N-{3-[3-fluoro-4-(4-(4-methyl-5-thioxo-4,5-dihydro-[l,2,4]triazol-l-yl)- piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; 180. (S)-N-{3-[4-(4-(isoxazol-3-yloxymethyl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
181. (S)-N-{3-[4-(4-([l,2,3]-triazol-l-yl)-methyl-piperidin-l-yl)-3-fluoro-phenyl]-5- (isoxazol-3-yloxymethyl)}-oxazolidin-2-one;
182. (R)-{3-[4-(4-((4-hydroxymethyl)-[l,2,3]-triazol-l-yl)-methyl-piperidin-l-yl)-3- fluoro-phenyl]- 5-(isoxazol-3-yloxymethyl)}-oxazolidin-2-one;
183. cJ5-(R)-{3-[4-(4-(5-ethoxycarbonyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-5-(5-ethoxycarbonyl-lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
184. cw-(R)-{3-[4-(4-(5-ethoxycarbonyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluoro- phenyl]-5-(4-ethoxycarbonyl-lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one; 185. ?ram-;(R)-{3-[4-(4-(5-ethoxycarbonyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluoro-phenyl]-5-(5-ethoxycarbonyl-lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
186. ?rαm-(R)-{3-[4-(4-(5-ethoxycarbonyl-lH-[l,2,3]-triazol-l-yl)-ρiperidin-l-yl)-3- fluoro-phenyl]-5-(4-ethoxycarbonyl-lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one; 187. ?rα7W-(R)-{3-[4-(4-(5-hydroxymethyl-lΗ-[l,2,3]-triazol-l-yl)-piρeridin-l-yl)-3- fluoro-phenyl] -5-(4-hydroxymethyl- lH-[ 1 ,2,3]-triazol-l -ylmethyl) }-oxazolidin-2-one;
188. ?ram-(R)-{3-[4-(4-(5-hydroxymethyl-lΗ-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluoro-phenyl] -5 -(5 -hydroxymethyl- IH- [ 1 ,2 ,3 ] -triazol- 1 -ylmethyl) } -oxazolidin-2-one ;
189. traw-(R)-{3-[4-(4-(5-cyano-lH-[l,2,3]-triazol-l-yl)-ρiperidin-l-yl)-3-fluoro-phenyl]- 5-(5-cyano-lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
190. trαn5-(R)-{3-[4-(4-(5-cyano-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluoro-phenyl]- 5~(4-cyano-lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
191. (3R,5S)-N-{3-[4-(Fluoro-4-(lH-[l,2,3]-triazol-l-yl)-ρiperidin-l-yl)-3-fluoro-phenyl]- 2-oxo-oxazolidin-5-ylmethyl}-acetamide; 192. (R)-{ 3-[4-(4-(5-ethoxycarbonylmethyl-2H-tetrazol-2-yl)-piperidin-l-yl)-3,5- difluoropheny^-S-ClΗ-f 1 ,2,3]-triazol- 1 -ylmethyl) } -oxazolidin-2-one;
193. (S)-N-{3-[4-(4-(5-hydroxyethyl-2H-tetrazol-2-yl)-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
194. (S)-N-{3-[4-(4-(5-acetylaminomethyl-2H-tetrazol-2-yl)-piρeridin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
195. (R)-{ 3-(4-phenyl-3-fluorophenyl)-5-iH-[l ,2,3]-triazol-l-ylmethyl}-5xazolidin-2-one;
196. (R)-{3-(4-phenyl-3-fluorophenyl)-5-iH-[l,2,4]-triazol-l-ylmethyl}-oxazolidin-2-one;
197. (R)-{3-(4-phenyl-3-fluorophenyl)-5--rH-[l,2,3]-triazol-2-ylmethyl}-oxazolidin-2-one;
198. (R)-{3-[4-(4-(piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl }-methanesulfonate;
199. (S)-N-{3-[4-(4-(piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo-oxazolidin- 5-ylmethyl } -acetamide;
200. (S)-{3-[4-(4-(piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-5-imidazol-l- ylmethyl }-oxazolidin-2-one; 201. (R)-{3-[4-(4-(piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-5-iH-/'i)2,37-triazol-
1 -ylmethyl } -oxazolidin-2-one;
202. (R)-{3-[4-(4-(piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-5-iH-/"i,2,37-triazol- 2-ylmethyl }-oxazolidin-2-one; 203. (R)-{3-[4-(4-(ρiperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-5-iH-tetrazol-l- ylmethyl } -oxazolidin-2-one;
204. (S)-N-{3-[4-(4-(4,4-dimethoxypiperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-acetamide; 205. (R)-{3-[4-(4-(l,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl)-3-fluorophenyl]- 2-oxo-oxazolidin-5-ylmethyl}-methanesulfonate;
206. (S)-N-{3-[4-(4-(l,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
207. (S)-N-{3-[4-(6-(l,4-dioxa-8-azaspiro[4.5]dec-8-yl)-pyridin-3-yl)-3-fluorophenyl]-2- oxo-oxazolidm-5-ylniethyl }-acetamide;
208. (R)-{3-[4-(4-(4-oxo-piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -methanesulfonate;
209. (S)-N-{3-[4-(4-(4-oxo-piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide; 210. (R)-{3-[4-(4-(4-hydroxy-piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-methanesulfonate;
211. (S)-N-{3-[4-(4-(4-hydroxy-piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
212. (S)-N-{3-[4-(6-(4-hydroxy-piperidin-l-yl)-ρyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
213. (R)-{3-[4-(4-(4-methanesulfonyloxy-piperidin-l-yl)-3-fluorophenyl)-3- fluorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } -methanesulfonate ;
214. (S)-N-{3-[4-(4-(4-methanesulfonyloxy-piperidin-l-yl)-3-fluorophenyl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; 215. (S)-N-{3-[4-(6-(4-methanesulfonyloxy-piperidm-l-yl)-pyridin-3-yl)-3- fluorophenyl] -2-oxo-oxazolidin-5-ylmethyl }-acetamide;
216. (S)-N-{3-[4-(4-(4-cyanomethylidene-piperidin-l-yl)-3-fluorophenyl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
217. (R)-{3-[4-(4-(4-cyanomethylidene-piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]- 5-(iH-[l,2,3]-triazol-l-yl)-methyl}-oxazolidin-2-one;
218. (R)-{3-[4-(4-(4-cyanomethylidene-piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]- 5-(iH-tetrazol- 1 -yl)methyl } -oxazolidin-2-one;
219. (S)-N-{3-[4-(4-(4-cyanomethyl-3,4-dehydropiperidin-l-yl)-3-fluorophenyl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; 220. (S)-N-{3-[4-(4-(4-cyanomethyl-piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-2- oxo-oxazolidm-5-ylmethyll-acetamide;
221. (S)-N-{3-[4-(4-(4-hydroxy-4-hydroxymethyl-piρeridin-l-yl)-3-fluorophenyl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; 222. (S)-N- { 3 -[4-(4-(4-azidomethyl-4-hydroxy-piperidin- 1 -yl)-3-fluorophenyl)-3- fluorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide;
223. (S)-N-{3-[4-(4-(4-(i/ϊ-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl)-3- fluorophenyl]-2-oxo-oxazolidm-5-ylmethyl}-acetamide and isomer thereof;
224. (S)-N-{3-[4-(4-(4-(iH-tetrazol-l-yl)-piperidin-l-yl)-3-fluorophenyl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide and isomer thereof ;
225. (S)-N- { 3 -[4-(6-(4-Oxopiperidin- 1 -yl)-pyridin-3-yl)-3 -fluorophenyl] -2-oxo- oxazolidin-5-ylmethyl }-acetamide;
226. (S)-N-{3-[4-(6-(4-Hydroxy-4-methoxymethylpiperidin-l-yl)-pyridin-3-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; 227. (S)-N-{3-[4-(6-(4-HydrQxy-4-acetyloxymethylpiperidin-l-yl)-pyridin-3-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
228. (R)-{3-[4-(4-(ρiperazin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-5-7H-/'i,2,37-triazol- 1 -ylmethyl } -oxazolidin-2-one;
229. (R)-{3-[4-(4-(piperazin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-5-iH-tetrazol-l- ylmethyl } -oxazolidin-2-one;
230. (R)- { 3 - [4-(4- (piperazin- 1 -yl)-3 -fluorophenyl)-3-fluorophenyl] -2-oxo-oxazolidin-5 - ylmethyl } -methanesulf onate hydrochloride;
231. (R)-{3-[4-(4-(piρerazin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-5-(l,2,3-triazol-l- yl)methyl }-oxazolidin-2-one hydrochloride; 232. (S)-{3-[4-(4-(4-hydroxymethylcarbonyl-piperazin-l-yl)-3-fluorophenyl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
233. (R)-{3-[4-(4-(4-(2-nitrofuran-5-yl-methyl)-ρiperazin-l-yl)-3-fluoroρhenyl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -methanesulf onate;
234. (S)-N-{3-[4-(4-(4-(2-nitrofuran-5-yl-methyl)-piρerazin-l-yl)-3-fluorophenyl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl} -acetamide;
235. (R)-{3-[4-(4-(4-benzyloxycarbonyl-piperazin-l-yl)-3-fluorophenyl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-methanesulfonate;
236. (S)-{3-[4-(4-benzyloxycarbonyl-piperazin-l-yl-3-fluorophenyl)-3-fluorophenyl]-5- IH-[1, 2,3 ]-tήazo\- 1 -ylmethyl } -oxazolidin-2-one; 237. (S)-N-{3-[4-(4-benzyloxycarbonyl-piperazin-l-yl-3-fluorophenyl)-3-fluorophenyl]- 2-oxo-oxazolidin-5-ylmethyl}-acetamide;
238, (S)-N- {3-[4-(4-(l-oxa-6-azaspiro[2.5]oct-6-yl)-3-fluorophenyl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-acetarnide; 239. (S)-N-{3-[4-(4-(moφholin-l-yl)-phenyl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl } -acetamide;
240. (S)-N-{3-[4-(4-(thiomorpholin-4-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
241. (S)-N- {3 -[4-(6-(thiomorρholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl }-methanesulfonate;
242. (S)-N-{3-[4-(6-(thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
243. (R)-{3-[4-(6-(Thiomoφholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo-oxazolidin -5-ylmethyl }-methansulphonate; 244. (S)-N-{3-[4-(6-(Thiomoφholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-formamide;
245. (S)-N-{3-[4-(6-(Thiomoφholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-propionamide;
246. (S)-{3-[4-(6-(thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo-oxazolidin- 5-ylmethyl }-carbamic acid methyl ester;
247. (S)-{3-[4-(6-thiomoφholin-4-yl-pyridin-3-yl)-3-fluorophenyl]-5-[l,2,3]-triazol-l- ylmethyl }-oxazolidin-2-one;
248. (S)-N-{3-[6-(6-(Thiomoφholin-4-yl)-pyridin-3-yl)-pyridin-3-yl]-2-oxo-oxazolidin- 5-ylmethyl }-acetamide; 249. (S)-N- {3-[6-(4-(Thiomoφholin-4-yl)-3-fluorophenyl)-pyridin-3-yl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
250. (S)-N- {3-[4-(6-(Thiomoφholin-4-yl)-pyridin-3-yl)-phenyl]-2-oxo-oxazolidin-5-yl methyl } -acetamide ;
251. (S)-N- { 3-[4-(2-(Thiomoφholin-4-yl)-pyrimidin-5-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl }-carbamic acid methyl ester;
252. (S)-N-{3-[4-(2-(Thiomoφholin-4-yl)-pyrimidin-5-yl)-3-fluorophenyl]-5- hydroxymethyl } -oxazolidin-2-one;
253. (S)-N-{3-[4-(2-(Thiomoφholin-4-yl)-pyrimidin-5-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide; 254. (S)-N-{3-[4-(2-(Thiomoφholin-4-yl)-pyrimidin-5-yl)-3-fluorophenyl]-5-[l,2,3]- triazol-l-ylmethyl}-oxazolidin-2-one;
255. (S)-N-{3-[4-(6-(Thiomoφholin-4-yl)-3-methylρyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-carbamic acid methyl ester; 256. (S)-N-{3-[4-(6-(Thiomoφholin-4-yl)-3-methylpyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethylJ-acetamide;
257. (S)-N-{3-[4-(6-(Thiomoφholin-4-yl)-3-methylpyridin-3-yl)-3-fluorophenyl]-5- hydroxymethylJ-oxazolidin-2-one;
258. (S)-N-{3-[4-(6-(Thiomoφholin-4-yl)-3-methylρyridm-3-yl)-3-fluorophenyl]-5- [l,2,3]-triazol-l-ylmethyl}-oxazolidin-2-one;
259. (S)-N- {3-[4-(2-(S-Oxo-thiomorpholin-4-yl)-pyrimidin-5-yl)-3-fluorophenyl]-5- hydroxymethyl } -oxazolidin-2-one ;
260. (S)-N-{3-[4-(4-(S-oxo-thiomorpholin-4-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide ; 261. (S)-N-{3-[6-[6-(S-oxo-thiomorpholin-4-yl)-pyridin-3-yl]-pyridin-3-yl]-2-oxo- oxazolidin-5-ylmethyl }-acetamide;
262. (S)-N-{3-[4-(6-(S-oxo-thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
263. (^-{S-K-Cό-CS-Oxo-thiomorpholin^-yO-pyridin-S-y^-S-fluoropheny^^-oxo- oxazolidin-5-ylniethyl }-methansulphonate;
264. (S)-N-{3-[4-(6-(S-Oxo-thiomorpholin-4-yl)-pyridin-3-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
265. (S)-N-{3-[4-(2-(S-Oxo-thiomorpholin-4-yl)-pyrimidin-5-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-carbamic acid methyl ester; 266. (S)-N-{3-[4-(2-(S-Oxo-thiomorpholin-4-yl)-pyrimidin-5-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-yl methyl}- acetamide;
267. (S)-N-{3-[4-(2-(S-Oxo-thiomorρholin-4-yl)-pyrimidin-5-yl)-3-fluorophenyl]-5- [l,2,3]-triazol-l-ylmethyl}-oxazolidin-2-one;
268. (S)-N-{3-[4-(6-(S-Oxo-thiomorρholin-4-yl)-ρyrimidin-5-yl)-3-fluorophenyl]-5- hydroxymethyl} -oxazolidin-2-one;
269. (S)-N-{3-[4-(6-(S-Oxo-thiomorpholin-4-yl)-3-methylpyridin-3-yl)-3-fluorophenyl]- 2-oxo-oxazolidin-5-ylmethyl}-carbamic acid methyl ester;
270. (S)-N-{3-[4-(6-(S-Oxo-thiomorpholin-4-yl)-3-methylpyridin-3-yl)-3-fluorophenyl]- 5-[l,2,3]-triazol-l-ylmethyl}-oxazolidin-2-one; 271. (S)-N-{3-[4-(6-(S-Oxo-thiomorpholin-4-yl)-3-methylpyridin-3-yl)-3-fluorophenyl]- 5-hydroxymethyl } -oxazolidin-2-one;
272. (S)-N-{3-[4-(6-(S-Oxo-thiomorpholin-4-yl)-3-methylpyridin-3-yl)-3-fluorophenyl]- 2-oxo-oxazolidin-5 -ylmethyl } -acetamide; 273. (S)-N-{3-[4-(6-(S-oxo-3-fluoro-thiomoφholin-4-yl)-pyridin-3-yl)-3-fluoroρhenyl]- 2-oxo-oxazolidin-5-ylmethyl}-acetamide;
274. (S)-N-{3-[4-(6-(S,S-dioxo-thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2- oxo-ox. azolidin-5-ylmethyl}-acetainide;
275. (S)-N-{3-[4-(6-(S,S-dioxo-thiomoφholin-4-yl)-pyridin-3-yl)-3,5-difluorophenyl]-2- oxo-oxazolidin-5-ylmethyl }-acetamide;
276. (S)-N-{3-[4-(6-(S,S-dioxo-3-methyl-thiomorpholin-4-yl)-pyridin-3-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
277. (S)-N-{3-[4-(4-(S,S-dioxo-thiomoφholin-4-yl)-3-fluorophenyl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-acetamide; 278. (S)-N-{3-[6-[6-(S,S-dioxo-thionioφholin-4-yl)-pyridin-3-yl]-pyridin-3-yl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
279. (S)-N-{3-[6-(4-(S,S-dioxo-thiomoφholin-4-yl)-3-fluorophenyl)-pyridin-3-yl]-2- oxo-oxazolidin-5-ylmethyl}-acetamide;
280. (R)-3-{4-[6-(S,S-dioxo-thiomoφholin-4-yl)-pyridin-3-yl]-3-fluorophenyl}-5- hydroxymethyl-oxazolidin-2-one;
281. (2S ,5R)-2- Amino-propionic acid 3- {4-[6-(S,S-dioxo-thiomoφholi'n-4-yl)-pyridin-3- yl]-3-fluoro-phenyl }-2-oxo-oxazolidin-5-ylmethyl ester;
282. (2S,5R)-2- Amino-propionic acid 3-{4-[6-(S,S-dioxo-thiomoφholin-4-yl)-pyrid in- 3-yl]-3-fluoro-phenyl}-2-oxo-oxazolidin-5-ylmethyl ester methanesulfonic acid salt; 283. (2S,5R)-2-Amino-3-methyl-butyric acid 3-{4-[6-(S,S-dioxo-thiomorpholin-4-yl)- pyridin-3-yl]-3-fluoro-phenyl}-2-oxo-oxazolidin-5-ylmethyl ester;
284. (2S,5R)-2-Amino-3-methyl-butyric acid 3-{4-[6-(S,S-dioxo-thiomorpholin-4-yl)- pyridin-3-yl]-3-fluoro-phenyl}-2-oxo-oxazolidin-5 -ylmethyl ester methane sulfonic acid salt; 285. (R)-Acetic acid 3-{4-[6-(SJS-dioxo-thiomoφholin-4-yl)-pyridin-3-yl]-3-fluoro- phenyl}-2-oxo-oxazolidin-5-ylmethyl ester;
286. (S)-N-{ 3-[4-(6-(S ,S-Dioxo-thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl } -formamide; 287. (^-{S-tΦCό-CS^-Dioxo-thioraorpholin^-y^-pyridin-S-yO-S-fluorophenyll^-oxo- oxazolidin-5-ylniethyl}-rnethansulphonate;
288. (S)-N-{3-[4-(6-(S,S-Dioxo-thiomoφholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl }-propionamide; 289. (S)-N-{3-[4-(6-(S,S-Dioxo-thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2- oxo-oκazolidin-5-ylmethyl }-carbamic acid methyl ester;
290. N-Acetyl-(R)-N-{3-4-{2-(S,S-Dioxo-thiomoφholin-4-yl)-pyridyl-5-yl-3- fluorophenyl-1-yl-] }-2-oxo-oxazolidin-5-yl methyl }-aminocarbonyl-oxymethyl acetate;
291. (S)-N-{3-[4-'(6-(S,S-Dioxo-thiomoipholm-4-yl)-pyridin-3-yl)-3-fluorophenyl]-5- [l,2,3]-triazol-l-ylmethyl}-oxazolidin-2-one;
292. (S)-N-{3-[4-(6-(S,S-Dioxo-thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-urea;
293. (S)-N-{3-[4-(6-(S,S-Dioxo-thiomorpholin-4-yl)-pyridin-3-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide; 294. (S)-N-{3-[6-(6-(S,S-Dioxo-thiom.θφholin-4-yl)-pyridin-3-yl)-pyridin-3-yl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
295. (S)-N-{3-[4-(2-(S,S-Dioxo-thiomoφholin-4-yl)-pyrimidin-5-yl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-carbamic acid methyl ester;
296. (S)-N-{3-[4-(2-(S,S-Dioxo-thiomoφholin-4-yl)-pyrimidin-5-yl)-3-fluorophenyl]-5- hydroxymethyl}-oxazolidin-2-one;
297. (S)-N-{3-[4-(2-(S,S-Dioxo-thiomoφholm-4-yl)-pyrimidin-5-yl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-acetamide;
298. (S)-N-{3-[4-(2-(S,S-Dioxo-thiomoφholin-4-yl)-pyrimidin-5-yl)-3-fluorophenyl]-5- [l,2,3]-triazol-l-ylmethyl}-oxazolidin-2-one; 299. (S)-N-{3-[4-(6-(S,S-Dioxo-thiomoφholin-4-yl)-3-methylpyridin-3-yl)-3- fluoroρhenyl]-2-oxo-oxazolidin-5-ylmethyl}-carbamic acid methyl ester;
300. (S)-N-{3-[4-(6-(S,S-Dioxo-thiomoφholin-4-yl)-3-methylpyridin-3-yl)-3- fluorophenyl]-5-hydroxymethyl }-oxazolidin-2-one;
301. (S)-N-{3-[4-(6-(S,S-Dioxo-thiomoφholin-4-yl)-3-methylpyridin-3-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
302. (S)-N-{3-[4-(6-(S,S-Dioxo-thiomoφholin-4-yl)-3-methylpyridin-3-yl)-3- fluorophenyl]-5-[l ,2,3]-triazol- 1-ylmethyl }-oxazolidin-2-one;
303. (S)-N-{3-[4-(6-(S,S-Dioxo-3-methyl-thiomoφholin-4-yl)-pyridin-3-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-difluoroacetamide; 304. (S)-N-{3-[4-(6-(S-Oxo-S-(N-methylimino)-thiomorpholin-4-yl)-pyridyl-3-yl)-3- fluorophenyl-1 -yl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
305. (S)-N- { 3-[4-(6-(S-Oxo-S-(N-methylimino)-thiomorpholin-4-yl)-pyridin-3-yl)- phenyl] -2-oxo-oxazolidin-5-ylmethyl } -acetamide; 306. (S)-N-{3-[4-(6-(S-Oxo-S-(N-acetylimino)-thiomorpholin-4-yl)-pyridyl-3-yl)-3- fluorophenyl-l-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
307. (S)-N-{3-[4-(6-(S-Oxo-S-(l-chloroethylurido)-thiomorpholin-4-yl)-pyridyl-3-yl)-3- fluorophenyl-1 -yl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
308. (S)-N- {3-[4-(6-(S-Oxo-S-imino-thiomorpholin-4-yl)-pyridyl-3-yl)-3-fluorophenyl- l-yl]-2-oxo-oxazolidin-5-ylmethyl }-acetamide;
309. (S)-N-{3-[4-(6-(l,4-Dioxa-8-azaspiro[4.5]dec-8-yl)-pyridin-3-yl)-3-fluorophenyl]- 2-oxo-oxazolidin -5-ylmethyl }-acetamide;
310. (S)-N-{3-[4-(6-(S-Oxo-3,3-dichloro-thiomorpholin-4-yl)-pyridin-3-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide; 311. (R)-Phosphoric acid { 3-[4-(6-(S,S-dioxo-thiomoipholin-4-yl)-pyridin-3-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl} ester disodium salt;
312. Phosphoric acid mono (R)- N-{3-{4-{2-(thiomorpholin-4-yl) -pyrimidin-5-yl}-3~ fluorophenyl]} -2-oxo-oxazolidin -5-yl methyl} ester;
313. Phosphoric acid mono (R)- N-{3-{4-{2-(S-oxo-thiomorpholin-4-yl)-pyrimidin-5- yl } -3 -fluorophenyl] } -2-oxo-oxazolidin -5-yl methyl} ester;
314. Phosphoric acid mono (R)- N-{ 3- {4-{ 2-(S,S-dioxo-thiomorpholin-4-yl) -pyrimidin- 5 -yl} -3 -fluorophenyl] } -2-oxo-oxazolidin -5-yl methyl} -ester;
315. (R)-Phosphoric acid mono {3-[4-(6-(S,S-dioxo-thiomorpholin-4-yl)-pyridin-3-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } ester; 316. Phosphoric acid mono (R)-N-{3-{4-{2-(S,S-Dioxo thiomorpholin-4-yl) -pyrimidin- 5 -yl} -3 -fluorophenyl] } -2-oxo-oxazolidin -5-yl methyl }-ester disodium salt;
317. (R)-Phosphoric acid mono {3-[4-(6-(thiomorpholin-4-yl)-3-methylpyridin-3-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } ester;
318. (R)-Phosphoric acid mono {3-[4-(6-(S-oxo-thiomoφholin-4-yl)-3-methylpyridin-3- yl)-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl} ester;
319. (R)-Phosphoric acid mono {3-[4-(6-(S,S-dioxo-thiomorpholin-4-yl)-3- methylpyridin-3-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl} ester;
320. (R)-Phosphoric acid mono {3-[4-(6-(S-oxo-thiomorpholin-4-yl)-3-methylpyridin-3- yl)-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl} ester disodium salt; 321. (5S)-iV-[3-(3'-Chloromethyl-2-fluoro-biρhenyl-4-yl)-2-oxo-oxazolidin-5-ylmethyl]- acetamide;
322. (5S)-iV-[3-(2-Fluoro-3'-fluoromethyl-biphenyl-4-yl)-2-oxo-oxazolidm-5-ylraethyl]- acetamide;
323. (5S)-Λ^-[3-(2-Fluoro-3'-azidomethyl-biphenyl-4-yl)-2-oxo-oxazolidin-5-ylmethyl]- acetamide;
324. (5S)-ΛA-[3-(3'-Aminomethyl-2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-ylmethyl]- acetamide; 325. (5S)-2-({ 4'-[5-(Acetylamino-methyl)-2^oxo-oxazolidin-3-yl]-2'-fluoro-biphenyl-3- ylmethyl } -amino)-acetamide;
326. (5S)-2-({4'-[5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-biphenyl-3- ylmethyl } -carbamoylmethyl-amino)-acetamide;
327. (5S)-{3-[2-Fluoro-l,l'-biphenyl-3'-methoxy-4-yl]-2-oxo-oxazolidin-5yl-methyl}- acetamide;
328. (5S)-{3-[(2-Fluoro-l,l'-biphenyl-3'-yl)methanol]-2-oxo-oxazolidin-5yl-methyl}- acetamide;
329. (5S)-{3-[(3,5-Difluoro-4-[6-(4-thiomorpholin-l,l-dioxide-4-yl)-3- pyridinyl]phenyl]-2-oxo-oxazolidin-5yl-methyl}-acetamide;
Particularly more preferred compounds of the invention of formula I are
(S)-N-{3-[4-(4-(lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide; (S)-N-{ 3-[4-(4-(1H-[1 ,2,3]-triazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(lH-[l,2,3]-triazol-l-yl)-3-fluoropiperidin-l-yl)-3,5-difluorophenyl]-2- oxo-oxazolidin-5-ylmethyl }-acetamide;
(S)-N-{3-[4-(4-(lH-[l,2,3]-triazol-l-yl)-3-fluoropiperidm-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl }-acetamide;
(S )-N- {3- [4-(4-( lH-tetrazol- 1 -yl)-piperidin- l-yl)-3-fluorophenyl] -2-oxo-oxazolidin-5- ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(2H-tetrazol-2-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl } -acetamide; (S)-N-{3-[4-(4-(lH-tetrazol-l-yl)-3-fluoropiperidm-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(4-formyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(4-formyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2- oxo-oxazolidin-5-ylmethyl }-acetamide;
(S)-N-{3-[4-(4-(4-formyl-lH-[l,2,3]-tπazol-l-yl)-3-fluoropiperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide; (R)-{3-[4-(4-(4-formyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]- 5-(lH-
[ 1 ,2, 3] -tri azol- 1 -ylmethyl) } -oxazolidin-2-one ; (S)-N-{3-[4-(4-(4-difluoromethyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide; (S)-N-{3-[4-(4-(4-[l,3]-Dioxolan-2-yl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-5-(lΗ-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one; (S)-N-{3-[4-(4-(5-ethoxycarbonyl-lH-[l,2,3]-triazol-l-yl)-methyl-piperidin-l-yl)-3- fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl }-acetamide;
(S)-N-{3-[4-(4-(4-ethoxycarbonyl -lH-[l,2,3]-triazol-l-yl)-3-fluoropiperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
(S )-N- { 3- [4-(4-(4-ethoxycarbonyl- lH-[ 1 ,2,3]-triazol- 1 -yl)-piperidin- 1 -yl)-3 ,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; (RJ-IS-^-CΦC^ethoxycarbonyl-lH-tl^.Sl-triazol-l-yO-piperidin-l-yO-S-fluorophenyl]-
5-(lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
(R)-{3-[4-(4-(4-ethoxycarbonyl-lH-[l,2,3]-triazol-l-yl)-ρiperidin-l-yl)-3,5- difluorophenyl]-5-(lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one; (S)-N-{3-[4-(4-(4-carboxamido-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-
2-oxo-oxazolidin-5-ylmethyl } -acetamide;
(R)-{3-[4-(4-(4-carboxamido-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-5-
( 1 H- [ 1 ,2, 3] -tri azol- 1 -y lmethyl) } -oxazolidin-2-one;
(S)-N-{3-[4-(4-(4-carboxamido-lH-[l,2,3]-triazol-l-yl)-methyl-piperidin-l-yl)-3-fluoro- phenyl]-2-oxo-oxazolidin-5-ylmethyl }-acetamide;
(S)-N-{3-[4-(4-(5-carboxamido-liϊ-[l,2,3],-triazol-l-yl)-methyl-piperidin-l-yl)-3-fluoro- phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N- { 3 -[4-(4-(4- acetyl- 1 H- [ 1 ,2,3]-triazol- l-yl)-piperidin- 1 -yl)-3 -fluorophenyl] -2-oxo- oxazolidin-5-ylmethyl}-acetamide; (S)-N-{3-[4-(4-(4-acetyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2- oxo-oxazolidin-5-ylmethyl }-acetamide;
(S)-N-{3-[4-(4-((4-((E/Z)-2-cyano-vinyl)-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl} -acetamide;
(S)-N-{3-[4-(4-(4-hydroxyimino-methyl)-lΗ-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(l-methoxyimino-methyl)-lH-[l,2,3]-triazol-l-yl)-piρeridin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(l-methoxyimino-methyl)-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide; (S)-N-{3-[4-(4-(2Η-tetrazol-2-ylmethyl)-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
(R)-{3-[4-(4-(l/ϊ-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-5-(lH-[l,2,3]- tri azol- 1-ylmethyl)} -oxazolidin-2-one;
(R)-{3-[4-(4-(lΗ-[l,2,3]-triazol-l-yl)-ρiρeridin-l-yl)-3,5-difluorophenyl]-5-(lH-[l,2,3]- triazol-1-ylmethyl) }-oxazolidin-2-one;
(R)-{3-[4-(4-(l//-[l,2,3]-triazol-l-yl)-3-fluoropiperidin-l-yl)-3,5-difluorophenyl]-5-(lH-
[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
(S)-N-{3-[4-(4-([l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl }-thioacetamide; (S)-N-{3-[4-(4-(2-methyl-2H-tetrazol-5-yl)-ρiperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidm-5-ylmethyl}-acetamide;
(S )-N- { 3- [4-(4-( 1 -methyl- lH-tetrazol-5 -yl)-piperidin- 1 -yl)-3 ,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetaτnide; (S)-N-{3-[4-(4-(2-methyl)-2H-tetrazol-5-ylmethyl-piperidin-l-yl)-3,5-difluoro-phenyl]-
2-oxo-oxazolidin-5-ylmethyl } -acetamide;
(S )-N- { 3- [4~(4-(5-methylsulf anylmethyl- lH-tetrazol- 1 -yl)-ρiperidin- 1 -yl)-3 ,5- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(5-methylsulfonylmethyl-lH-tetrazol-l-yl)-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(5-(thiophen-2-yl-methyl)-lH-tetrazol-l-yl)-ρiρeridin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(5-(4-pyridinyl)-lΗ-tetrazol-l-yl)-ρiperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide; (S)-N-{3-[4-(4-(5-(4-pyridinyl)-lΗ-tetrazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2- oxo-oxazolidin-5-ylmethyl }-acetamide;
(S)-N-{3-[4-(4-(5-amino-2H-tetrazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- ' oxazolidin-5-ylmethyl}-acetamide;
(R)-{3-[4-(4-(l//-tetrazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-5-(lH-[l,2,3]-triazol-l- ylmethyl)}-oxazolidin-2-one;
(R)-{3-[4-(4-(2H-tetrazol-2-yl)-piperidin-l-yl)-3-fluorophenyl]-5-(lH-[l-,2,3]-triazol-l- ylmethyl) }-oxazolidin-2-one;
(S)-N-{3-[4-(4-(5-methyl-[l,2,4]-oxadiazol-3-ylmethyl)-piperidin-l-yl)-3,5-difluoro- phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; (S)-N-{3-[4-(4-((5-pyridin-3-yl)-[l,2,4]-oxadiazol-3-ylmethyl)-piperidin-l-yl)-3-fluoro- phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(5-phenyl-[l,3,4]-oxadiazol-2-ylmethyl)-piperidin-l-yl)-3-fluoro-phenyl]-
2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(5-Amino-[l,3,4]-thiadiazol-2-yl)-piperidin-l-yl)-3,5-difluoro-phenyl]-2- oxo-oxazolidin-5-ylmethyl }-acetamide;
(S)-N-{3-[4-(4-([l,2,4]-oxadiazol-3-yl)-ρiρeridin-l-yl)-3,5-difluoro-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
(S )-N- { 3- [4-(4-(5-hydroxyethyl-2H-tetrazol-2-yl)-piperidin- 1 -yl)-3 ,5-difluorophenyl] -2- oxo-oxazolidin-5-ylmethyl}-acetamide; (S)-N-{3-[4-(4-(5-acetylaminomethyl-2H-tetrazol-2-yl)-ρiperidm-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(lΗ-tetrazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo-oxazolidin-
5-ylmethyl}-acetamide; (S)-N-{3-[4-(4-(2H-tetrazol-2-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo-oxazolidin-
5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(2H-benzotriazol-2-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[3,5-Difluoro-4-(4-2H-tetrazol-2-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl}-propionamide;
(S)-N-{3-[3,5-Difluoro-4-(4-lH-tetrazol-l-yl-pipeiidin-l-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl } -propionamide;
(S)-N-{3-[3,5-Difluoro-4-(4-[l,2,3]triazol-l-yl-piρeridin-l-yl)-phenyl]-2-oxo-oxazolidin-
5-ylmethyl } -propionamide ; (S)-N-3- { 3,5-Difluoro-4-[4-(5-methyl-tetrazol-2-yl)-piperidin-l -yl]-phenyl } -2-oxo- oxazolidin-5-ylmethyl)-propionamide;
(S)-N-3-{3,5-Difluoro-4-[4-(5-methyl-tetrazol-l-yl)-piperidin-l-yl]-phenyl}-2-oxo- oxazolidin-5-ylmethyl)-propionamide;
(S)-N-{3-[3,5-Difluoro-4-(4-[l,2)3]triazol-l-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin- 5 -ylmethyl} -propionamide;
(S)-N-{3-[3,5-Difluoro-4-(4-lH-tetrazbl-l-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl }-carbamic acid methyl ester;
(S)-N-{3-[3,5-Difluoro-4-(4-[l,2,3]triazol-l-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-
5-ylmethyl }-carbamic acid methyl ester; (S)-N- { 3 -[3 ,5 -Difluoro-4-(4- [ 1 ,2,3] triazol- 1 -yl-piperidhv 1 -yl)-phenyl]-2-oxo-oxazolidin-
5-ylmethyl}-2,2-difluoro-acetamide;
(S)-N-(3-{3,5-Difluoro-4-[4-(4-methyl-5-thioxo-4,5-dihydro-tetrazol-l-yl)-piperidin-l- yl]-phenyl}-2-oxo-oxazolidin-5-ylmethyl)-acetamide;
(S)-N-{3-[3-fluoro-4-(4-2H-tetrazol-2-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl }-carbamic acid methyl ester;
(S)-TSf-{3-[3-fluoro-4-(4-lH-tetrazol-l-yl-piρeridin-l-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl}-carbamic acid methyl ester; (R)-{3-(4-phenyl-3-fluorophenyl)-5-iH-[l,2,3]-triazol-l-ylmethyl}-oxazolidin-2-one; (S)-N-{3-[4-(4-(piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylrnethyl } -acetamide;
(S)-N-{3-[4-(4-(4,4-dimethoxypiperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide ; (S)-N-{3-[4-(4-(l,4-dioxa-8-azasρiro[4.5]dec-8-yl)-3-fluorophenyl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(4-oxo-piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo-oxazolidin-
5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(4-hydroxy-piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo- oxazolidm-5-ylmethyl }-acetamide;
(S )-N- { 3 - [4-(4-(4-methansulfbnyloxy -piperidin- 1 -yl)-3 -fluorophenyl)-3 -fluorophenyl] -2- oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(4-cyanomethylidene-piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-acetaπiide; (S)-N- {3-[4-(4-(4-cyanomethyl-3,4-dehydropiperidin-l-yl)-3-fluorophenyl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(4-cyanomethyl-piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(4-azidomethyl-4-hydroxy-piperidin-l-yl)-3-fluorophenyl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl }-acetamide;
(S)-N- { 3-[4-(4-(4-(iH-/"i,2,3J-triazol-i-yl)-piperidin- l-yl)-3-fluorophenyl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide and isomer thereof;
(R)- { 3~[4-(4-(piperazin- l-yl)-3-fluorophenyl)-3-fluorophenyl]-5-(l ,2,3-triazol-l- yl)methyl }-oxazolidin-2-one hydrochloride; (S)-N-{3-[4-(4-(4-(2-nitrofuran-5-yl-methyl)-piρerazin-l-yl)-3-fluorophenyl)-3- fl uorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(thiomorpholin-4-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo-oxazolidin-
5-ylmethyl } -acetamide; (S)-N-{3-[4-(4-(S-oxo-thiomorpholin-4-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl} -acetamide;
(S)-N-{3-[4-(4-(S,S-dioxo-thiomoφholin-4-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(6-(thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl }-acetamide; (S)-N-{3-[4-(6-(S-oxo-thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(6-(S,S-dioxo-thiomorpholin-4-yl)-pyridin-3-yl)-3-fluoroρhenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide; (S)-N-{ 3-[4-(6-(S ,S-dioxo-3-methyl-thiomorphoIin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-
2-oxo-oxazolidin-5-ylmethyl } -acetamide;
(S)-N-|3-[4-(6-(l,4-Dioxa-8-azaspiro[4.5]dec-8-yl)-pyridin-3-yl)-3-fluoroρhenyl]-2-oxo- oxazolidin -5-ylmethyl }-acetamide;
(S)-N-13- [4-(6-(4-Oxopiperidin-l-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5- ylmethyl} -acetamide;
(S)-N-13-[4-(6-(4-Hydroxy-4-methoxymethylpiperidin-l-yl)-pyridin-3-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5 -ylmethyl } -acetamide;
(R)-3-|4-[6-(S,S-Dioxo-thiomoipholin-4-yl)-pyridin-3-yl]-3-fluoroρhenyl}-5- hydroxymethyl-oxazolidin-2-one; (R)-Phosphoric acid mono |3-[4-(6-(S,S-dioxo-thiomoφholin-4-yl)-pyridin-3-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } ester;
(R)-Phosphoric acid { 3-[4-(6-(S,S-dioxo-thiomorpholin-4-yl)-pyridin-3-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl} ester disodium salt;
(2S,5R)-2-Amino-propionic acid 3-|4-[6-(S,S-dioxo-thiomorpholin-4-yl)-pyridin-3-yl]-3- fluoro-phenyl}-2-oxo-oxazolidin-5-ylmethyl ester;
(2S,5R)-2-Amino-propionic acid 3-|4-[6-(S,S-dioxo-thiomorpholin-4-yl)-pyridin-3-yl]-3- fluoro-phenyl}-2-oxo-oxazolidin-5-ylmethyl ester methanesulphonic acid salt;
(2S , 5R)-2- Amino-3 -methyl-butyric acid 3 - { 4- [6-(S ,S -dioxo-thiomorpholin-4-yl)-pyridin-
3-yl]-3-fluoro-phenyl }-2-oxo-oxazolidin-5-ylmethyl ester; (2S,5R)-2-Amino-3-methyl-butyric acid 3-|4-[6-(S,S-dioxo-thiomorpholin-4-yl)-pyridin-
3-yl]-3-fluoro-phenyl}-2-oxo-oxazolidin-5-ylmethyl ester methanesulphonic acid salt;
(5R)-Acetic acid 3-{4-[6-(S,S-dioxo-thiomoφholin-4-yl)-pyridin-3-yl]-3-fluoro-phenyl }-
2-oxo-oxazolidin-5-ylmethyl ester;
(R)-|3-[4-(6-(Thiomoφholin-4-yl) -pyridin-3-yl)-3-fluorophenyl]-2-oxo-oxazolidin -5- ylmethyl }-methansulphonate;
(R)-|3-[4-(6-(S-Oxothiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo-oxazolidin-
5-ylmethyl }-methansulρhonate;
(R)-|3-[4-(6-(S,S-Dioxo-thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -methansulphonate; (S)-N-{ 3-[4-(6-(Thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylrnethyl } -formamide;
(S)-N-{3-[4-(6-(S,S-Dioxo-thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl }-formamide; (S)-N-{3-[4-(6-(S-Oxo-S-(N-methylimino)-thiomorpholin-4-yl)-pyridyl-3-yl)-3- fluorophenyl- 1 -yl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(6-(S-Oxo-S-(N-acetylimino)-thiomorpholin-4-yl)-pyridyl-3-yl)-3- fluorophenyl-1 -yl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(6-(S-Oxo-S-(l-chloroethylurido)-thiomoi-pholin-4-yl)-pyridyl-3-yl)-3- fluorophenyl- 1 -yl]-2-oxo-oxazolidin~5-ylmethyl } -acetamide;
(S)-N-{3-[4-(6-(S-Oxo-S-imino-thiomorpholin-4-yl)-pyridyl-3-yl)-3-fluorophenyl-l-yl]-
2-oxo-oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(6-(S,S-Dioxo-thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl }-propionamide; (S)-{3-[4-(6-(thiomoφholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl}-carbamic acid methyl ester;
(S)-N-{3-[4-(6-(S,S-Dioxo-thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl }-carbamic acid methyl ester;
N-Acetyl-(R)-N- { 3-4- { 2-(S ,S-Dioxo thiomorpholin-4-yl) -pyridyl-5-yl-3-fluorophenyl- 1- yl-]} -2-oxo-oxazolidin -5-yl methyl }-aminocarbonyl-oxy methyl acetate;
(S)-{3-[4-(6-thiomoφholin-4-yl-pyridin-3-yl)-3-fluorophenyl]-5-[l,2,3]-triazol-l- ylmethyl } -oxazolidin-2-one;
(S)-N-{3-[4-(6-(S,S-Dioxo-thiomoφholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-5-[l,2,3]- triazol- 1-ylmethyl } -oxazolidin-2-one; (S)-N-{3-[4-(6-(S-Oxo-3,3-dichloro-thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(6-(S,S-Dioxo-thiomoφholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl }-urea;
(S)-N-{3-[4-(6-(Thiomorpholin-4-yl)-pyridin-3-yl)-phenyl]-2-oxo-oxazolidin-5-yl methyl }-acetamide;
(S)-N-{3-[4-(6-(S-Oxo-thiomorρholin-4-yl)-pyridin-3-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl } -acetamide;
(S)-N-{3-[4-(6-(S,S-Dioxo-thiomoφholin-4-yl)-pyridin-3-yl)-phenyl]-2-oxo-oxazolidin-
5-ylmethyl } -acetamide; (S)-N-{3-[4-(6-(S-Oxo-S-(N-methylimino)-thiomorpholin-4-yl)-pyridin-3-yl)-ρhenyl] -2- ox.o-oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{ 3-[4-(2-(S,S-Dioxo-thiomorpholin-4-yl)-pyrimidin-5-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethylJ-carbarnic acid methyl ester; (R)-Phosphoric acid N-{3-{4-{2-(Thiomorpholin-4-yl) -pyrimidin-5-yl}-3-fluorophenyl] }
-2-oxo-ox.azolidin -5-yl methyl} -ester;
(R)-Phosphoric acid N-{3-{4-{2-(S-Oxo thiomorpholin-4-yl) -pyrimidin-5-yl}-3- fluorophenyl] } -2-oxo-oxazolidin -5-yl methyl} -ester;
(R)-Phosphoric acid N-{3-{4-{2-(S,S-Dioxo thiomoφholin-4-yl) -pyrimidin-5-yl}-3- fluorophenyl]} -2-oxo-oxazolidin -5-yl methyl} -ester;
(R)-Phosphoric acid N-{3-{4-{2-(S,S-Dioxo thiomorpholin-4-yl) -pyrimidin-5~yl}-3- fluorophenyl]} -2-oxo-oxazolidin -5-yl methyl} -ester disodium salt;
(S)-N-{3-[4-(2-(S,S-Dioxo-thiomorpholin-4-yl)-pyrimidin-5-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide; (S)-N-{3-[4-(2-(S,S-Dioxo-thiomoφholin-4-yl)-pyrimidin-5-yl)-3-fluorophenyl]-5-
[ 1 ,2,3] -tri azol- 1-ylmethyl } -oxazolidin-2-one ;
(S)-N-{3-[4-(6-(S,S-Dioxo-thiomoφholin-4-yl)-3-methylpyridin-3-yl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-carbamic acid methyl ester;
(S)-N-{3-[4-(6-(S,S-Dioxo-thiomoφholin-4-yl)-3-methylpyridin-3-yl)-3-fluorophenyl]-5- hydroxymethyl } -oxazolidin-2-one;
(R)-Phosphoric acid mono {3-[4-(6-(S,S-dioxo-thiomoφholin-4-yl)-3-rriethylpyridin-3- yl)-3-fluoiOphenyl]-2-oxo-oxazolidin-5-ylmethyl } ester;
(R)-Phosphoric acid mono {3-[4-(6-(S-oxo-thiomorpholin-4-yl)-3-methylpyridin-3-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl} ester disodium salt; (S)-N-{3-[4-(6-(S,S-Dioxo-thiomoφholin-4-yl)-3-methylpyridin-3-yl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(6-(S,S-Dioxo-thiomoφholin-4-yl)-3-methylpyridin-3-yl)-3-fluorophenyl]-5-
[ 1 ,2,3] -triazol- 1-ylmethyl } -oxazolidin-2-one;
(5S)-{3-[(3,5-Difluoro-4-(6-(4-S,S-dioxo-thiomoφholin-4-yl)-3-pyridinyl)phenyl]-2-oxo- oxazolidin-5yl-methyl }-acetamide.
A further embodiment of the invention is to provide methods of preparation of the compound of the invention. Following schemes describe the preparation of compounds of Formula I of the present invention. All of the starting materials are prepared by procedures described in US Patent 5,668,286 and in PCT patent application PCT/IN03/00237, PCT/IN03/00238 or by procedures that would be well known to one of ordinary skill in organic chemistry. The variables used in the following Schemes are as defined above. Optically pure material could be obtained either by one of a number of asymmetric synthesis or alternatively by resolution from a racemic mixture.
Oxazolidinone compounds bearing substituted heteroaryl and substituted heteroarylmethyl piperidine moiety may be prepared as per schemes described below:
Figure imgf000049_0001
A = CH2 or absent R10 = H1-COOC2H5 or -CH2OH or COOH or CONH2
a) ethyl propiolate or ethyl propiolate then 0.1 N KOH or ethyl propiolate then NH4OH b) propargyl alcohol, CuI c) 2,5-norbornadiene
Scheme- 1
As per scheme- 1, oxazolidinone compound of formula 1 is heated with ethyl propiolate in a solvent such as toluene or xylene for 3 to 14 hours at a temperature between 100-120 0C to provide oxazolidinone compound 2, wherein R10 is CO2C2H5. On further hydrolysis in presence of a base such as potassium hydroxide or sodium hydroxide in tetrahydrofuran, water mixture to provide oxazolidinone compound 2 wherein R1O is CO2H. Alternately the compound 2 with R10 as CO2C2H5 on further hydrolysis in presence of a base such as ammonium hydroxide in tetrahydrofuran, water mixture to provide oxazolidinone compound 2 wherein R10 is CONH2. Optionally heteroarylmethyl oxazolidinone compound was reacted with 2,5-norbornadiene in dioxane at a temperature O - 80 0C to provide oxazolidinone compound 2 of the invention.
Figure imgf000050_0001
RIl = H, CH3, pyridyl a) TMSN3, Bn3SnO; OrTMSN3, Bu3SnO then MeI b) hydroxylamine then ethyl propiolate c) hydroxylamine then RnCOCl
Scheme-2
As per scheme-2, oxazolidinone compound of formula 3 is heated with trimethylsilylazide and tributyltinoxide in a solvent such as toluene or xylene for 3 to 14 hours at a temperature between 100-120 0C to provide oxazolidinone compound 4 of the invention. Optionally n oxazolidinone compound was alkylated with alkylhalide such as methyliodide in presence of base such as sodium hydride in tetrahydrofuran to provide oxazolidinone compound 4 of the invention.
Oxazolidinone compound 3 was reacted with hydroxylamine hydrochloride in presence of a base such as sodium bicarbonate in methanol at a temperature 30-50 °C to provide hydroxyliminomethylpieridino oxazolidinone compound which subsequently upon reaction with ethylpropiolate in diphenyl ether solvent at reflux temperature provided oxazolidinone compound 5 of the invention.
Optionally oxazolidinone compound was subsequently reacted with organic acid chloride in presence of base such as sodium bicarbonate provided oxazolidinone compound 6 of the invention.
Figure imgf000051_0001
Scheme-3
As per scheme-3, oxazolidinone compound of formula 3 is reacted with thiosemicarbazide in methanesulfonic acid for 3 to 14 hours at a temperature between 40-80 0C to provide oxazolidinone compound 7 of the invention.
Figure imgf000051_0002
R11 = CH3, phenyl Scheme-4
As per scheme-4, oxazolidinone compound of formula 8 is reacted with organic acid chloride in presence of base for example potassium carbonate, sodium carbonate, triethylamine for 3 to 14 hours at a temperature between 0-500C to provide oxazolidinone compound 9 of the invention.
heterocycle
Figure imgf000051_0004
Figure imgf000051_0003
10 H
R1P = CKSOp- or p-tolyl-SO,- Het = unsubstituted or substituted
12 3 2 ^ * 2 heteroaryl
Scheme-5
For the synthesis of substituted heteroarylpiperidine wherein the point of attachment is via the nitrogen atom of the heteroaryl, alkylsulfonyloxy or arylsulfonyloxy substituted piperidino oxazolidinone compound of formula 10 is reacted with unsubstituted or substituted heteroaryl for example imidazole, triazole, tetrazole in the presence of a base such as potassium carbonate for 3 to 24 hours at a temperature between 50-100 0C to provide oxazolidinone compound 11 of the invention (Scheme 5).
Oxazolidinone compounds bearing biaryl moieties may be prepared as per schemes described below:
Figure imgf000052_0001
12 13a 14a 15a
+
Figure imgf000052_0002
16a 17a
Figure imgf000052_0003
18a 19a
R2 = H ; CH3 ; F
Z = CH2 ; -OCH2CH2O-; PhCH2-N-; O; S
X and Y = CH; CF
A = F; Br
A' = Br; I
R4 = -OH; -OSO2CH3 ; -NHCOCH3J-OC(O)OCH3. heteroaryl
a) Base, acetonitrile ; b) Reducing agent, Hydrogen source c) NaNO2 or KNO2, HCl, KI or NaI; d) trialkyl borate, n-BuLi; e) Pd(OAc)2, Ph3P, K2CO3, THF, DME, water
Scheme-6A
As per scheme-6A, nitrogen bearing heterocycle 12 (Z selected from CH2, -OCH2CH2O-, PhCH2N-, O, S) is reacted with compound 13a (A is either fluorine or bromine and X and Y selected from CH, CF) in presence of base such as triethylamine or diisopropylethylamine in solvent such as acetonitrile or dimethyl formamide or tetrahydrofuran, or mixture thereof at a temperature between 70-85 0C for 1 to 12 hours to provide compound 14a. The compound 14a is reduced in presence of catalyst such as 5% or 10% palladium on carbon or 20% palladium hydroxide on carbon in presence of hydrogen source such as hydrogen gas optionally under pressure, or cyclohexene or ammonium formate in the presence of solvents such as methanol or ethanol or ethyl acetate at a temperature between 30-65 0C for 1 to 12 hours to provide heterocyclic aromatic amino compound 15a. Optionally, the reduction is carried out in presence of metal such as iron or zinc in presence of hydrochloric acid in a solvent such as methanol or ethanol at a temperature between 30-65 0C for 1 to 12 hours to provide compound 15a.
The compound 15a is diazotized with sodium nitrite or potassium nitrite in the presence of hydrochloric acid in a solvent such as water or ethanol or mixture thereof at a temperature between 0-10 °C for 1 to 2 hours, which upon further treatment with potassium iodide or sodium iodide in water at a temperature between 0-10 0C for 1 to 12 hours provided compound 16a.
The compound 16a is treated with trialkyl borate such as trimethyl borate or triethyl borate or tributyl borate in the presence of n-butyllithium in a solvent such as tetrahydrofuran or toluene or mixture thereof at a temperature between 0-40 °C for 1 to 24 hours there upon optional aqueous hydrochloric acid treatment furnished aryl boronic acid 17a.
The heterocyclic aromatic boronic acid 17a is reacted with compound 18a in presence of catalyst such as a mixture of palladium acetate and triphenyl phosphine or tetrakistriphenylphosphine or bisdiphenylphosphine palladium acetate in presence of base such as potassium carbonate or triethylamine, in a solvent such as dimethoxyethane or tetrahydrofuran or toluene, or aqueous ethanol, or mixture thereof at a temperature between 30-90 0C for 1 to 24 hours to furnish oxazolidinone compound 19a of the invention of formula I.
Figure imgf000054_0001
12 13b 16b
Figure imgf000054_0002
17b 18b
Figure imgf000054_0003
19b
R2 = H ; CH3 ; F
Z = CH2 ; -OCH2CH2O- ; PhCH2-N- ; O ; S
X and Y = CH, CF, N
R4 = -OH; -OSO2CH3 ; -NHCOCH3; -OC(O)OCH3; heteroaryl
a) Base, N-methylpyrrolidinone; b) trialkyl borate, n-BuLi; c) Pd(OAc)2, Ph3P, K2CO3, THF, DME, water.
Scheme-6B
As per scheme-6B, nitrogen bearing heterocycle 12 (Z selected from CH2, -OCH2CH2O-, PhCH2N-, O, S) is reacted with 2,5-dibromo-pyridine (13b) in presence of base such as triethylamine or diisopropylethylamine in solvent such as N-methylpyrrolidinone, acetonitrile, dimethyl formamide, or mixture thereof at a temperature between 70-85 C for 1 to 12 hours to provide compound 16b.
The compound 16b is treated with trialkyl borate such as triniethyl borate or triethyl ^borate, tributyl borate in the presence of n-butyllithium in a solvent such as tetrahydrofuran, toluene or mixture thereof at a temperature between 0-40 0C for 1 to 24 hours there upon optional aqueous hydrochloric acid treatment furnished boronic acid 17b.
The boronic acid 17b is reacted with compound 18b in presence of catalyst such as a mixture of palladium acetate and triphenyl phosphine or tetrakistriphenylphosphine or bisdiphenylphosphine palladium acetate in presence of base such as potassium carbonate or triethylamine, in a solvent such as dimethoxyethane or tetrahydrofuran, or mixture thereof at a temperature between 30-90 0C for 1 to 24 hours to furnish oxazolidinone compound 19b of the invention of formula I.
Figure imgf000055_0001
12 13c 14c
Figure imgf000055_0002
15c . 17c 18c
Figure imgf000055_0003
c
R2 = H ; CH3 ; F
Z = CH2 ; -OCH2CH2O- ; PhCH2-N- ; O ; S
X and Y = CH; CF; N
R4 = -OH; -OSO2CH3 ; -NHCOCH3. -OC(O)OCH3; heteroaryl a) Base, ethanol; b) N-broniosuccinamide, acetonitrile; c) trialkyl borate, n-BuLi; d) Pd(OAc)2, Ph3P, K2CO3, THF, DME, water.
Scheme-6C
As per scheme-6C, nitrogen bearing heterocycle 12 (Z selected from CH2, -OCH2CH2O-, PhCH2N-, O, S) is reacted with 2-chloro-pyrimidine (13c) in presence of base such as triethylamine or diisopropylethylamine in solvent such as ethanol, or n-butanol or mixture thereof at a temperature between 70-100 C for 1 to 12 hours to provide compound 14c.
The compound 14c is reacted with brominating agent such as N-bromosuccinamide in a solvent such as acetonitrile or chloroform or mixture thereof at a temperature 25-45 °C for 5 - 14 hours to furnish compound 15c. The compound 15c is treated with trialkyl borate such as trimethyl borate or triethyl borate, tributyl borate in the presence of n-butyllithium in a solvent such as tetrahydrofuran or toluene or mixture thereof at a temperature between 0-40 0C for 1 to 24 hours there upon optional aqueous hydrochloric acid treatment furnished boronic acid 17c.
The boronic acid 17c is reacted with compound 18c in presence of catalyst such as a mixture of palladium acetate and triphenyl. phosphine or tetrakistriphenylphosphine or bisdiphenylphosphine palladium acetate in presence of base such as potassium carbonate or triethylamine, in a solvent such as dimethoxyefhane or tetrahydrofuran, or mixture thereof at a temperature between 30-90 0C for 1 to 24 hours to furnish oxazolidinone compound 19c of the invention of formula I.
Figure imgf000056_0001
12 14d
13d
Figure imgf000056_0002
15d .. 17d 18d
Figure imgf000056_0003
19d
R2 = H ; CH3 ; F
Z = CH2 ; -OCH2CH2O- ; PhCH2-N- ; O ; S
X and Y = CH; CF; N
R4 = -OH; -OSO2CH3 ; -NHCOCH3. -OC(O)OCH3. heteroaryl a) Pd(OAc)2, PdCl2(DPPF)2: CH2Cl2 complex, base, toluene; b) N-bromosuccinamide, acetonitrile; c) trialkyl borate, n-BuLi; d) Pd(OAc)2, Ph3P, K2CO3, THF, DME, water.
Scheme-6D As per scheme-6D, nitrogen bearing heterocycle 12 (Z selected from CH2, -OCH2CH2O-, PhCH2N-, O, S) is reacted with 2-bromo-3-methyl-pyridine (13d) in presence of palladium acetate and catalyst such as [l,l-bis(dipheylphosphino)-ferrocene]-dichloropalladium (II) complex with dichloromethane 1:1 also known as PdCl2(DPPF)2 : CH2Cl2 complex and base such as sodium tert-butoxide in a solvent such as toluene or xylene or mixture thereof at a temperature between 70-140 0C for 5 to 12 hours to provide compound 14d.
The compound 14d is reacted with brominating agent such as N-bromosuccinamide in a solvent such as acetonitrile or chloroform or mixture thereof at a temperature 25-45 0C for 5 - 14 hours to furnish compound 15d.
The compound 15d is treated with trialkyl borate such as trimethyl borate or triethyl borate, tri butyl borate in the presence of n-butyllithium in a solvent such as tetrahydrofuran, toluene or mixture thereof at a temperature between 0-40 0C for 1 to 24 hours there upon optional aqueous hydrochloric acid treatment furnished heterocyclic aryl boronic acid 17d.
The boronic acid 17d is reacted with compound 18d in presence of catalyst such as a mixture of palladium acetate and triphenyl phosphine or tetrakistriphenylphosphine or bisdiphenylphosphine palladium acetate in presence of base such as potassium carbonate or triethylamine, in a solvent such as dimethoxyethane or tetrahydrofuran, or mixture thereof at a temperature between 30-90 0C for 1 to 24 hours to furnish oxazolidinone compound 19d of the invention of formula I.
Figure imgf000057_0001
20 21
X and Y = CH; CF; N
R4 = -OH; -OSO2CH3; -NHCOCH3; -OC(O)OCH3; heteroaryl
Scheme-7
As per scheme-7, the oxazolidinone 20 (prepared as described in scheme-6A to 6D) is stirred with organic acid such as /7-toluene sulfonic acid or inorganic acid such as dilute hydrochloric acid or dilute sulfuric acid in solvent such as acetone or water or tetrahydrofuran, or mixture thereof at a temperature between 30-80 0C for 1 to 12 hours to provide oxazolidnone compound 21 of the invention.
Figure imgf000058_0001
23
X and Y = CH; CF; N
R4 = -OH; -OSO2CH3 ; -NHCOCH3; -OC(O)OCH3; heteroaryl
Scheme-8
As per scheme 8, the oxazolidinone compound 21 (prepared as described above) is reacted with trimethylsulphoxonium iodide ((CHs)3SO+T) or trimethylsulphonium iodide ((CH3)3S+F) in the presence of a base such as sodium hydride or potassium tert-butoxide or lithium diisopropylamine or n-butyl lithium in a solvent such as dimethyl formamide or tetrahydrofuran or mixture thereof at a temperature between 0-85 0C for 1 to 12 hours to provide oxazolidinone compound 22 of the invention.
As per scheme-8, the oxazolidinone compound 21 is stirred with p-toluenesulfonic acid in methanol at a temperature between 0-85 °C for 1 to 12 hours to provide oxazolidinone compounds 23 of the invention.
Figure imgf000058_0002
19 24
Z = S
Z = SO ; SO2
X and Y = CH; CF; N
R4 = -OH; -OSO2CH3 ; -NHCOCH3; -OC(O)OCH3; heteroaryl Scheme-9
As per Scheme-9, the oxazolidinone 19 is optionally oxidized with sodium peroidate in solvent such as aqueous methanol or rectified spirit at a temperature between 0-80 °C for 1 to 48 hours to provide oxazolidinone compound 24 of the invention.
Figure imgf000059_0001
26
X and Y = CH; CF; N
R4 = -OH; -OSO2CH3 ; -NHCOCH3; -OC(O)OCH3; heteroaryl
R13 = H; CH3 ;CN ; CONH2 ; pyridyl
Scheme- 10
As per scheme-10, the oxazolidinone compound 21 (prepared as described above) is reacted with appropriate Wittig reagent such as diethylcyanomethylphosphonate or diethyl-(l- cyanoethyl)-phosphonate or diethyl(l-cyano-2-carboxamidomethyl)-phosphonate or diethyl(l-cyano-2-(3-pyridylmethyl)-phosphonate in the presence of base such as triethylamine or diisopropylethylamine and lithium bromide in a solvent such as dimethyl formamide or tetrahydrofuran or mixture thereof at a temperature between 0-85 0C for 1 to 12 hours to provide oxazolidinone compound 25 of the invention.
Compound 25 is optionally reduced with reducing agent such as 5% or 10% palladium on carbon or 20% palladium hydroxide on carbon in presence of hydrogen source such as hydrogen gas optionally under pressure, or cyclohexene or ammonium formate in the presence of solvents such as methanol or ethanol or ethyl acetate at a temperature between 30-65 0C for 1 to 12 hours to provide oxazoldinone compound 26 of the invention.
Figure imgf000060_0001
21 27 R14SO2CI, base cyclic amine
Figure imgf000060_0002
28
Figure imgf000060_0003
29
X and Y = CH; CF; N
R4 = -OH; -OSO2CH3 ; -NHCOCH3; -OC(O)OCH3; heteroaryl.
R5 = heteroaryl
RU = CH3SO2-; P-CH3C6H4-SO2-
Scheme-11
As per scheme-11, the oxazolidinone compound 21 (prepared as described above) is reacted with appropriate reducing reagent such as sodium borohydride in a solvent such as methanol or ethanol at a temperature between 0-35 0C for 1 to 12 hours to provide oxazolidinone compound 27 of the invention.
Compound 27 is optionally reacted with alkylsulfonyl chloride such as methanesulfonylchloride or ethanesulfonylchloride or aryl sulfonylchloride such as p-toleύne sulfonylchloride or p-bromosulfonylchloride in presence of base such as triethylamine or pyridine or diisopropylethylamine in a solvent such as dichloromethane or chloroform or tetrahydrofuran at a temperature between 0-35 0C for 1 to 12 hours to provide oxazolidinone compound 28 of the invention.
Compound 28 is optionally reacted with heteroaryl amine such as pyrrole, or pyrazole, or imidazole or triazole or tetrazole or aliphatic cyclic amine such as pyrrolidine or piperidine or piperazine or morpholine in presence of base such as potassium carbonate or sodium carbonate in a solvent such as dimethylformamide or dioxane at a temperature between 35-80 0C for 1 to 12 hours to provide oxazoldinone compound 28 of the invention.
Figure imgf000061_0001
21 30
X and Y = CH; CF; N
R4 = -OH; -OSO2CH3 ; -NHCOCH3; -OC(O)OCH3; heteroaryl
Scheme-12
As per scheme-12, the oxazolidinone compound 21 (prepared as described above) is reacted with cyanoacetic acid and base such as pyridine or triethylamine or piperidine in presence of ammonium acetate in a solvent such as toleune or xylene at a temperature between 80-120 0C for 1 to 12 hours to provide oxazolidinone compounds 30 of the invention.
Figure imgf000061_0002
22
Figure imgf000061_0003
X and Y = CH; CF; N
R4 = -OH; -OSO2CH3 ; -NHCOCH3; -OC(O)OCH3; heteroaryl
R15 = CN ; OH ; OCH3 ; N3 ; amine
Scheme- 13
In accordance with scheme-13, oxazolidinone 22 (prepared as per procedure described above) is reacted with appropriate acid catalyst such as p-toluene sulfonic acid or hydrochloric acid or sulfuric acid or with a nucleophilic reagent such as sodium azide, sodium cyanide, sodium methoxide or amine such as methyl amine dimethyl amine or with a cyclic amines, such as pyrrolidine or piperidine, or with an aromatic amine such as imidazole or triazole or tetrazole in a solvent such as dimethylformamide or dimethylacetamide or methanol or ethanol or mixture thereof and stirred for 3 to 48 hours at a temperature between 10-100 0C to provide oxazolidinone 31 of the invention.
Figure imgf000062_0001
19 32 z = CH2Ph, R2 = H
R4
Figure imgf000062_0002
R4 = -OH; -OSO2CH3 ; -NHCOCH3; -OC(O)OCH3; heteroaryl a) 10% Pd on carbon, H2 ; b) 2-benzyloxyacetylchloride, K2CO3 c) Pd(OH)2, H2
Scheme-14
In accordance with scheme-14, oxazolidinone compound 19 (prepared as per procedure described above) ds stirred in hydrogen atmosphere in presence of catalyst such as 5% or 10% palladium on carbon or 20% palladium hydroxide on carbon in a solvent such as methanol or ethanol or ethylacetate for 3 to 48 hours at a temperature between 35-60 0C to provide oxazolidinone 32 of the invention.
Optionally compound 32 is optionally reacted with ethanolic hydrochloric acid to provide hydrochloride salt of compound 32 of the invention. Optionally compound 32 is reacted with 2-benzyloxyacetylchloride in presence of potassium carbonate or sodium carbonate in a acetone, water mixture 1 to 14 hours at a temperature between 0-35 0C to provide oxazolidinone 33 of the invention.
Optionally compound 33 is stirred in hydrogen atmosphere in presence of catalyst such as 5% or 10% palladium on carbon or palladium hydroxide in a solvent such as methanol or ethanol or ethyl acetate for 3 to 48 hours at a temperature between 35-60 0C to provide oxazolidinone
34 of the invention.
Figure imgf000062_0003
R4 = -OH; -OSO2CH3 ; -NHCOCH3; -OC(O)OCH3; heteroaryl a) 2-nitrofuran-5-aldehyde, sodiumtriacetoxyborohydride
Scheme-15 In accordance with scheme-15, oxazolidinone 32 (prepared as per procedure described above) is stirred with 2-nitro-furan-aldehyde in a solvent such as dichloromethane or chloroform or methanol or ethanol followed by addition of sodiumtriacetoxyborohydride for 3 to 10 hours at a temperature between 35-60 0C to provide oxazolidinone 35 of the invention.
Figure imgf000063_0001
36 37
Figure imgf000063_0002
X and Y = CH; CF; N
R16 = alkyl, aryl
R4 = -OH; -OSO2CH3 ; -NHCOCH3; -OC(O)OCH3; heteroaryl
Scheme- 16
In accordance with scheme-16, oxazolidinone compound 36 (prepared as per procedure described above) is stirred with sodium azide and polyphosphoric acid (PPA) for 10 to 14 hours at a temperature between 50-600C to provide oxazolidinone compound 37 of the invention.
The oxazolidinone compound 37, upon reacting with formic acid and aqueous formaldehyde mixture for 10 to 14 hours at a temperature between 60-80 0C provided oxazolidinone compound 38 of the invention. The oxazolidinone compound 37, upon reacting with alkyl chloride such as acetyl chloride and base such as triethylamine or diisopropyl ethylamine mixture for 10 to 14 hours at a temperature between 0-350C provided oxazolidinone compound 39 of the invention.
Figure imgf000064_0001
Z = O, S, SO, SO2. X and Y = CH; CF; N a) 1) Di-tert-butyl-diisopropylphosphoramidite, tetrazole
2) H2O2 or m-chloroperbenzoic acid
3) trifluoroacetic acid
Scheme-17 In accordance with scheme-17, oxazolidinone compound 41 (prepared as per procedure described above) is stirred with a mixture of tetrazole and di-tert-butyl- diisopropylphosphoramidite in a mixture of tetrahydrofuran and dichloromethane, for 10 to 14 hours at a temperature between 30-45 0C. The reaction mixture is stirred with oxidizing agent such as hydrogen peroxide or m-chloroperbenzoic acid at 0- 20 °C temperature for additional 5-6 hours. The crude product is isolated by work up and the isolated product is stirred with trifluoroacetic acid to provide oxazolidinone compound 42 of the invention. The di-sodium salt of the compound 42 is prepared by dissolving compound 42 in aqueous sodium hydroxide and evaporating to the dryness.
Alternatively, compound 42, by using mixture of tetrazole and di-benzyl- diisopropylphosphoramidite, m-chloroperbenzoic acid followed by removal of benzyl group by using catalytic amount of 5-10% Pd on carbon in presence of hydrogen atmosphere.
Alternatively, compound 42, by using mixture of phosphorous trichloride, benzyl alcohol and iodine.
Optionally, the compound 41 can be treated with Cl-P(O)(OM)2, wherein M is methyl, ethyl, t-butyl, phenyl, in presence of triethylamine, N,N-dimethylaminopyridine in a solvent such as dichloromethane at rt for 1-24 h to afford the compound 42, wherein M is methyl, ethyl, t- butyl or phenyl.
Figure imgf000065_0001
Z = O, S1 SO, SO2. X and Y = CH; CF; N R17 = alkyl, aryl a) 1) Boc-NH-(CR16)-COOH, DCC, DMAP 2) CH3SO3H, acetone
Scheme- 18
In accordance with scheme- 18, oxazolidinone compound 41 (prepared as per procedure described above) is stirred with a mixture of suitably protected amino acid such as N-Boc protected amino acid, dicyclohexylcarbodimide and N,N-dimethylaminopyridine in a solvent such as chloroform and dichloromethane, for 2 to 14 hours at a temperature between -100C to
30 0C. The crude product is isolated by work up and the isolated product is stirred with methane sulfonic acid in solvent such as acetone, ethylmethyl ketone to provide methane sulfonic acid salt of amino acid ester oxazolidinone compound 42 of the invention.
Figure imgf000065_0002
Z = O, S, SO, SO2.
X and Y = CH; CF; N
R15 = alkyl, aryl or -0-CH2-O-CO-CH3 a) R18COCl, base, DMAP
Scheme- 19
In accordance with scheme- 19, oxazolidinone compound 41 (prepared as per procedure described above) is stirred with a mixture of suitable alkyl or aryl or substituted formyl acid chloride such as acetyl chloride or benzoyl chloride or acetoxymethyloxycarbonyl chloride and N,N-dimethylarninopyridine in presence of base such as triethylamine or pyridine or diisopropylethylamine in a solvent such as chloroform and dichloromethane, for 2 to 14 hours at a temperature between 0°C to 30 0C to provide methane sulfonic acid salt of amino acid ester oxazolidinone compound 44 of the invention.
Figure imgf000066_0001
Z= O, S, SO, S02. X and Y = CH; CF; N a) 0.6 N aqueous HCl; b) acetoxymethyloxycarbonyl chloride, DMAP, base; c) Acetic anhydride, base, DMAP
Scheme-20
In accordance with scheme-20, oxazolidinone compound 45 (prepared as per procedure described above) is stirred with a 0.6N aqueous hydrochloric acid in a solvent such as methanol or ethanol for 2 to 8 hours at a temperature between 60°C to 80 0C to provide oxazolidinone compound 46.
The oxazolidinone compound 46 is treated with acetoxymethyloxycarbonyl chloride and N,N-dimethylaminopyridine in presence of base such as triethylamine or pyridine or diisopropylethylamine in a solvent such as chloroform and dichloromethane, for 2 to 14 hours at a temperature between O0C to 30 0C to provide oxazolidinone compound 47.
The oxazolidinone compound 47 is treated with acetic anhydride and N,N- dimethylaminopyridine in presence of base such as triethylamine or pyridine or diisopropylethylamine in a solvent such as chloroform and dichloromethane, for 10 to 14 hours at a temperature between 30°C to 50 0C to provide oxazolidinone compound 48 of the invention.
The oxazolidinone antibacterial agents of this invention have potential for treatment of microbial infections. The microbial infection can be caused by Gram-positive including multi-resistant bacteria, Gram-negative bacteria, anaerobic organism, acid-fast organism. In contrast to compounds of the prior art, they demonstrate therapeutically useful activity against different resistant microorganisms and in particular different strains of Enterococcus faecalis. In addition they display activity against linezolid-resistant S. aureus strains, linezolid-resistant E. faecalis strains and in particular linezolid-resistant S. pneumoniae strains. These compounds are useful for the treatment of Gram-positive or Gram-negative microbial infections in animals and human. The animals which can be treated by bacterial infections include but not limited to birds, mammals, fishes. These compounds are useful for the treatment of microbial infections by either parenteral, oral or topical administration. The infection in human and animals can be systemic or topical.
The compounds of this invention may be used to prevent infections caused by Gram-positive and Gram-negative bacteria by administering the compound to a subject that is at risk for developing an infection caused by Gram-positive or Gram-negative bacteria. A subject at risk for developing an infection may be a health care worker, surgical patient and the like.
The compositions of the present invention include compositions such as suspensions, solutions, elixirs, aerosols, and solid dosage forms. Carriers as described in general above are commonly used in the case of oral solid preparations (such as powders, capsules and tablets), with the oral solid preparations being preferred over the oral liquid preparations. The most preferred oral solid preparation is tablets.
Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are employed. Examples of suitable carriers include excipients such as lactose, white sugar, sodium chloride, glucose solution, urea, starch, calcium carbonate, kaolin, crystalline cellulose and silicic acid, binders such as water, ethanol, propanol, simple syrup, glucose, starch solution, gelatin solution, carboxymethyl cellulose, shellac, methyl cellulose, potassium phosphate and polyvinyl pyrrolidone, disintegrants such as dried starch, sodium alginate, agar powder, laminaria ' powder, sodium hydrogen carbonate, calcium carbonate, Tween (fatty acid ester of polyoxyethylenesorbitan), sodium lauryl sulfate, stearic acid monoglyceride, starch, and lactose, disintegration inhibitors such as white sugar, stearic acid glyceryl ester, cacao butter and hydrogenated oils, absorption promoters such as quaternary ammonium bases and sodium lauryl sulfate, humectants such as glycerol and starch, absorbents such as starch, lactose, kaolin, bentonite and colloidal silicic acid, and lubricants such as purified talc, stearic acid salts, boric acid powder, polyethylene glycol and solid polyethylene glycol.
The tablet, if desired, can be coated, and made into sugar-coated tablets, gelatin-coated tablets, enteric-coated tablets, film-coated tablets, or tablets comprising two or more layers.
If desired, tablets may be coated by standard aqueous or non-aqueous techniques. In molding the pharmaceutical composition into pills, a wide variety of conventional carriers known in the art can be used. Examples of suitable carriers are excipients such as glucose, lactose, starch, cacao butter, hardened vegetable oils, kaolin and talc, binders such as gum arabic powder, tragacanth powder, gelatin, and ethanol, and disintegrants such as laminaria and agar.
In molding the pharmaceutical composition into a suppository form, a wide variety of carriers known in the art can be used. Examples of suitable carriers include polyethylene glycol, cacao butter, higher alcohols, gelatin, and semi-synthetic glycerides.
A second preferred method is parenterally for intramuscular, intravenous or subcutaneous administration.
A third preferred route of administration is topically, for which creams, ointments, shampoos, lotions, dusting powders and the like are well suited. Generally, an therapeutically effective amount of the compound according to this invention in a topical form is from about 0.1% w/w to about 10% w/w of the total composition. Preferably, the therapeutically effective amount of the compound of the invention is 1% w/w of the total composition.
In addition to the common dosage forms set out above, the compounds of the present invention may also be administered by controlled release means and/or delivery devices such as those described in U.S. Patent Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123 and 4,008,719; the disclosures of which are hereby incorporated by reference.
Desirably, each tablet contains from about 200 mg to about 1500 mg of the active ingredient. Most preferably, the tablet, cachet or capsule contains either one of four dosages, about 200 mg, about 400 mg, 600 mg or about 800 mg of the active ingredient. When the pharmaceutical composition is formulated into an injectable preparation, in formulating the pharmaceutical composition into the form of a solution or suspension, all diluents customarily used in the art can be used. Examples of suitable diluents are water, ethyl alcohol, polypropylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol, and sorbitan esters. Sodium chloride, glucose or glycerol may be incorporated into a therapeutic agent.
The antimicrobial pharmaceutical composition may further contain ordinary dissolving aids, buffers, pain-alleviating agents, and preservatives, and optionally coloring agents, perfumes, flavors, sweeteners, and other drugs.
For topical application, there are employed as non-sprayable forms, viscous to semi-solid or solid forms comprising a carrier compatible with topical application and having a dynamic viscosity preferably greater than water. Suitable formulations include but are not limited to solutions, suspensions, emulsions, creams, ointments, powders, liniments, salves, aerosols, etc., which are, if desired, sterilized or mixed with auxiliary agents, e.g. preservatives, antioxidants, stabilizers, wetting agents, buffers or salts for influencing osmotic pressure, etc. For topical application, also suitable are sprayable aerosol preparations wherein the active ingredient preferably in combination with a solid or liquid inert carrier material.
A specific embodiment of the invention is the preparation of storage stable compositions of the compounds of the invention of formula I. Such stable compositions can be advantageously made through the use of selective stabilizers. Different stabilizers are known to those skilled in the art of making pharmaceutical compositions. Of special utility for making storage stable compositions of the compound of the invention of formula I, stabilizers such as disodium ethylenediaminetetraacetic acid (EDTA), tromethamine, cyclodextrins such as gamma-cyclodextrin, hydroxy-propyl-gamma-cyclodextrin have been found to be useful.
In a specific embodiment of the invention, the pharmaceutical compositions contain an therapeutically effective amount of the active compounds of the invention, its derivatives, salts or hydrates thereof described in this specification as hereinbefore described in admixture with a pharmaceutically acceptable carrier, diluent or excipients, and optionally other therapeutic ingredients. The invention is further defined by reference to the following examples describing in detail the preparation of the composition of the present invention as well as their utility. It will be apparent to those skilled in the art that many modifications, both to materials and methods may be practiced without departing from the purpose and scope of this invention.
The compounds of this invention are useful antimicrobial agents effective against various humans and veterinary pathogens specially including Linezolid-resistant strains.
Examples of infections that may be treated with the compounds of the present invention include central nervous system infections, external ear infections, infections of the middle ear, such as acute otitis media, infections of the cranial sinuses, eye infections, infections of the oral cavity, such as infections of the teeth, gums and mucosa, upper respiratory tract infections, lower respiratory tract infections, genitourinary infections, gastrointestinal infections, gynecological infections, mastitis, septicemia, bone and joint infections, skin and sldn structure infections, bacterial endocarditis, burns, antibacterial prophylaxis of surgery, and antibacterial prophylaxis in immunosuppressed patients, such as patients receiving cancer chemotherapy, or organ transplant patients. Specifically, infectious diseases that may be treated with the compounds of the present invention are gram-positive infections such as osteomyelitis, endocarditis and diabetic foot.
The compounds described herein are useful for the treatment or prophylaxis of Gram-positive or Gram-negative microbial infections in humans and other warm-blooded animals. The oxazolidinone antibacterial compounds of this invention are useful for treatment of Gram- positive infections including those, which result from multi-resistant strains. The compounds of this invention are useful antimicrobial agents effective against various humans and veterinary pathogens specially included Linezolid-resistant strains.
In contrast to Linezolid, the compounds described herein demonstrate bactericidal activity against different resistant microorganisms and in particular different strains of Enterococcus faecalis. In addition they display activity against linezolid-resistant S. aureus strains.
For the purpose of this invention the pharmaceutical compositions may contain the active compounds of the invention, their derivatives, salts and hydrates thereof, in a form to be administered alone, but generally in a form to be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. Suitable carriers which can be used are, for example, diluents or excipients such as fillers, extenders, binders, emollients, wetting agents, disintegrants, surface active agents and lubricants which are usually employed to prepare such drugs depending on the type of dosage form.
Any suitable route of administration may be employed for providing the patient with an effective dosage of the compound of the invention their derivatives, salts and hydrates thereof. For example, oral, rectal, vaginal, parenteral (subcutaneous, intramuscular, intravenous), nasal, transdermal, topical and like forms of administration may be employed. Dosage forms include (solutions, suspensions, etc) tablets, pills, powders, troches, dispersions, suspensions, emulsions, solutions, capsules, injectable preparations, patches, ointments, creams, lotions, shampoos and the like.
The prophylactic or therapeutic dose of the compounds of the invention, their derivatives, salts or hydrates thereof, in the acute or chronic management of disease will vary with the severity of condition to be treated, and the route of administration. In addition, the dose, and perhaps the dose frequency, will also vary according to the age, body weight and response of the individual patient. In general, the total daily dose range, for the compounds of the invention, the derivatives, salts or hydrates thereof, for the conditions described herein, is from about 200 mg to about 1500 mg, in" single or divided doses. Preferably, a daily dose range should be between about 400 mg to 1200 mg, in single or divided dosage, while most preferably a daily dose range should be between about 500 mg to about 1000 mg in divided dosage. While intramuscular administration may be a single dose or up to 3 divided doses, intravenous administration can include a continuous drip. It may be necessary to use dosages outside these ranges in some cases as will be apparent to those skilled in the art.
Further, it is noted that the clinician or treating physician will know how and when to interrupt, adjust, or terminate therapy in conjunction with individual patient's response. The term "an amount sufficient to eradicate such infections but insufficient to cause undue side effects" is encompassed by the above - described dosage amount and dose frequency schedule. "Antibacterially effective amount" is the amount required to provide a desirable biological effect of restricting the growth of bacteria or killing bacteria. Pharmaceutical compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, or tablets, or aerosol sprays, each containing a predetermined amount of the active ingredient, as a powder or granules, or as a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion, or a water-in-oil liquid emulsion. Such compositions may be prepared by any of the methods of pharmacy, but all methods include the step of bringing into association the active ingredient with the carrier, which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.
Biological activity
The compounds of this invention are useful antimicrobial agents, effective against various human and veterinary pathogens, including multiple-resistant staphylococci and streptococci, enteroccoci, as well as anaerobic organisms such bacteroides and Clostridia species, and acid resistant organisms such as Mycobacterium tuberculosis and Mycobacterium avium.
Test Example 1
MIC Test Method
Overnight grown cultures of S. aureus organisms in Tryptic Soya broth were diluted in Mueller Hinton Broth to give optical density matching with MacFarland tube 0.5 standard. Cultures were further diluted 1:10 in Mueller Hinton broth. Using Denley's mutipoint inoculator, 104 cells were deposited on Mueller Hinton agar (Difco) containing range of 2 fold dilutions of test compounds. These plates were incubated for 24 hrs at 350C and MIC results recorded. MIC is defined as minimum drug concentration that inhibits test organisms. For determining MIC of test compounds against Streptococcus pneumoniae, Mueller Hinton agar containing 5% sheep blood was employed. The following strains were used to screen the compounds of invention Strain
Staphylococcus aureus ATCC 25923
Staphylococcus aureus 014
Staphylococcus epidermidis 110
Staphylococcus haemolyticus ATCC 25923
Enterococcus faecalis 401
Enterococcus faecium 303
Streptococcus pneumoniae 49619
Streptococcus pneumoniael '06
Streptococcus pyogenes 801
Streptococcus pyogenes 805
Haemophilus influenzae 49247
Mycobacterium tuberculosis
Mycobacterium avium
The MIC values of the selected oxazolidinone compounds of the invention have displayed antibacterial activity for Staphylococcus aureus ATCC 25923 is 0.5 to >8 mcg/ml; for Staphylococcus aureus 014 is 0.5 to >8 mcg/ml; Staphylococcus epidermidis 110 is 0.5 to >8 mcg/ml; Staphylococcus haemolyticus ATCC 25923 is 0.5 to >8 mcg/ml; Enterococcus faecalis 401 is 0.5 to >8 mcg/ml; Enterococcus faecium 303 is 0.5 to >8 mcg/ml; Streptococcus pneumoniae 49619 is 0.25 to >8 mcg/ml; Streptococcus pneumoniael '06 is 0.5 to >8 mcg/ml; Streptococcus pyogenes 801; is 0.25 to >8 mcg/ml; Streptococcus pyogenes 805 is 0.25 to >8 mcg/ml; Haemophilus influenzae 49247 is 2.0 to >8 mcg/ml; Mycobacterium avium is 2.0 to >8 mcg/ml.
The following examples are provided to further illustrate this invention but they should not be taken as limiting.
Experimental
Example- 1 (5S)-N-{3-[4-(4-(2RS-Cyanoaziridin-l-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}~acetamide;
Figure imgf000074_0001
To a solution of (S)-N-{3-[4-(4-amino-piperidin-l-yl)-3-fluoro-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide (1.37 g,3.91 mmol) in tetrahydrofuran was added triethylamine (1.18 g, 11.74 mmol) followed by the 2,3-dibromopropionitrile (0.99 g,
4.69 mmol) and the resulting solution stirred at 8O0C for 16 hours. The solvent was removed completely in vacuum and 50 ml water was added to residue and extracted with
3 x 50 ml ethyl acetate. The combined organic layers were washed with brine, dried (Na2SO4) and concentrated to give crude compound. Purification by column chromatography eluting with CHCl3 :CH3θH (98:2) afforded the pure compound in 75% yield. M.P. 118-120 0C and MS (M+l) = 402 (MH+, 100%) M.F. = C20H24FN5O3.
Example-2 (S)-N-{3-[4-(4-pyrrol-l-yl-piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl } -acetamide;
Figure imgf000074_0002
To a solution of (S)-N-{3-[4-(4-Amino-piperidin-l-yl)-3-fluoro-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide (1.25 mmol) in acetic acid(2.5 ml), water (5 ml) and dichloroethane(lθ ml) was added 2,5 dimethoxy tetrahydrofuran (1.25 mmol) at 25°C and the resulting mixture heated at 800C for 3 hour. The organic layer was separated, washed with distilled water(lθml) and evaporated under reduced pressure to obtain the product as off- white solid, in 70 % yield.
M.P. 208-2100C and MS (M+l) = 401 (MH+, 100%) M.F. = C20H25FN4O3
Example-3
(S)-N-{3-[3,5-Difluoro-4-(4-pyrrol-l-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl } -acetamide ;
Figure imgf000075_0001
To a solution of (S)-N- { 3-[4-(4-arnino-piperidin- l-yl)-3, 5-difluoro-phenyl]-2-oxo- oxazolidin-5-ylmethyl} -acetamide (1.25 mmol) in acetic acid(2.5 ml), water (5 ml) and dichloroethane(10 ml) was added 2,5 dimethoxy tetrahydrofuran (1.25 mmol) at 250C and the resulting mixture heated at 800C for 3 hour. The organic layer was separated, washed with distilled water(lθml) and evaporated under reduced pressure to obtain the product as off- white solid, in 80 % yield. M.P. 186-188°C and MS (M+l) = 419 (MH+, 100%) M.F. = C20H24F2N4O3
Example-4
(S)-N-{3-[4-(4-(iH-imidazol-l-yl)-ρiperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin- 5-ylmethyl}-acetamide;
Figure imgf000075_0002
To the solution of (S)-N-{3-[4-(4-(ρ-toluenesulfonyloxy)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (0.5 mmol) in dimethyl formamide (5 ml) was added K2CO3 (85 mg, 0.6 mmol) and IH-[1, 2,3] -triazole (45 μl, 0.6 mmol) at room temperature and it was further heated at 70°C for 15 h. The reaction mixture was slowly poured on the crushed ice and stirred for 15 min. A solid precipitated out was filtered and dried. The crude solid upon purification over silica gel has afforded a white solid in 40% yield. M.P. 160-162 °C and MS (M+ 1) = 402 (MH+, 100%) M.F. = C20H24FN5O3.
Example-5 and 6
(S)-N- {3-[4-(4-( lH-[ 1,2,3] -triazol- l-yl)-piperidin- 1 -yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide; and (S)-N-{3-[4-(4-(2flr-[l,2,3]-triazol-2-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000076_0001
and
Figure imgf000076_0002
To the solution of (S)-N-{3-[4-(4-(p-toluenesulfonyloxy)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (0.5 mmol) in DMF (5 ml) was added K2CO3 (85 mg, 0.6 mmol) and lH-[l,2,3]-triazole (45 μl, 0.6 mmol) at room temperature and it was further heated at 7O0C for 15 h. The reaction mixture was slowly poured on the crushed ice and stirred for 15 min. A solid precipitated out was filtered and dried. The crude solid upon purification over silica gel has afforded a non polar isomer as white solid in 52% yield. MP. 200-10C and MS (M+l) = 403 (MH+, 100%) M.F. = C1OH23FNeO3 and on further elution afforded a polar isomer as a white solid in 43% yeild, polar Isomer M.P. 197°C and MS (M+l) = 403 (MH+, 100%) M.F. = C19H23FN6O3. Example-7
(S)-N-{3-[4-(4-(lH-[l,2!3]-triazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000077_0001
To the solution of (S)-N-{3-[4-(4-(p-toluenesulfonyloxy)-3-fluoro-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-l,2,3-traizol-l-yl (0.5 mmol) in DMF (5 ml) was added K2CO3 (0.6 mmol) and lH-[l,2,3]-triazole (0.6 mmol) at room temperature and it was further heated at 70°C for 15 h. The reaction mixture was slowly poured on the crushed ice and stirred for 15 min. A solid precipitated out was filtered and dried. The cruϋe solid upon purification over silica gel has afforded a white solid in 55% yield. MP. 188-90 0C and MS (M+l) = 421 (MH+, 100%) M.F. = Ci9H22F2N6O3.
Example-8
(S)-N-{3-[4-(4-(lH-[l,2,3]-triazol-l-yl)-3-fluoropiperidin-l-yl)-3,5-difluorophenyl]- 2-oxo-oxazolidin-5-ylmethyl } -acetamide;
Figure imgf000077_0002
To the solution of (S)-N-{3-[4-(4-(p-toluenesulfonyloxy)-3-fluoro-piperidin-l-yl)- 3,5-difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (0.5 mmol) in DMF (5 ml) was added K2CO3 (0.6 mmol) and lH-[l,2,3]-triazole (0.6 mmol) at room temperature and it was further heated at 7O0C for 15 h. The reaction mixture was slowly poured' on the crushed ice and stirred for 15 min. A solid precipitated out was filtered and dried. The crude solid upon purification over silica gel has afforded a a pale yellow solid was obtained in 42 % yield M.P. 176-78 0C and MS (M+l) = 439
(MH+, 100%) M.F. = C19H21F3N6O3. Example-9
(S)-N-{3-[4-(4-(lH-[l,2,3]-triazol-l-yl)-3-fluoropiperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000078_0001
The title compound was prepared by using the method as described above. A white solid was obtained in 48% yield. MP. 15S-6O °C and MS (M+ 1) = 421 (MH+, 100%) M.F. = C19H22F2N6O3.
Example- 10
(S)-N- { 3-[4-(4-(tetrazol-5-yl)-piperidin- l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethylj-acetamide;
Figure imgf000078_0002
To the solution of N-{3-[4-(4-cyanomethyl-piperidin-l-yl)-3-fluoro-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide (0.8 mmol) in toluene (7 ml) was added trimethylsilyl azide (210 μl, 1.6 mmol) and dibutyltin Oxide (40 mg, 0.16 mmol) and the reaction mixture was refluxed at 1200C for 24 h. The solvent was evaporated under reduced pressure and the residue obtained was purified by the column chromatography to provide a white solid in 66% yield. M.P. 148-150 0C and MS (M+ 1) = 404 (MH+, 100%) M.F. =
C18H22FN7O3.
Example- 11 (S)-N- { 3- [4- (4- (tetrazol-5 -yl)-piperidin- 1 -yl)-3 , 5 -difluorophenyl] -2-oxo-oxazolidin-
5-ylmethyl }-acetamide;
Figure imgf000078_0003
To the solution of N-{3-[4-(4-cyanomethyl-piperidin-l-yl)-3,5-difluoro-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide (0.8 mmol) in toluene (7 ml) was added trimethylsilyl azide (210 ml, 1.6 mmol) and dibutyltin oxide (40 mg, 0.16 mmol) and the reaction mixture was refluxed at 1200C for 24 h. The solvent was evaporated under reduced pressure and the residue was purified by the column chromatography, to provide a white solid was obtained in 65% yield.
M.P. 180-82 0C and MS (M+ 1) = 422 (MH+, 100%) MP. = Ci8H21F2N7O3.
Example-12 and 13 (S)-N-{3-[4-(4-(lH-tetrazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-
5 -ylmethyl } -acetamide and
(S)-N- { 3-[4-(4-(2Η-tetrazol-2-yl)-piperidin- l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-
5 -ylmethyl } -acetamide
Figure imgf000079_0001
and
Figure imgf000079_0002
To a stirred solution of (S)-N-{3-[4-(4-(p-toluenesulfonyloxy)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5 -ylmethyl} -acetamide (1.0 gm,1.9 mmol) and 1Η- tetrazole (0.133 gm, 1.9 mmol) in DMF was added powdered K2CO3 (0.262 mg, 1.9 mmol) and heated at 70 °C for 18 hrs. Heating was stopped and cold water was added to the reaction mixture under stirring and then extracted with ethyl acetate (2 x 75 ml). Combined organic layer was then washed with brine, dried over Na2SO4 and evaporated under vacuum. Crude product upon purification by column chromatography over a silica gel using (9.8:0.2) as an eluent afforded a white solid (0.2 g, 25 % yield). M.P. 186-
188°C and MS (M+ 1) = 404 (MH+, 100%) M.F. = C18H22FN7O3. Further elution of the column afforded the polar isomer as a white solid in 17% yield as a cream colored solid. M.P, 189-90 0C and MS (M+l) = 404 (MH+, 100%) MP. = C18H22FN7O3.
Example- 14 and 15
(S)-N- { 3- [4-(4-(2H-tetrazol-2-yl)-piperidin- 1 -yl)-3 , 5-difluorophenyl] -2-oxo-oxazolidin-
5-ylmethyl }-acetamide and
(S)-N- { 3- [4-(4-(l H-tetrazol- 1 -yl)-piperidin- 1 -yl)-3 , 5-difluorophenyl] -2-oxo-oxazolidin-
5-ylmethyl }-acetamide
Figure imgf000080_0001
and
Figure imgf000080_0002
A mixture of (S)-N-{3-[4-methanesulphonyloxy piperidin-l-yl)-3,5-difluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-acetamide (1.12 mM), tetrazole (1.68 mM), and K2CO3 (1.68 mM) in DMF (6 ml) was heated for 22 hrs at 850C. The resulting mixture was poured into ice-water mixture, stirred for 30 min. And the separated solid was purified by column chromatography to obtain two isomeric products in 18% and 12% yields respectively. Isomer A: M.P. 234-2370C; MS(M+1)- 422 ; M.F. C18H21F2N7O3 Isomer B: M.P. 214-2170C; MS(M+1)- 422 ; M.F. C18H2JF2N7O3
Example- 16
(S)-N- { 3 -[4-(4-( lH-tetrazol- 1 -yl)-3-hydroxypiperidin- 1 -yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide and isomer thereof
Figure imgf000081_0001
To a stirred solution of (S)-N- { 3- [4-(4-toluenesulf onyloxy-3-hydroxypiperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetarnide (2.0 mmol) and lH-tetrazole (2.5 mmol) in DMF was added powdered K2CO3 (2.5 mmol) and heated at 700C for 18 hrs. Heating was stopped and cold water was added to the reaction mixture under stirring and then extracted with ethyl acetate (2 x 75 ml). Combined organic layer was then washed with brine and dried over Na2SO4 and evaporated under vacuum. Crude product upon purification by column chromatography over a silica gel using (9.8:0.2) as an eluent afforded white solid in 32% yield. MS (M+ 1) = 420 (MH+, 100%) M.F. = C18H22FN7O4.
Example- 17
(5S)-N-{3-[4-(4-(lH-tetrazol-l-yl)-(3RS)-fluoropiperidin-l-yl)-3,5-difluorophenyl]- 2-oxo-oxazolidin-5-ylmethyl } -acetamide;
Figure imgf000081_0002
To a stirred solution of (S)-N-{3-[4-(4-toluenesulfonyloxy-3-fluoro-piρeridin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl} -acetamide (1.9 mmol) and lH-tetrazole (1.9 mmol) in DMF was added powdered K2CO3 (1.9 mmol) and heated at 700C for 18 hrs. Heating was stopped and cold water was added to the reaction mixture under stirring and then extracted with ethyl acetate (2 x 75 ml). Combined organic layer was then washed with brine and dried over Na2SO4 and evaporated under vacuum. Crude product upon purification by column chromatography over a silica gel using (9.8:0.2) as an eluent afforded white solid in 50% yield. M.P. 194-96 0C and MS (M+ 1) = 440 (MH+, 100%) M.F. = C18H20F3N7O3. Example- 18 and 19
(S)-N-{3-[4-(4-(l-methyl-lH-tetrazol-5-ylmethyl)-piperidin-l-yl)-3-fluoro-phenyl]-2- oxo-oxazolidin-5-ylmethyl } -acetamide ; and
(S)-N- { 3 -[4-(4-(2-methyl-2Η-tetrazol-5 -ylmethyl)-piperidin- 1 -yl)-3-fluoro-phenyl] -2- oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000082_0001
and
Figure imgf000082_0002
To the solution of N-(3-{3-Fluoro-4-[4-(lH-tetrazol-5-ylmethyl)-piperidin-l-yl]-phenyl}- 2-oxo-oxazolidin-5-ylmethyl)-acetamide (150 mg, 0.4mmol) in THF (3 ml) was added sodium hydride (20 mg, 0.5 mmol) at an ambient temperature and stirred for 15 min. Methyl iodide (27 μl, 0.5 mmol) in THF (1 ml) was added slowly. The reaction mixture was stirred for 15h. The reaction mixture'was quenched by adding ice cold water and it was extracted into ethyl acetate (3 x 15 ml). The combined organic layer was washed with brine and dried over Na2SO4. The residue was obtained on the removal of the solvent was purified by the column chromatography over silica gel using CHCl3:MeOH (98:2) as an eluent. A white solid was obtained (100 mg, 40%). M.P. 136-1380C and MS
(M+ 1) = 432 (MH+, 100%) M.F. = C20H26FN7O3. Upon further elution of the column by CHC^MeOH (95:5) the polar isomer was obtained as a white solid (40mg, 26%). MP. 154-560C and MS (M+ 1) = 432 (MH+, 100%) M.F. = C20H26FN7O3.
Using the above procedure and appropriate starting material the following compounds were prepared.
Figure imgf000083_0001
Figure imgf000084_0001
Example-28
(S)-N-{3-[4-(4-(4-hydroxymethyl-m-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide
Figure imgf000084_0002
To a stirred solution of (S)-N-{3-[4-(4-(4-ethoxycarbonyl-l,2,3-tetrazol-l-yl)-piperidin- l-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (0.2 gm, 0.4 mmoi) in EtOH (5 ml) was added NaBH4 (31 mg, 0.8 mmol) and continue to stir for 4 hr. Solvent was evaporated under vacuum, ice-cold water was added to the resulting sticky mass, solid separated was filtered under vacuum and dried. The title compounds was obtained a white solid (0.140 gm) . M.P. 160-62 0C and MS (M+l) = 433 (MH+, 100%) M.F. = C20H25FN6O4.
Using the above procedure and appropriate starting material the following compounds were prepared.
Figure imgf000084_0003
Figure imgf000085_0001
Example-31
(R)-{3-[4-(4-(4-hydroxymethyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-5-(li/-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
Figure imgf000085_0002
To the stirred solution of (R)-3-[4-(4-azido-piperidin-l-yl)-3-fluoro-phenyl]-5- l,2,3]triazol-l-ylmethyl-oxazolidin-2-one (0.3 g, 0.77 mmol) in toluene (3 ml) was added ethyl propiolate (0.110 Dl, 1.2 mmol) and the resulting solution was heated at 1200C for 15 h. The solvent was removed under reduced pressure and the residual sticky mass on trituration with the ether provided a pale brown solid (180 mg). The solid obtained was taken into the methanol (5 ml) and sodium borohydride (30 mg, 0.7 mmol) was added to it and stirred for 3h at room temperature. Water was added to the reaction mixture and pH was adjusted to 6. It was" then extracted with ethyl acetate (3 x 15 ml) and the combine organic layer was dried over Na2SO4. The residual mass obtained on evaporation of the solvent was subjected to the column chromatographic purification over silica gel using CHC13:MeOH as an eluent. A white solid was obtained (140 mg, 77 %). M.P. 210-212 °C and MS (M+ 1) = 443 (MH+, 100%) M.F. = C20H23FN8O3.
Example-32
(R)-{3-[4-(4-(4-hydroxymethyl-lH-[l,2,3]-triazol-l-yl)-ρiperidin-l-yl)-3,5- difluorophenyl]-5-(lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
Figure imgf000086_0001
The title compound was prepared by using the procedure mentioned for the above compound, (R)-3-[4-(4-Azido-piperidin-l-yl)-3, 5-difluoro-phenyl]-5-l,2,3]triazol-l- ylmethyl-oxazolidin-2-one (0.3 g, 0.70 mmol) has afforded cream colored solid (160 mg, 67 %) M.P. 238-4O0C and MS (M+l) = 461 (MH+, 100%) M.F. = C20H22F2N8O3.
Example-33 (S)-N-{3-[4-(4-(4-formyl-l//-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-2- ox.o-oxazolidin-5-ylmethyl } -acetamide;
Figure imgf000086_0002
To the solution of (S)-N-{3-[4-(4~(4-(nydroxymethyl- IH-[1, 2,3]-triazol-l-yl)-ρiperidin- l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (0.2 g, 0.46 mmol) in dichloromethane (10 ml) was added Dess-Martin periodinane (0.214 g, 0.5 mmol) and stirred for 2h at an ambient temperature"1. The organic layer was washed with water (2 x 20 ml), dried over Na2SO4 and evaporated. The crude product obtained was purified by the column chromatography using CHCl3:MeOH (9.5:0.5) as an eluent. The white solid was obtained (0.150 g, 75%). M.P. 168-70 0C and MS (M+l) = 431 (MH+, 100%) M.F. = C20H23FN6O4.
Using the above procedure and appropriate starting material the following compounds were prepared.
Figure imgf000087_0001
Example-37
(S)-N-{3-[4-(4-(4-difluoromethyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000087_0002
To a stirred solution of (S)-N-{ 3-[4-(4-(4-formyl-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (0.2g, 0.46 mmol) in dichloromethane was added DAST (285 ul, 1.76 mmol) at 1O0C slowly and stirred at ambient temperature for 12h. Reaction mixture was quenched with satd. NaHCO3 solution and extracted with dichloromethane (15 ml x 2). Combined organic layer was dried over sodium sulphate and evaporated under vacuum the residue obtained was purified by column chromatography over silica gel using (95:5) CHCl3-MeOH as an eluent to provide the title compound as an off-white solid (120 mg) in 60% yield. M.P. 186-88 °C and MS (M+ 1) = 453 (MH+, 100%) M.F. = C20H23F3N6O3.
Example-38
(S)-N-{3-[4-(4-(4-difluoromethyl-iH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
Figure imgf000088_0001
The title compound was prepared by using procedure as described above and by using (S)-N- { 3-[4-(4-(4-f ormyl- [ 1 ,2,3]-triazol- 1 -yl)-piperidin- 1 -yl)-3-fluorophenyl] -2-oxo- oxazolidin-5-ylmethyl} -acetamide in 55% yield after silica gel column chromatographic purification.
Exaniple-39
(S)-N-{3-[4-(4-(4-[l,3]-Dioxolan-2-yl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-5-(luT-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
Figure imgf000088_0002
To the solution of (S)-N-{3-[4-(4-(4-formyl-l,2!3-trizoly-l-yl)-piperidin-l-yl)-3,5- difluorophenyl]-2-ox.o-oxazolidin-5-ylmethyl}-[l,2,3]-triazol-l-yl (0.25 g, 0.55 mmol) in toluene (5 ml) was added p-toluene sulfonic acid (0.1 lmmol) and ethylene glycol (1. lmmol) The reaction mixture was heated at 120°C for 3h. The solvent was removed under reduced pressure and the residue obtained was taken into the ethyl acetate and washed with the aqueous solution of sodium bicarbonate and followed by the brine. The combined organic layer was dried (Na2SO4) and the solvent was removed under reduced pressure. The crude solid obtained was purified by the column chromatography over the silica gel by using CHCl3 :MeOΗ as an eluent. A white solid was obtained in 80% yield. M.P. 198-200 °C and MS (M+ 1) = 485 (MH+, 100%) M.F. = C22H25FN8O4. Exam.ple-40a and 40b
(S)-N-{3-[4-(4-(4-ethoxycarbonyl-lH-[l,2,3]-triazol-l-yl)-methyl-piperidin-l-yl)-3- fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide; and
(S)-N-{3-[4-(4-(5-ethoxycarbonyl-lH-[l,2,3]-triazol-l-yl)-methyϊ-piperidin-l-yl)-3- fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
Figure imgf000089_0001
and
Figure imgf000089_0002
To the stirred solution of (S)-N-{3-[4-(4-azidomethyl-piperidin-l-yl)-3-fluoro-phenyl]~2- oxo-oxazolidin-5-ylmethyl} -acetamide (3 g , 7.69 mmol) in toluene (30 ml) was added ethyl propiolate (2.26 g , 23.07 mmol) and the resulting solution was heated at 1150C for 5h. The solvent was removed in~vacuun\and 50 ml water was added to the residue. It was extracted with ethyl acetate (3 x 50 ml) and the combined organic layer was washed with brine, dried (Na2SO4) and concentrated to give crude compound as a mixture of two regioisomers. Purification by column chromatography eluting with CHCl3: CH3OH (98:2) afforded the non-polar isomer in Ig quantity along with the other polar isomer in 2.1 g quantity. Non polar isomer: M.P. 75-770C and MS (M+ 1) = 489 (MH+, 100%) M.F. = C23H29FN6O5. Polar isomer: M.P. 150-520C and MS (M+l) = 489 (MH+, 100%) M.F. = C23H29FN6O5.
Example-41
(S)-N-{3-[4-(4-(4-cyano-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl } -acetamide;
Figure imgf000090_0001
To a stirred solution of (S)-N-{3-[4-(4-(4-(p-toluenesulfonyloxy)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (1.9 mmol) and 4-cyano-lH- [l,2,3]-triazole (1,9 mmol) in DMF was added powdered K2CO3 (0.262 mg, 1.9 mmol) and heated at 70 0C for 18 hrs. Heating was stopped and cold water was added to the reaction mixture under stirring and then extracted with ethyl acetate (2 x 75 ml). Combined organic layer was then washed with brine and dried over Na2SO4 and evaporated under vacuum. Crude product upon purification by column chromatography over a silica gel using (9.8:0.2) as an eluent afforded white solid in 60 % yield. M.P. 148-150 0C and MS (M+ 1) = 428 (MH+, 100%) M.F. = C20H22FN7O3.
Example-42
(S)-N-{3-[4-(4-(4-carboxamido-lH-[l,2,3]-triazol-l-yl)-piρeridin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetarnide;
Figure imgf000090_0002
To the solution of N-(3-{4-[4-(4-cyano-lH-[l)2,3]-triazol-l-yl)-piperidin-l-yl]-3-fluoro- phenyl}-2-oxo-oxazolidin-5-ylmethyl)-acetamide (150 g, 0.35 mmol) in f-butyl alcohol (3 ml) was added potassium hydroxide (20 mg, 0.35 mmol) and heated at 8O0C for 1.5 h. To the reaction mixture water (10 ml) was added and the pΗ was adjusted to 6. It was extracted into ethyl acetate (3 x 10 ml). The combine organic layer was dried (Na2SO4) and evaporation of the solvent provided a crude solid, which was recrystallized from methylenechloride and n-hexane to furnish the pale yellow solid (80 mg, 53 %).
M.P. 260 °C and MS (M+ 1) = 446 (MH+, 100%) M.F. = C20H24FN7O4. Example-43
(R)-{3-[4-(4-(4-carboxamido-lH-[l,2,3]-triazol-l-yl)-piρeridin-l-yl)-3-fluorophenyl]-5- (IH-[1, 2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
Figure imgf000091_0001
The title compound was prepared by using the same as described for the above compound. A. pale yellow solid was obtained in 61% yield. M.P. 284-86 0C and MS (M+l) = 456 (MH+, 100%) M.F. = C20H22FN9O3.
Example-44
(S)-N-{3-[4-(4-(4-carboxamido-lH-[l,2,3]-triazol-l-yl)-methyl-piperidin-l-yl)-3-fluoro- phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000091_0002
To the stirred solution of (S)-N-{3-[4-(4-(4-ethoxycarbonyl-[l,2,3]-triazol-i-yl)-methyl- piperidin-l-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (0.9 gm) in acetonitrile (30 ml ) was added aqueous ammonia (30 ml) and the resulting solution was stirred at 600C for 5 h. The solvent was removed in vacuum & the aqueous layer was extracted with ethyl acetate (3 x 50 ml). The combined organic layers was washed with brine, dried (Na2SO4) and concentrated to give crude compound. The crude compound was triturated and stirred with ether (3x 25 ml), filtered, washed with excess of ether & dried completely to get pure compound as white solid (0.2 g). M.P. 165-1670C and MS (M+l) = 460 (MH+, 100%) M.F. = C21H26FN7O4. Example-45
(S)-N-{3-[4-(4-(5-carboxamido-lH-[l,2,3],-triazol-l-yl)-methyl-piperidin-l-yl)-3-fluoro- phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000092_0001
The title compound was prepared by using the same as described for the above compound. A white solid was obtained in 56% yield. MS (M+ 1) = 460 (MH+, 100%) M-E = C21H26FN7O4.
Example-46 (S)-N-{3-[4-(4-(4-hydroxycarbonyl-lH-[l,2,3]-triazol-l-yl)-methyl-piperidin-l-yl)-3- fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000092_0002
The title compound was obtained by stirring (S)-N-{3-[4-(4-(4-ethoxycarbonyl-lH- [ 1 , 2,3] -tetrazol - 1 -yl) -methyl -piperidin- 1 -yl)-3 -fluoro-phenyl] -2-oxo-oxazoli din-5 -ylmeth yl}-acetamide with 0.1 N KOΗ in tetrahydrofuran at 350C for 24 h followed by purification over silica gel by column chromatography in 46% yield. M.P. 172-74°C and
MS (M+l) = 461 (MH+, 100%) M.F. = C2IH25FN6O5.
Example-47 (S)-N-{ 3-[4-(4-(5-hydroxycarbonyl- lH-[l,2,3]-triazol-l-yl)-methyl-piperidin-l-yl)-3- fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000092_0003
The title compound was prepared by using the same as described for the above compound. A white solid was obtained in 41% yield. M.P.245-247 0C and MS (M+ 1) = 461 (MH+, 100%) M.F. = C21H25FN6O5.
Example-48 (S)-N-{ 3-[4-(4-(4-acetyl-lH-[l ,2,3]-triazol- l-yl)-piperidin- l-yl)-3-fluorophenyl]-2- oxo-oxazolidin-5 -ylmethyl } -acetamide;
Figure imgf000093_0001
To the sqlution of (S)-N- {3- [4-(4-azido-piperidin- 1 -yl)-3-fluorophenyl] -2-oxo- oxazolidin-5-ylmethyl} -acetamide (0.5 mmol) in toluene (5 ml) was added butyne-2-one (50 μl, O.75mmol) and heated at 12O0C for 6h. The solvent was removed under reduced pressure and the residue was purified by the column chromatography over silica gel. A white solid (140 mg, 70 %) was obtained. M.P. 220-220C and MS (M+l) = 445 (MH+, 100%) M.F. = C2IH25FN6O4.
Using the above procedure the following^compounds were synthesized
Figure imgf000093_0002
Examτ>le-51
(S)-N-{3-[4-(4-(4-acetyl-lH-[l,2,3]-trizol-l-ylmethyl)-lH-[l,2,3]-triazol-l-yl)- piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000094_0001
To the solution of (S)- N-(3-{4-[4-(4-azidomethyl-[l,2,3]-triazol-l-yl)-piperidin-l-yl]-3- fluoro-phenyl}-2-oxo-oxazolidin-5-ylrn.ethyl)-acetamide (0.5 mmol) in toluene (5 ml) was added butyne-2-one (0.75mmol) and heated at 12O0C for 6h. The solvent was removed under reduced pressure and the residue was purified by the column chromatography over silica gel to afford off-white solid. (160 mg, 60 %). M.P. 206-208 0C and MS (M-H 1) = 526 (MH+, 100%) MP. = C24H28FN9O4.
Example-52
(S)-N-{3-[4-(4-(4-(lRS-hydroxyethyl)-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
Figure imgf000094_0002
To the solution of (S)-N-(3-{4-[4-(4-acetyl-[l,2,3]triazol-l-yl)-piperidin-l-yl]-3-fluoro- phenyl}-2-oxo-oxazolidin-5-ylrnethyl)-acetamide (0.2 g, 0.4 mmol) in methanol (3 ml) was added sodium borohydride (35 mg, 0.8mmol) at an ambient temperature and stirred for 2h. The solvent was removed and the residue was taken into the water and the pH was adjusted to 6 and extracted with ethyl acetate (3 x 15 ml). The combined organic layer was dried (Na2SO4) and evaporated. The crude compound obtained was purified by column chromatography over silica gel using CHCl3:MeOH (98:2) as an eluent. A white solid (115 mg, 58%) was obtained. M.P. 194-96 0C and MS (M+l) = 447 (MH+, 100%) M.F. = C2IH27FN6O4. Using the above procedure the following compounds were synthesized
Figure imgf000095_0002
Example-55
(S)-N- { 3- [4-(4-(4-(2-methyl-oxiranyl> IH-[1 ,2,3] -triazol- 1 -yl)-ρiperidin- l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
Figure imgf000095_0001
To the solution sodium hydride (60%, 27 mg, 0.66mmol) in DMSO (1.0 ml) was added trimethylsulfoxonium iodide (132 mg, 0.6 mmol) at an ambient temperature and stirred for 20 min. To this (S)-N-(3-{4-[4-(4-acetyl-[l,2,3]-triazol-l-yl)-piperidin-l-yl]-3-fluoro- phenyl }-2-oxo-oxazolidin-5-ylmethyl)-acetamide (0.25 g, 0.5 mmol) at an ambient temperature and stirred for 2h. The reaction mixture was quenched by adding crashed ice and extracted with ethyl acetate (3 x 10 ml). The combined organic layer was dried (Na2SO4) and evaporated. The crude compound obtained was purified by column chromatography over silica gel using CHCIsMeOH (98:2) as an eluent. A white solid (0.17 g, 70 %) was obtained. M.P. 158-160 0C and MS (M+l) = 459 (MH+, 100%) M.F. = C22H27FN6O4. Example-56
(R)-{3-[4-(4-(4-(2-methyl-oxiranyl)-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-5-(lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
Figure imgf000096_0001
To the solution sodium hydride (60%, 27 mg, 0.66mmol) in DMSO (1.0 ml) was added trimethylsulfoxonium iodide (132 mg, 0.6 mmol) at an ambient temperature and stirred for 20 min. To this (R)-N-{3-[4-(4-(4-acetyl)-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-lH-[l,2,3]-triazol-l-yl (0.5 mmol) at an ambient temperature and stirred for 2h. The reaction mixture was quenched by adding crushed ice and extracted with ethyl acetate (3 x 10 ml). The combined organic layer was dried (Na2SO4) and evaporated. The crude compound obtained was purified by column chromatography over silica gel using CHCl3 :MeOH (98:2) as an eluent to provide title compound in 62 % yield. M.P. 138-140 °C and MS (M+ 1) = 469 (MH+, 100%) M.F. = C22H25FN8O3. Example-57
(S)-N-{3-[4-(4-((4-((E/Z)-2-cyano-vinyl)-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-(3xazolidin-5-ylmethyl }-acetamide;
Figure imgf000096_0002
To the solution of (S)-N-{3-[4-(4-(4-formyl)-[l,2,3]-triazol-l-yl)-piρeridin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (0.2 g, 0.46 mmol) in TΗF (3.0 ml) was added lithium bromide (60 mg, 0.70 mmol), triethylamine (100 μl, 0.70 mmol) and followed by the diethylcyanomethyl phosphonate (85 ul, 0.50 mmol) and stirred at room temperature for 2h. The solvent was removed and the residue was taken into chloroform and washed with water and followed by the brine, dried (Na2SO4) and on removal of the solvent provided the white solid (0.170 g, 85 %). M.P. 214-216 0C and
MS (M+l) = 454 (MΗ+ 100%) M.F. = C22H24FN7O3. Example-58 (S)-N-{3-[4-(4-(4-hydroxyimino-methyl)-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl] -2-oxo-oκazolidin-5 -ylmethyl } -acetamide;
Figure imgf000097_0001
To the solution of the (S)-N-{3-[4-formyl-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluoro phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetaniide (0.2g, 0.46 mmol) in methanol (3 ml) was added hydroxylamine hydrochloride (64 mg, 0.92 mmol) and stirred at an ambient temperature for 4h. Upon evaporation of the solvent under reduced pressure provided a gummy mass, which was taken up into ice cold water and resulting white solid was filtered and dried to provide the oxime (0.160 g, 80 %). M.P. 194-96 0C and MS (M+l) =
446 (MH+, 100%) M.F. = C20H24FN7O4.
Example-59
(S)-N-{3-[4-(4-(l-methoxyimino-ethyl)-lH-[l,2,3]-triazol-l-yl)-piperidm-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000097_0002
To the solution of (S)-N-{3-[4-(4-(4-(acetyl)-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5 -ylmethyl} -acetamide (0.46 mmol) in methanol (3 ml) was added hydroxylamine hydrochloride (0.92 mmol) and stirred at an ambient temperature for 4h. Upon evaporation of the solvent under reduced pressure provided a gummy mass, which was taken up into ice cold water and resulting white solid was filtered and dried to provide title compound was obtained in 69% yield as a white solid.
M.P. 164-166 0C and MS (M+l) = 492 (MH+, 100%) M.F. = C22H27F2N7O4. Using the above procedure the following compounds were prepared
Figure imgf000098_0002
Example-63
(S)-N- { 3 -[4-(4-( 1 -methoxyimino-methyl)- IH-[1 ,2,3] -triazol- 1 -yl)-ρiρeridin- 1 -yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000098_0001
To the solution of (S)-N-{3-[4-(4-(4-(formyl)-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (0.46 mmol) in methanol (3 ml) was added methoxylamine hydrochloride (0.92 mmol) and stirred at an ambient temperature for 4h. Upon evaporation of the solvent under reduced pressure provided a gummy mass, which was taken up into ice cold water and resulting white solid was filtered and dried to provide title compound in 86% yield. M.P. 198-200 0C and MS
(M+l) = 460 (MΗ+ 100%) M.F. = C21H26FN7O4. Example-64
(S)-N-{3-[4-(4-(l-methoxyimino-methyl)-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)- 3 ,5 -difluorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide ;
Figure imgf000099_0001
To the solution of (S)-N-{3-[4-(4-(4-(formyl)-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl} -acetamide (0.46 mmol) in methanol (3 ml) was added methoxyl amine hydrochloride (0.92 mmol) and stirred at an ambient temperature for 4h. Upon evaporation of the solvent under reduced pressure provided a gummy mass, which was taken up into ice cold water and resulting white solid was filtered and dried to provide title compound in 72% yield as buff colored solid. M.P. 154-
56 0C and MS (M+l) = 478 (MH+, 100%) M.F. = C2IH25F2N7O4.
Example-65
(S)-N-{3-[4-(4-(l-benzyloxyimino-methyl)-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
Figure imgf000099_0002
To the solution of (S)-N-{3-[4-(4-(4-(formyl)-[l,2,3]-triazol-l-yl)-ρiρeridin-l-yl)-3- fluorophenyl] -2 -oxo-oxazolidin-5 -ylmethyl} -acetamide (0.46 mmol) in methanol (3 ml) was added benzyloxyamine hydrochloride (0.92 mmol) and stirred at an ambient temperature for 4h. Upon evaporation of the solvent under reduced pressure provided a gummy mass, which was taken up into ice cold water and resulting white solid was filtered and dried to provide title compound in 65% yield. M.P. 224-26°C and MS (M+l) = 536 (MH+, 100%) M.F. = C27H30FN7O4. Example-66
(S)-N- { 3 -[4-(4-(4-hydroxyiminoamino-methyl)- IH- [ 1 ,2,3]-triazol- 1 -yl)-piperidin- 1 - yl)-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000100_0001
To the solution of (S)-N-{3-[4-(4-cyano-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (0.45 mmol) in methanol was added hydroxylamine hydrochloride (0.9 mmol) and the reaction mixture was heated for 5h. The solvent was removed under reduced pressure and resulting sticky mass was taken into water (15 ml) and stirred for 10 min. The white solid separated out was filtered and dried to give the title compound (0.16 g, 80 %). MP. 242-44 0C and MS (M+ 1) = 461 (MH+, 100%) M.F. = C20H25FN8O4.
Example-67
(S)-N-{ 3-[4-(4-(4-N,N-dimethylaminoethylaminomethyl)- lH-[l,2,3]-triazol-l-yl)- piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000100_0002
To the solution of (S)-N-{3-[4-(4-(formyl-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (0.5 mmol) in methanol (5.0 ml) was added N,N-dimethylethylene diamine (0.6 mmol) and stirred for 2h at room temperature. Sodium cyanoborohydride (0.6 mmol) was added to the reaction mixture and further stirred for 5h at room temperature. The solvent was removed and the residue obtained was taken into the brine and extracted with ethyl acetate (3 x 10 ml). The combined organic layer was dried (Na2SO4) and evaporated to the crude solid which was on successive trituration with the ether has afforded a white solid (160 mg, 80%), M.P. 270(d)°C and MS (M+ 1) = 503 (MH+, 100%) M.F. = C24H35FN8O3. Examρle-68 and 69
(S)-N-{3-[4-(4-(2H-benzotriazol-2-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide and
(S)-N-{3-[4-(4-(lH-benzotriazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide
Figure imgf000101_0001
To the solution of (S)-N-{3-[4-(4-Methanesulfonyloxy-piperidin-l-yl)-3,5-difluoro phenyl] -2-oxo-oxazolidin-5-ylmethyl} -acetamide (1.37 mmol) in DMF (10 ml) benzotriazole (2.20 mmol) & K2CO3(2.20 mmol) were added and the mixture heated at 80°C for 14 hour. The reaction mixture was poured in to crushed ice and the separated solid was purified by silica gel column chromatography to obtain two isomeric products in 35 and 30% yield.
Isomer A: M.P. 167-169°C and MS (M+l) = 471.1 (MH+, 100%) for M.F. =
C23H24F2N6O3.
Isomer B: M.P. 187-189°C and MS (M+l) = 471.1 (MH+, 100%) for M.F. =
C23H24F2N6O3. Example-70 and 71
(S)-N-{ 3-[4-(4-Benzotriazol-2-yl- piperidin- l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl }-acetamide and
(S)-N-{3-[4-(4-Benzotriazol-l-yl- ρiperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethylj-acetamide
Figure imgf000102_0001
and
Figure imgf000102_0002
Following the procedure described above and using (S)-N- {3-[4-(4-methanesulfonyloxy- 2-yl-piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl }-acetamide the two products were obtained as isomeric products in 32% and 27% yields respectively Isomer
A: M.P.144-146 0C; MS (M+ 1) = 453.1 (MH+, 100%) for M.F. C23H25FN6O3 Isomer B :M.P.- 172-174 0C. MS (M+l) = 453.1 (MH+, 100%) for M-RC23H25FN6O3.
Exanaple-72 and 73
(S)-N-{3-[4-(4-(4-(lH-tetrazol-l-ylmethyl)-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; and
(S)-N- { 3-[4-(4-(2H-tetrazol-2-ylmethyl)-[ l,2,3]-triazol-l -yl)-piperidin- 1 -yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
Figure imgf000102_0003
and
Figure imgf000102_0004
To a stirred solution of (S)-N- { 3- [4-(4-(4-p-toluensulfonyloxy methyl)-[l,2,3]-triazol-l- yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (1.9 mmol) and lH-tetrazole (01,9 mmol) in DMF ( 5 ml) was added powdered K2CO3 (1.9 mmol) and heated at 70 0C for 18 hrs. Heating was stopped and cold water was added to the reaction mixture under stirring and then extracted with ethyl acetate (2 x 75 ml). Combined organic layer was then washed with brine and dried over Na2SO4 and evaporated under vacuum. Crude product upon purification by column chromatography over a silica gel a non polar product A as white solid in 15 % yield, M.P. 166-68 0C, MS (M+l) = 485 (MH+, 100%) M.F. = C21H25FNi0O3 and a polar product B in 10 % yield, MP. 154-56 0C, MS (M+l) = 485 (MH+, 100%) M.F. = C21H25FN10O3.
Example-74
(S)-N-{3-[4-(4-(lH-imidazol-l-ylmethyl)-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl }-acetamide;
Figure imgf000103_0001
To a stirred solution of (S)-N-{3-[4-(4-(4-p-toluensulfonyloxy methyl)-[l,2,3]-triazol-l- yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (1.9 mmol) and lH-imidazole (01,9 mmol) in DMF ( 5 ml) was added powdered K2CO3 (1.9 mmol) and heated at 700C for 18 hrs. Heating was stopped and cold water was added to the reaction mixture under stirring and then extracted with ethyl acetate (2 x 75 ml). Combined organic layer was then washed with brine and dried over Na2SO4 and evaporated under vacuum. Crude product upon purification by column chromatography over a silica gel provided off white solid in 62 % yield M.P. 132-34 0C and MS (M+l) = 483 (MH+, 100%) M.F. = C23H27FN8O3.
Example-75
(^-{S-^-Ci-ClH-tl^^l-triazol-l-y^-S-fluoropiperidin-l-yO-S-fluorophenylJ-S-ClH- [ 1,2,3 ]-triazol-l -ylmethyl) }-oxazolidin-2-one;
Figure imgf000104_0001
To the solution of (S)-N-{3-[4-(4-(ρ-toluenesulfonyloxy)-3-fluoro-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-[l,2,3]-triazol-l-yl (0.5 mmol) in DMF (5 ml) was added K2CO3 (0.6 mmol) and 1 H-[1, 2,3 ]-triazole (0.6 mmol) at room temperature and it was further heated at 700C for 15 h. The reaction mixture was slowly poured on the crushed ice and stirred for 15 min. A solid precipitated out was filtered and dried. The crude solid upon purification over silica gel has afforded a white solid in 35% yield.
M.P. 226-228(d) 0C and MS (M+ 1) = 431 (MH+, 100%) M.F. = C19H20F2N8O2.
Using the above procedure the following compounds were prepared
Figure imgf000104_0002
Example-79
(S)-N-{3-[4-(4-([l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-flviorophenyl]-2-oxo-oxazolidin-
5-ylmethyl }-thioacetamide;
Figure imgf000105_0001
To a stirred solution of (S)-N-{3-[4-(4-([l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (0.2 gm, 0.55 mmol) in THF(IO ml) was added Lawesson's reagent (0.23 gm,0.55 mmol ). Reaction mixture was stirred at 50-600C temperature for 4 hrs. Solvent was evaporated under vacuum and desired compound was purified by column chromatography using CHCl3-MeOH (98:2) as an eleunt affording pale yellow solid in (140 mg) 70% yield. M.P. 171-172 0C and MS
(M+l) = 419 (MH+, 100%) M.F. = C19H23FN6O2S.
Example-80 and 81
(S)-N- { 3- [4-(4-(5 -methyl-2H~tetrazol-2-yl)-piperidin- 1 -yl)-3 -fluorophenyl] -2-oxo- oxazolidin-5-ylmethyl }-acetamide; and
(S)-N-{3-[4-(4-(5-methyl-lH-tetrazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000105_0002
To a solution of (S)-N-{3-[4-(4-methanesulfonyloxy-2-yl-piperidin-l-yl)-3- fluoroρhenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (1.37 mmol) in DMF (10 ml) were added 5-methyl-lH-tetrazole (2.20 mmol) & K2CO3 (2.20 mmol) and the mixture heated at 8O0C for 14 hour. The reaction mixture was poured in to crushed ice and the separated solid was purified by silica gel column chromatography to obtain two isomeric products in 36% and 31% yields. Isomer A: MP. 184-186 0C; MS (M+l) = 418 (MH+, 100%) for M.F. Ci9H24FN7O3 Isomer B: M.P.-205-207 0C; MS (M+l) = 418 (MH+, 100%) for M.F. C19H24FN7O3
Example-82 and 83
(S)-N- { 3- [4-(4-(5 -methyl- lH-tetrazol- 1 -yl)-piperidin- 1 -yl)-3 ,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl }-acetamide; and
(S)-N-{3-[4-(4-(5-methyl-2H-tetrazol-2-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000106_0001
To a solution of (S)-N-{3-[4-(4-methanesulfonyloxy-ρiperidin-l-yl)-3,5-difluoro phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (1.37 mmol) in DMF (10 ml ) were added 5-methyl-lH tetrazole (2.20 mmol) & K2CO3 (2.20 mmol) and the mixture heated at 80°C for 14 hour . The mixture was poured in to crushed ice and the separated solid was purified by silica gel column chromatography to obtain two isomeric products in 29% and 23% yields respectively. Isomer A: M.P. 214-216 0C; (M+l) = 435 (MH+, 100%) for M.F. C19H23F2N7O4 Isomer B: M.P.-232-234 0C; (M+l) = 435 (MH+, 100%) for M.F. C19H23F2N7O4. Example-84 and 85
(S)-N-{3-[4-(4-(5-methylsulfanylmethyl-2H-tetrazol-2-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; and
(S)-N-{3-[4-(4-(5-methylsulfanylmethyl-lH-tetrazol-l-yl)-piperidin-l-yl)-3- fluorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide ;
Figure imgf000107_0001
and
Figure imgf000107_0002
To a stirred solution of (S)-N-{3-[4-(4-p-toluensulfonyloxy-piperidin-l-yl)-3-fluoro phenyl]-2-oxo-oxazolidin-5-ylmethyl} -acetamide (1.0 gm,1.9 mmol) and 5- methylsulfanylmethyl-lΗ-tetrazole (0.26 g, 0.2 mol) in DMF (5 ml) was added powdered K2CO3 (0.262 mg, 1.9 mmol). The reaction mixture was heated at 700C for 18 h. Heating was stopped and cold water was added- to the reaction mixture under stirring and then extracted with ethyl acetate (2 x 75 ml). Combined organic layer was then washed with brine and dried over Na2SO4 and evaporated under vacuum. Crude product upon purification by column chromatography over a silica gel using (9.8:0.2) as an eluent afforded white solid (non-polar isomer, 150 mg, 15%) as a cream colored solid. M.P.
118-119 0C and MS (M+l) = 464 (MH+, 100%) M.F. = C20H26FN7O3S. and second isomer was obtained in 12% yield as a pale solid. M.P. 199-200 °C and MS (M+l) = 464 (MH+, 100%) M.F. = C20H26FN7O3S.
Example-86 and 87
(S)-N-{3-[4-(4-(5-benzylsulfanyl-iH-tetrazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]- 2-oxo-oxazolidin-5-ylmethyl }-acetamide; and
(S)-N-{3-[4-(4-(5-(benzylsulfanyl)-2H-tetxazol-2-yl)-piperidin-l-yl)-3,5-difluorophenyl]-
2-oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000108_0001
To a solution of (S)-N- {3-[4-(4-Methanesulfonyloxy-2-yl- piperidin-l-yl)-3,5-di fluorophenyl] -2-oxo-oxazolidin-5-ylmethyl}-acetamide (1.37 mmol) in DMF (10 ml ) were added 5(thiobenzyl)-lH-tetrazole (3.01 mmol)&K2CO3 (2.05mmol) and the mixture heated at 80°C for 14 hour . The reaction mixture was poured in to crushed ice and the separated solid was purified by silica gel column chromatography to obtain two isomeric products in 30% and 25% yields respectively.
Isomer A: M.P. 152-1540C and MS (M+l) = 544(MH+, 100%) for M.F. C25H27F2N7O3S
Isomer B: M.P. 146-1480C and MS (M+l) = 544(MH+, 100%) for M.F. C25H27F2N7O3S
Example-88 and 89
(S)-N- { 3-[4-(4-(5-(benzylsulfanyl)-2H-tetrazol-2-yl)-piperidin- l-yl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-acetamide; and (S)-N-{3-[4-(4-(5-(benzylsulfanyl)-2H-tetrazol-2-yl)-piperidin-l-yl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000109_0001
and
Figure imgf000109_0002
To a solution of (S)-N-{3-[4-(4-methanesulfonyloxy-2-yl-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (1.37 mmol) in DMF (10 ml ) were added 5-(thiobenzyl)-lH-tetrazole (3.01 mmol) & K2CO3 (2.05 mmol) and the mixture heated at 800C for 14 hour . The reaction mixture was poured in to crushed ice and the separated solid was purified by silica gel column chromatography to obtain two isomeric products in 28% and 26% yields respectively
Isomer A: M.P. 178-18O0C and MS (M+l) = 525(MH+, 100%) for M.F. C25H28FN7O3S Isomer B: M.P. 144-1460C and MS (M+l) = 525(MH+, 100%) for M.F. C25H28FN7O3S
Example-90
(S)-N-{3-[4-(4-(5-methylsulfonylmethyl-lH-tetrazol-l-yl)-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000109_0003
By following the procedure as described in above example and by using (S)-N-{3-[4-(4- p-toluensulfonyloxy-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}- acetamide, 5-methylsulfonylmethyl-lΗ-tetrazole and K2CO3, followed by purification by column chromatography over a silica gel using (9.8:0.2) as an eluent afforded white solid non-polar isomer, in 15% yield as a cream colored solid. M.P. 192 0C and MS (M+l) =
514 (MH+, 100%) M.F. = C20H25F2N7O5S. Example-91
(S)-N-{3-[4-(4-(5-methylsulfonylmethyl-lH-tetrazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide
Figure imgf000110_0001
By following the procedure as described in above example and by using (S)-N-{3-[4-(4- p-toluensulfonyloxy-piperidin-l-yl)-3-fluorophenyl]-2~oxo-oxazolidin-5-yl methyl }- acetamide, 5-methylsulfonylmethyl-lΗ-tetrazole and K2CO3, followed by purification by column chromatography over a silica gel using (9.8:0.2) as an eluent afforded white solid non-polar isomer, in 15% yield as a cream colored solid. M.P. 192 0C and MS (M+l) = 496 (MH+, 100%) M.F. = C20H26FN7O5S.
Exanτple-92 and 93 (S)-N-{3-[4-(4-(5-(thioρhen-2-yl-methyl)-2H-tetrazol-2-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide; and
(S)-N-{3-[4-(4-(5-(thiophen-2-yl-methyl)4H-tetrazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl }-acetamide; ■
Figure imgf000110_0002
By following the procedure as described in above example and by using (S)-N- {3-[4-(4- p-toluensulfonyloxy-piperidin- l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } - acetamide, 5-thiophen-2-ylmethyl-lH-tetrazole and K2CO3, followed by purification by column chromatography over a silica gel using (9.8:0.2) as an eluent afforded white solid non-polar isomer, in 20% yield as a cream colored solid. M.P. 149-150 0C and MS (M+l) = 500 (MH+, 100%) M.F. = C23H26FN7O3S. and further elution gave second compound in 15% yield. M.P. 171-172 0C and MS (M+l) = 500 (MH+, 100%) M.F. = C23H26FN7O=S.
Example-94 and 95
(S)-N-{3-[4-(4-(5-(thiophen-2-yl-methyl)-lH-tetrazol-l-yl)-piρeridin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; and
(S)-N-{3-[4-(4-(5-(thiophen-2-yl-methyl)-2H-tetrazol-2-yl)-piperidin-l-yl)-3,5- difluorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide;
Figure imgf000111_0001
By following the procedure as described in above example and by using (S)-N- { 3-[4-(4- p-toluensulfonyloxy-piperidiri-l-yl)-3,5-difluoroρhenyl]-2-oxo-oxazolidin-5-ylmethyl}- acetamide, 5-thiophene2-methyl-lΗ-tetrazole and K2CO3, followed by purification by column chromatography over a silica gel using (9.8:0.2) as an eluent afforded white solid non-polar isomer, in 28% yield as a cream colored solid. MP 142-144 0C and MS (M+l)
= 518 (MH+, 100%) M.F.= C23H25F2N7O3S.
Further elution afforded polar isomer as white solid in 12% yield. M.P. 204-206 0C and
MS (M+l) = 518 (MH+, 100%) M.F. = C23H25F2N7O3S. Example-96
(S)-N- { 3 -[4-(4-(5-(morpholinocarbonylmethyl)- 1 H-tetrazol- l-yl)-piperidin- 1 -yl)-3- fluorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide;
Figure imgf000112_0001
By following the procedure as described in above example and by using (S)-N-{ 3-[4-(4- p-toluensulfonyloxy-piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}- acetamide, l-Morpholin-4-yl-2-(2Η-tetrazol-5-yl)-ethanone and K2CO3, followed by purification by column chromatography over a silica gel using (9.8:0.2) as an eluent afforded white solid non-polar isomer, in 20% yield as a cream colored solid. M.P. 146- 48 0C and MS (M+ 1) = 532 (MH"1-, 100%) MP. = C24H31FN8O5.
Example-97
(S)-N-{3-[4-(4-(5-(morpholinocarbonylmethyl)-lH-tetrazol-l-yl)-piperidin-l-yl)-3,5- difluorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide;
Figure imgf000112_0002
The title compound is prepared as per the procedure mentioned for the above compound. Use of toluene-4-sulfonic acid l-{4-[5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-3, 5-difluoro-phenyl}-piperidin-4-yl ester (1.0 gm,2.0 mm) and l-Morpholin-4-yl-2-(2Η- tetrazol-5-yl)-ethanone (0.430 g, 2.2 mol) in DMF was added powdered K2CO3 (0.276 mg, 2.0mm) has afforded the title compound as non-polar isomer (165 mg, 17 %) as white solid. M.P. 128-130 0C and MS (M+l) = 549 (MH+, 100%) M.F. = C24H30F2N8O5.
Example-98
(S)-N- { 3-[4-(4-(5-(morpholin-4-yl)-2H-tetrazol-2-yl)-piperidin- l-yl)-3-fluoroρhenyl]-2- oxo-oxazolidin-5-ylmethyl } -acetamide;
Figure imgf000113_0001
To a solution of (S)-N-{3-[4-(4-methanesulfonyloxy-2-yl-piperidin-l-yl)-3-fluoro phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (1.37 mmol) in DMF (10 ml ) were added 5-Morpholin-4-yl-lH-tetrazole (3.01 mmol) & K2CO3 (2.05mmol) and the mixture heated at 800C for 14 hour . The reaction mixture was poured in to crushed ice and the separated solid was purified by silica gel column chromatography to obtain the product in 35%yield M.P. 210-2140C and MS (M+l) = 489 (MH+, 100%) for M.F. = C22H28FN8O4.
Example-99 (S)-N-{3-[4-(4-(5-(morpholin-4-yl)-2H-tetrazol-2-yl)-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000113_0002
To a solution of (S)-N-{3-[4-(4-methanesulfonyloxy-2-yl-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (1.37 mmol) in DMF (10 ml ) were added 5-morpholin-4-yl-lΗ-tetrazole (3.01 mmol) & K2CO3 (2.05 mmol) and the mixture heated at 80°C for 14 hour . The reaction mixture was poured in to crushed ice and the separated solid was purified by silica gel column chromatography to obtain the product in 60%yield. M.P. 232-2340C and MS (M+l) = 507 (MH+, 100%) for M.F. = C22H27F2N8O4. Example- 100
((S)-N-{3-[4-(4-(5-phenyl-2H-tetrazol-2-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000114_0001
To a solution of (S)-N-{3-[4-(4-methanesulfonyloxy-2-yl-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetarnide (1.37 mmol) in DMF (10 ml ) were added phenyl lH-tetrazole (3.01 mmol) & K2CO3 (2.05mmol) and the mixture heated at 8O0C for 14 hour . The reaction mixture was poured in to crushed ice and the separated solid was purified by silica gel column chromatography to obtain the product in 45%yield MP. 212-2140C and MS (M+ 1) = 480(MH+, 100%) for MJF. = C24H25FN7O3.,
Example- 101
(S)-N- {3-[4-(4-(5-(4-Nitrophenyl tetrazol)-2-yl- piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000114_0002
To a solution of (S)-N-{3-[4-(4-methanesulfonyloxy-2-yl-piperidin-l-yl)-3- fluorophenyl] -2-oxo-oxazolidin-5-ylmethyl}-acetamide (1.37 mmol) in DMF (10 ml) were added 4-nitrophenyl-lH-tetrazole (3.01 mmol) & K2CO3 (2.05 mmol) and the mixture heated at 80 0C for 14 hour . The reaction mixture was poured in to crushed ice and the separated solid was purified by silica gel column chromatography to obtain the product in 56% yield. M.P. 184-186 °C and MS (M+l) = 525 (MH+, 100%) for M.F. = C24H25FN8O5.
Example- 102
(S)-N-{3-[4-(5-(4-Nitrophenyl-tetrazol)-2-yl-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
Figure imgf000115_0001
To a solution of (S)-N- {3-[4-(4-methanesulfonyloxy-2-yl-piperidin-l-yl)-3,5-difluoro phenyl]-2-oxo-oxazolidin~5-ylmethyl}-acetamide (1.37 mmol) in DMF (10 ml) were added 5(4-nitrophenyl)-lH-tetrazole (3.01 mmol) & K2CO3 (2.05mmol) and the mixture heated at 8O0C for 14 hour . The reaction mixture was poured in to crushed ice and the separated solid was purified by silica gel column chromatography to obtain the product in
68% yield. M.P. 203-205 0C and MS (M+ 1) = 543 (MH+, 100%) for M.F. = C24H24F2N8O5.
Example- 103
(S)-N- { 3-[4-(4-(5-Pyridin-3-yl -tetrazol)-2-yl- piperidin- 1 -yl)-3-fluorophenyl] -2-oxo- oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000115_0002
To a solution of (S)-N-{3-[4-(4-methanesulfonyloxy-2-yl-piperidin-l-yl)-3-fluorophenyl ]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (1.37 mmol) in DMF (10 ml ) were added 5- pyridin-3-yl-lH-tetrazole (3.01 mmol) & K2CO3 (2.05mmol) and the mixture heated at 800C for 14 hour . The reaction mixture was poured in to crushed ice and the separated solid was purified by silica gel column chromatography to obtain the product in 49% yield M.P. 184-186°C and MS (M+ 1) =481(MH+, 100%) for M.F. = C23H25FN8O3
Example- 104
(S)-N-{3-[4-(4-(5-Pyridin-3-yl -tetrazol)-2-yl- piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
Figure imgf000116_0001
To a solution of (S)-N-{3-[4-(4-methanesulfonyloxy-2-yl-piperidin-l-yl)-3-fluoro phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (1.37 mmol) in DMF (10 ml ) were added 5-pyridin-3-yl-lH-tetrazole (3.01 mmol) & K2CO3 (2.05mmol) and the mixture heated at 800C for 14 hour . The reaction mixture was poured in to crushed ice and the separated solid was purified by silica gel column chromatography to obtain the product in 49% yield. M.P. 214-217°C and MS (M+l) = 499(MH+, 100%) for M.F. = C23H24F^N8O3.
Example- 105 (S)-N-{3-[4-(4-(5-(4-pyridinyl)-tetrazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl }-acetamide
Figure imgf000116_0002
By following the procedure as described in above example and by using (S)-N- {3-[4-(4- p-toluensulfonyloxy-piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}- acetamide, 4-(lH-tetrazol-5-yl)-pyridine and K2CO3, followed by purification by column chromatography over a silica gel using (9.8:0.2) as an eluent afforded white solid non- polar isomer, in 17% yield as a cream colored solid. M.P. 182-84 °C and MS (M+l) = 481 (MH+, 100%) M.F. = C23H25FN8O3.
Example-106 •
(S)-N-{3-[4-(4-(5-(4-pyridmyl)-tetrazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2- oxo-oxazolidin-5~ylrnethyl}-acetamide
Figure imgf000117_0001
By following the procedure as described in above example and by using (S)-N-{3-[4-(4- p-toluensulfonyloxy-ρiperidin-l-yl)-3,5-difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}- acetamide, 4-(lH-tetrazol-5-yl)-pyridine and K2CO3, followed by purification by column chromatography over a silica gel using (9.8:0.2) as an eluent afforded white solid non- polar isomer, in 22% yield as a cream colored solid. M.P. 202-204 0C and MS (M+ 1) = 499 (MH+, 100%) M.F. = C23H24F2N8O3.
Example- 107 (S)-N-{3-[4-(4-(5-amino-lH-tetrazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide
Figure imgf000117_0002
By following the procedure as described in above example and by using (S)-N- {3- [4-(4- p-toluensulfonyloxy-piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}- acetamide, 5-amino-lH tetrazole and K2CO3, followed by purification by column chromatography over a silica gel using (9.8:0.2) as an eluent afforded white solid (polar isomer), in 12% yield as a cream colored solid. M.P. 174-176 °C and MS (M+ 1) = 419
(MH+, 100%) M.F. = Ci8H23FN8O3.
Example- 108
(S)-N- { 3-[4-(4-5-amino- lH-tetrazol- l-yl)-piperidin- l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide
Figure imgf000118_0001
By following the procedure as described in above example and by using (S)-N-{ 3-[4-(4- p-toluensulfonylox.y-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}- acetamide, 5-amino-lH-tetrazole and K2CO3, followed by purification by column chromatography over a silica gel using (9.8:0.2) as an eluent afforded white solid (polar isomer), in 12% yield as a cream colored solid. M.P. 218-220°C and MS (M+ 1) = 437 (MH+, 100%) M.F. = Ci8H22F2N8O3.
Example- 109
(S)-N-{3-[4-(4-(5-(diethylamino)-2H-tetrazol-2-yl)-piperidin-l-yl)-3,5-difluorophenyl]-
2-oxo-oxazolidin-5-ylmethyl } -acetamide
Figure imgf000118_0002
To a solution of (S)-N- {3-[4-(4-Methanesulfonyloxy-2-yl- piperidin-l-yl)-3,5-difluoro phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (1.37 mmol) in DMF (10 ml) were added 5-diethylamino-lΗ-tetrazole (3.01 mmol) & K2CO3 (2.05 mmol) and the mixture heated at 80° C for 14 hour . The reaction mixture was poured in to crushed ice and the separated solid was purified by silica gel column chromatography to obtain the product in 55%yield M.P. 197-1990C and MS (M+ 1) = 507 (MH+, 100%) for M.F. = C22HSoF2N8O3. Example- 110
(S)-N-{3-[4-(4-(5-(piperazin-l-yl)-2H-[l,2,3,4],-tetrazol-2-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylrnethyl } -acetamide
Figure imgf000119_0001
(S)-N-[3-(4-{4-[5-(4-Benzyl-piperazin-l-yl)-tetrazol-2-yl]-piperidin-l-yl}-3-fluoro- phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide(0.86mmoles) was reacted with Ammonium formate (6.9 mmoles) and 10% palladium charcoal(0.5%w/w) in methanol (25 ml) under reflux for 2 h. The mixture was filtered through celite and the filtrate was concentrated to obtain the product in 90%yield. M.P. 184-186°C and MS (M+l) = 488 (MH+, 100%) for M.F. = C22H30FN9O3.
Example-I ll
(S )-N- { 3- [4-(4-(5 -(piperazin- 1 -yl)-2H-tetrazol-2-yl)-piperidin- 1 -yl j-3 ,5-difluorophenyl]-
2-oxo-oxazolidin-5-ylmethyl } -acetamide
Figure imgf000119_0002
(S)-N-[3-(4-{4-[5-(4-Benzyl-piperazin-l-yl)-tetrazol-2-yl]-piperidin-l-yl}-3,4-difluoro- phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide (0.83 mmoles) was reacted with Ammonium formate (6.7 mmoles) and 10% palladium charcoal (0.5%w/w) in methanol 25 ml under reflux for 2 hour. The mixture was filtered through celite and the filtrate was concentrated to obtain the product (90%yield). M.P. 18O-185°C and MS (M+l) = 506
(MH+, 100%) for M.F. = C22H29F2N9O3. Example-112
(S)-N-[3-(3-Fluoro-4-{4-[5-(4-methyl-piperazin-l-yl)-tetrazol-2-yl]-piperidin-l-yl}- phenyl)-2-oxo-oxazolidin-5-ylrnethyl]-acetamide;
Figure imgf000120_0001
To a solution of (S)-N-(3-{3-Fluoro-4-[4-(5-piperazin-l-yl-tetrazol-2-yl)-piperidin-l-yl]- phenyl}-2-oxo-oxazolidin-5-ylmethyl)-acetamide(0.2mmoles) in 10 ml dry tetra hydro furan, at 0-50C, was added sodium hydride (0.24 mmoles) in small portions. After 30min, was added methyl iodide and the resulting mixture for 3h at the same temp. The solvent was evaporated under reduced pressure and the residue chromatographed on a column of silica gel to obtain the product in 56 % yield. M.P. 174-176°C and MS (M+ 1)
= 502.2 (MH+, 100%) for M.F. = C23H32FN9O3.
Example- 113
(S)-N- { 3-[4-(4-(5-(4-methylpiperazin-l -yl)-2H-tetrazol-2-yl)-piperidin- 1 -yl)-3,5- difluorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide;
Figure imgf000120_0002
(S)-N-(3-{3,5-difluoro-4-[4-(5-piperazin-l-yl-tetrazol-2-yl)-piperidin-l-yl]-phenyl}-2- oxo-oxazolidin-5-ylmethyl)-acetamide (0.44mmoles) was added portionwise to a stirred solution of aq. 88% formic acid ( 3.1mmoles) and 37% aq. formaldehyde (2.68 mmoles) in 10 ml water at 5 0C. The solution is heated under reflux for 12 hours, cooled basified with 10% aq. Na2CO3 and extracted with ethyl acetate. Evaporation of ethyl acetate layer under reduced pressure afforded titled compound in 60 % yield. M.P. 184-188 °C and MS (M+l) = 520.2 (MH+, 100%) for M.F. = C23H3IF2N9O3. Example- 114
(S)-N-{3-[4-(4-(5-(4-acetyl-piperazin-l-yl)-2H-tetrazol-2-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
Figure imgf000121_0001
(S)-N-(3 - { 3-Fluoro-4-[4-(5-piperazin- 1 -yl-tetrazol-2-yl)-piperidin- 1 -yl] -phenyl } -2-oxo- oxazolidin-5-ylmethyl)-acetamide (2.0mmoles) was reacted with acetic anhydride (2.4mrαoles) at 25- 30 °Cin presence of triethyl amine (3.2 mmol) in 25 ml of THF for 2 hours. The solvent was evaporated under reduced pressure and residue was treated with 20 ml water. The separated solid was filtered and dried to obtain the product in 55% yield. M.P. 216-218 0C and MS (M+l) = 530 (MH+, 100%) for M.F. = C24H33FN9O4
Example- 115
(S)-N- { 3-[4-(4-(5-(4-Acetyl-piperazin- l-yl)-tetrazol-2-yl)-piperidin- 1 -yl)-3,5-difluoro- phenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide ;
Figure imgf000121_0002
(S)-N-(3-{3,5-Difluoro-4-[4-(5-piperazin-l-yl-tetrazol-2-yl)-piperidin-l-yl]-phenyl}-2- oxo-oxazolidin-5-ylmethyl)-acetamide (1.97 mmol) was reacted with Acetic anhydride(2.37mmoles) at 25- 30 °C in presence of base triethyl amine (3.16mmoles) in
25 ml tetrahydrofuran for 2 hours. The solvent was evaporated under reduced pressure and residue was treated with 20 ml of water. The separated solid was filtered and dried to obtain the product in 41% yield. M.P. 200-205 0C and MS (M+l) = 548(MH+, 100%) for M.F. = C24H31FN9O4. Example- 116
(S)-N-{ 3-[4-(4-(5-(4-Cyano-piperazin-l-yl)-tetrazol-2-yl)-piperidin-l-yl)-3 -fluoro- phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000122_0001
in 25 ml methanol for 5 hours. The solvent was evaporated under reduced pressure residue was treated with 20 ml of water. The separated solid was filtered and dried to obtain the product in 57% yield. M.P. 208-2100C and MS (M+l) = 513.2 (MH+, 100%)
Figure imgf000122_0002
Example- 117 (S)-N- [3 -(4- { 4-[5-(4-Cyano-piperazin- 1 -yl)-tetrazol-2-yl] -piperidin- 1 -yl } -3 ,5-difluoro- phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;
Figure imgf000122_0003
(S)-N-(3-{3,5-Difluoro-4-[4-(5-piperazin-l-yl-tetrazol-2-yl)-piperidin-l-yl]-phenyl}-2- oxo-ox.azolidin-5-ylmethyl)-acetamide(1.98mmoles) was reacted with Cyanogen bromide (2.17mmoles) at 25- 300C in presence of sodium hydrogen carbonate (3.16mmoles) in 25 ml methanol for 5 hours. The solvent was evaporated under reduced pressure and residue was treated with 20 ml of water. The separated solid was filtered and dried to obtain the product in 57% yield. M.P. 198-2000C and MS (M+l) = 531.1 (MH+, 100%) for M.F. = C23H28F2N1OO3. Example-118
(S)-N-{3-[4-(4-(5-(4-Benzyl-piperazin-l-yl)-tetrazol-2-yl)-piperidin-l-yl)-3-fluoro- phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000123_0001
To a solution of (S)-N- {3-[3-fluoro-4-(4-hydroxy-4-methanesulphonyloxymethyl- piperidin- 1 -yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide (2.32mmol) in N,N-dimethylformamide (10 ml), l-benzyl-4-(2H-tetrazol-5-yl)-piperazine (3.72mmol) and K2CO3 (3.72mmol) were added. The resulting mixture was stirred at 90° for 18 h. The reaction mixture was poured on to crushed ice. The separated solid was filtered and purified by column chromatography over silica gel to obtain the product as a white solid in 46% yield. M.P. 2O2-204°C and MS (M+ 1) = 578.1(MH+, 100%) M.F. = C29H36FN9O3.
Example- 119
(S)-N-{3-[4-(4-(5-(4-Benzyl-piperazin-l-yl)-tetrazol-2-yl)-piperidm-l-yl)-3,5-difluoro- phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000123_0002
(S)-N-{3-[3,5-difluoro-4-(4-methanesulphonyloxymethyl-piperidin-l-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl} -acetamide (2.2mmol) was reacted with 1 -Benzyl -4-(2H-tetrazol- 5-yl)-piperazine. (3.56mmol) and K2CO3 (3.56mmol) in N, N-dimethylformamide (10 ml) at 250C for 18 hour and by purifying the compound by silica gel column chromatography the product was obtained as off white solid in 47% yield.
M.P. 188-190°C and MS (M+ 1) = 597 (MH+, 100%) for M.F. = C29H35F2N9O3. Example- 120
(S)-N-{3-[4-(4-(lH-tetrazol-5-ylmethyl)-piperidin-l-yl)-3-fluoro-phenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide
Figure imgf000124_0001
To the solution of N-{3-[4-(4-cyanomethyl-piperidin-l-yl)-3-fluoro-phenyl]-2-oxo- oxazolidin-5-ylmethyl} -acetamide (0.3 g, 0.8 mmol) in toluene (7 ml) was added trimethylsilyl azide (210 μl, 1.6 mmol) and dibutyltin oxide (40 mg, 0.16 mmol) and the reaction mixture was refluxed at HO0C for 24 h. The solvent was evaporated under reduced pressure and the residue was purified by the column chromatography. A white solid was obtained (0.2 g, 66%) as a title compound.
M.P. 164-1660C and MS (M+l) = 418 (MH+, 100%) M.F. = C19H24FN7O3.
Example- 121
(S)-N-{3-[4-(4-(lH-tetrazol-5-ylmethyl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide
Figure imgf000124_0002
The title compound was obtained as per procedure described above and by using N- { 3- [4-(4-cyanopiperidin-l-yl)-3,4-difluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl} -acetamide and purification over silica gel column to provide a white solid in 66% yield. M.P. 176- 78 °C and MS (M+ 1) = 436 (MH+, 100%) M.F. = C19H23F2N7O3.
Example- 122
(R)-{3-[4-(4-(lH-tetrazol-l-yl)-piρeridin-l-yl)-3-fluorophenyl]-5-(lH-[l,2,3]-triazol-
1 -ylmethyl) }-oxazolidin-2-one;
Figure imgf000125_0001
To a stirred solution of (S)-N-{3-[4-(4-toluenesulfonyloxy-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-[l,2,3]-triazol-l-yl (2.0 mmol) and IH- tetrazole (2.1 mmol) in DMF was added powdered K2CO3 (2.5 mmol) and heated at 700C for 18 hrs. Heating was stopped and cold water was added to the reaction mixture under stirring and then extracted with ethyl acetate (2 x 75 ml). Combined organic layer was then washed with brine and dried over Na2SO4 and evaporated under vacuum. Crude product upon purification by column chromatography over a silica gel using (9.8:0.2) as an eluent afforded white solid. Non-polar isomer: M.P. 192-194 0C and MS (M+ 1) = 414 (MH+, 100%) M.E = C]8H20FN9O2.
Example- 122 and 123 (R)-{3-[4-(4-(lH-tetrazol-l-yl)-ρiperidin-l-yl)-3-fluoroρhenyl]-5-(lH-[l,2,3]-triazol- l-ylmethyl)}-oxazolidin-2-one; and
(S)-N-{3-[4-(4-(tetrazol-2-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl-}-[ 1 ,2,3]-triazol- 1 -yl;
Figure imgf000125_0002
To a stirred solution of (R)-N-{3-[4-(4-toluenesulfonyloxy-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-[l,2,3]-triazol-l-yl (2.0 mmol) and 1Η- tetrazole (2.1 mmol) in DMF was added powdered K2CO3 (2.5 mmol) and heated at 700C for 18 hrs. Heating was stopped and cold water was added to the reaction mixture under stirring and then extracted with ethyl acetate (2 x 75 ml). Combined organic layer was then washed with brine and dried over Na2SO4 and evaporated under vacuum. Crude product upon purification by column chromatography over a silica gel using (9.8:0.2) as an eluent afforded white solid. Non-polar isomer: M.P. 192-194 0C and MS (M+l) = 414 (MH+, 100%) M.F. = Ci8H2OFN9O2. Polar isomer: M.P. 184-186 0C and MS (M+l) = 414 (MH+, 100%) M.F. = C18H20FN9O2.
Example- 124
(R)-N-{3-[4-(4-(tetrazol-5-yl)-piperidin-l-yl)-3-fluorophenyl]-5-(lH-[l,2,3]-triazol- l-ylmethyl)}-oxazolidin-2-one;
Figure imgf000126_0001
To the solution of N-{3-[4-(4-cyanomethyl-piperidin-l-yl)-3-fluoro-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-[l,2,3]-triazol-l-yl (0.8 mmol) in toluene (7 ml) was added trimethylsilyl azide (210 ml, 1.6 mmol) and dibutyltin oxide (40 mg, 0.16 mmol) and the reaction mixture was refluxed at 12O0C for 24 h. The solvent was evaporated under reduced pressure and the residue was purified by the column chromatography. Purification over1 silica gel provided a white solid in 62% yield. M.P. 208(d) °C and MS
(M+l) = 414 (MH+, 100%) M.F. = C18H20FN9O2.
Example- 125
(S)-N-{3-[4-(4-([l,2,3]-triazol-l-yl)-methyl-piperidin-l-yl)-3-fluoro-phenyl]-5-(isoxazol-
3-yloxymethyl)}-oxazolidin-2-one;
Figure imgf000126_0002
To the stirred solution of (R)-3-[4-(4-azidomethyl-piperidin-l-yl)-3-fluoro-phenyl]-5- (isoxazol-3-yloxymethyl)-oxazolidin-2-one (1 gm, 2.4 mmoles) in dioxane (20 ml) was added 2,5-norbornadiene (0.33 gm, 3.6 mmoles) and the resulting solution was stirred at 800C for 16 hours. Solvent was removed in- vacuum & the crude compound was purified by column eluting with CHC13:CH3OH (99:1) to afford the pure compound as off-white solid. M.P. 123-250C and MS (M+l) = 445(MH+,100%) M. F. ^C21H25FN6O4.
Example- 126
(R)-{3-[4-(4-((4-hydroxymethyl)-[l,2,3]-triazol-l-yl)-methyl-piperidin-l-yl)-3-fluoro- phenyl]- 5-(isoxazol-3-yloxymethyl)}-oxazolidin-2-one;
Figure imgf000127_0001
To the stirred solution of (R)-3-[4-(4-azidomethyl-piperidin-l-yl)-3-fluoro-phenyl]-5- (isoxazol-3-yloxymethyl)-oxazolidin-2-one (1 gm, 2.4 mmoles) in acetonitrile (10 ml) was added propargyl alcohol (0.161 gm , 2.88 mmoles) and CuI (0.09 gm, 0.48 mmoles) and the resulting solution was stirred under nitrogen at 250C for 16 hours. Solvent was removed in-vacuum & the crude compound was purified by column eluting with CHC13:CH3OH (98:2) to afford the pure compound as white solid, 65% yield. M.P. 154- 1570C and MS (M+l) = 473(MH+,100%) M. F. ^22H25FN6O5.
Example- 127
(S)-N- { 3-[4-(4-(5-methyl- [1 ,2,4]-oxadiazol-3-ylmethyl)-ρiperidin- 1 -yl)-3-fluoro- phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000127_0002
To the solution of (S)-N- {3-[4-(4-cyanomethyl-piperidin-l-yl)-3-fluoro-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide (0.3 g, 0.8 mmol) in methanol (10 ml) was added hydroxyl amine hydrochloride (330 mg, 4.8 mmol) and sodium bicarbonate (435 mg, 4.2 mmol) at room temperature. The reaction mixture was then heated under reflux for 4 h. The solvent was removed and the crude mass obtained was taken into the water stirred for 15 min., filtered and dried. The solid (250 mg, 0.6 mmol) obtained was then reacted with the acetyl chloride (50 ul, 0.66 mmol) in the presence of K^CO3 (90 nig, 0.66 mmol) in dioxane (3 ml) at room temperature for 15h. To then reaction mixture water (10 ml) was added and extracted with the ethyl acetate (3 x 10 ml). The combined organic layer was dried (Na2SO4) and evaporated under reduced pressure to. furnish the pale yellow solid (200 mg). This solid was then taken into toluene and heated under reflux for 16h. The solvent was removed under reduce pressure. The residue obtained was purified by the column chromatography over silica gel using CHCl3:MeOH (98:2) as an eluent to furnish the white solid (150 mg, 65 %). M.P. 136-138 0C and MS (M+ 1) = 432 (MH+, 100%) M.F. = C21H26FN5O4.
Example- 128
(S)-N-{3-[4-(4-(5-methyl-l,2,4-oxadiazol-3-ylmethyl)-piperidin-l-yl)-3,5-difluoro- phenyl]- 2-oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000128_0001
The title compound was obtained by using procedure as described in above example and by using (S)-N-{ 3-[4-(4-cyanomethyl-piperidin-l-yl)-3,5-difluoro-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide in the place of N-{3-[4-(4-cyanomethyl-piperidin-l- yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide in 67% yield as a pale yellow solid. M.P. 134-136 °C and MS (M+l) = 450 (MH+, 100%) M.F. =
C21H25F2N5O4. Example- 129
(S)-N-{3-[4-(4-(5-methyl-[l,2,4]-oxadiazol-3-yl)-piperidin-l-yl)-3-fluoro-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000129_0001
To the solution of (S)-N-{3-[4-(4-cyano-piperidin-l-yl)-3-fluoro-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide (0.3 g, 0.8 mmol) in methanol (10 ml) was added hydroxyl amine hydrochloride (330 mg, 4.8 mmol) and sodium bicarbonate (435 mg, 4.2 mmol) at room temperature. The reaction mixture was then heated under reflux for 4 h. The solvent was removed and the crude mass obtained was taken into the water stirred for 15 min., filtered and dried. The solid (250 mg, 0.6 mmol) obtained was then reacted with the acetyl chloride (50 μl, 0.66 mmol) in the presence of K2CO3 (90 mg, 0.66 mmol) in dioxane (3 ml) at room temperature for 15h. To then reaction mixture water (10 ml) was added and extracted with the ethyl acetate (3 x 10 ml). The combined organic layer was dried (Na2SO^ and evaporated under reduced pressure to furnish the pale yellow solid (200 mg). This solid was then taken into toluene and heated under reflux for 16h. The solvent was removed under reduce pressure. The residue obtained was purified by the column chromatography over silica" gel using CHCBMeOH (98:2) as an eluent to furnish the white solid (150 mg, 65 %).
M.P. 136-138 0C and MS (M+l) = 418 (MH+, 100%) M.F. = C20H24FN5O4.
Example- 130
(S)-N-{3-[4-(4-(5-phenyl-[l,2,4]-oxadiazol-3-ylmethyl)-piperidin-l-yl)-3-fluorophenyl]-
2-oxo-oxazolidin-5-ylmethyl } -acetamide;
Figure imgf000129_0002
The title compound was obtained by using procedure as described in above example and by using N-{3-[4-(4-cyanomethyl-piperidin-l-yl)-3-fluoro-phenyl]-2-oxo-oxazolidin-5- ylmethyl}-acetamide and benzoyl chloride in 65% yield as a white solid. M.P. 144-46 0C and MS (M+ 1) = 494 (MH+, 100%) M.F. = C26H28FN5O4.
Example-131
(S)-N-{ 3-[4-(4-(5-phenyl-l,2!4-oxadiazol-3-ylmethyl)-piperidin-l-yl)-3,5-difluoro- phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000130_0001
The title compound was obtained by using procedure as described in above example and by using (S)-N- {3-[4-(4-cyanomethyl-piperidin-l-yl)-3,5-difluoro-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide and benzoyl chloride in 65% yield as a white solid.
M.P. 152-54 0C and MS (M+l) = 512 (MH+, 100%) M.F. = C26H27F2N5O4.
Example- 132
(S)-N- { 3-[4-(4-(4-(5-pyridin-3-yl)-[l?2,4]-oxadiazol-3-ylmethyl)-piperidin- l-yl)-3- fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000130_0002
The title compound was obtained by using procedure as described in above example and by using N-{3-[4-(4-cyanomethyl-piperidin-l-yl)-3,5-difluoro-phenyl]-2-oxo-oxazolidin- 5-ylmethyl}-acetamide and nicotinyl chloride in 70% yield as a white solid. M.P.150 - 152°C and MS (M+l) = 495 (MH+, 100%) M.F. = C25H27FN6O4. Example- 133
(S)-N-{3-[4-(4-(5-methyl-l,3,4-oxadiazol-2-ylmethyl)-piperidin-l-yl)-3-fluoro-phenyl]-
2-oxo-oxazolidin-5-ylmethyl } -acetamide;
Figure imgf000131_0001
To the solution of N-{3-[4-(4-hydrazinocarbonylmethyl-piperidin-l-yl)-3-fluorophenyl]- 2-oxo-oxazolidin-5-ylmethyl } -acetamide (0.2 g, 0.5 mmol) in THF (5 ml) was added acetyl chloride (55 ul, 0.73 mmol) and refluxed for 2h. The residue obtained after the evaporation of the solvent was taken into the water and extracted with the ethyl acetate (3 x 10 ml). The combined organic layer was dried (Na2SO4) and it was evaporated to give the crude solid, which was purified by the column chromatography over silica gel. A white solid (110 mg, 55%) was obtained as a title compound. M.P. 0C and MS (M+l) = 432 (MU+, 100%) MF. = C2]H26FN5O4.
Example- 134 (S)-N-{ 3-[4-(4-(5-phenyl-[l,3,4]-oxadiazol-2-ylmethyl)-piperidin-l-yl)-3-fluoro-phenyl]-
2-oxo-oxazolidin-5-ylmethyl } -acetamide;
Figure imgf000131_0002
By using the same method as described above was used to obtain the title compound in 45% yield. MP. 199-200 0C and MS (M+l) = 494 (MH+, 100%) M.F. = C26H28FN5O4.
Example-135
(S)-N-{3-[4-(4-(5-Amino-l)3,4-thiadiazol-2-ylmethyl)-piperidin-l-yl)-3-fluoro-phenyl]-
2-oxo-oxazolidin-5-ylmethyl}-acetamide
Figure imgf000132_0001
To a stirred solution of (S)-N-{3-[4-(4-cyanomethylpiperidin-l-yl)-3-fluorophenyl]-2- oxo-l,3-oxazolidin-5-ylmethyl}-acetamide (250 mg, 0.7mmol) and thiosemicarbazide (67 mg, 0.7 mmol) in methane sulphonic acid (3.0 ml) was stirred at an ambient temperature for 6 hr. The mixture was poured to the crushed ice and extracted with ethyl acetate (20 ml x 3) organic layer was evaporated under vacuum yielding crude solid was recrystallized from MeOH-Ether resulting off white solid in (65 mg) 45 % yield. M.P.
206-207 0C and MS (M+ 1) = 449 (MH+, 100%) M.F. = C20H25FN6O3S.
Example-136
(S)-N-{3-[4-(4-(5-Amino-2ff-l,3,4-thiadiazol-2-yl)-piperidin-l-yl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl } -acetamide
Figure imgf000132_0002
Title compound was prepared as by using (S)-N-{3~[4-(4-cyanopiperidin-l-yl)-3- fluorophenyl]-2-oxo-l,3-oxazolidin-5-yl}methyl)acetamide and thiouarea following the procedure as mentioned in synthesis of above example in 42% yield. M.P. 168-69 0C and MS (M+l) = 435 (MH+, 100%) M.F. = Ci9H23FN6O3S.
Example- 137 (S)-N-{3-[4-(4-(3-ethoxycarbonyl-imidazol-l-yl)-methyl-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide
Figure imgf000132_0003
To a solution of (S)-N-{3-{4-[4-(N-hydroxyimnoamino-methyl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetarnide (0.2 gm,0.5 mmol) and ethyl propiolate (0.1 ml, 1.0 mmol) in diphenyl ether (8 ml) was heated at 170 0C for 3 hrs. After completion of reaction solvent was evaporated and compound was purified by column chromatography over silica gel using CHCl3:MeOH (98:2) as an eluent yielding off white solid 80 mg (25 %), M.P. 198-2000C and MS (M+l) = 488 (MH+, 100%) M.F. = C24H30FN5O5.
Example -138
(S)-N- { 3- [3 , 5-Difluoro-4-(4-2H-tetrazol-2-yl-piperidin- 1 -yl)-ρhenyl] -2-oxo- oxazolidin-5-ylmethyl}-carbarnic acid methyl ester
Figure imgf000133_0001
A solution of (S)-5-Aminomethyl-3-[3,5-difluoro-4-(4-2Η-tetrazol-2-yl-piperidin-l-yl)- phenyl]-oxazolidin-2-one (1.25 mmol) in dichloromethane(lθml), containing triethyl amine (3.75 mmol) was cooled to 00C. Methyl chloroformate (2.0 mmol) was added dropwise. The resulting mixture was stirred for 5h at room temp. The solvent was evaporated under reduced pressure and the residue chromatographed on a column on silica gel to obtain the product as white solid in 90% yield. M.P. 168-170°C and MS
(M+l) = 438 (MH+, 100%) M.F. = C18H21F2N7O4.
Using the above procedure the following compounds were prepared
Figure imgf000133_0002
Figure imgf000134_0001
Example -144
(S)-N-{ 3-[3,5-Difluoro-4-(4-[l,2,3]triazol-2-yl-piperidin-l-yl)-phenyl]-2-oxo- ox.azolidin-5-ylmethyl } -2,2-difluoro-acetamide
Figure imgf000134_0002
To a solution of (S)-5-Aminomethyl-3-[3,5-difluoro-4-(4-[l,2,3]triazol -2-yl-piperidin-l- yl)-phenyl]-oxazolidin-2-one (1.25 mmol) in dimethylformamide (10ml), were added successively difluoroacetic acid (1.25 mmol), HOBt (1.25mmol), EDCHCl (1.50mmol) and NMM(1.75mmol). The reaction mixture was stirred for 14h at room temp. The resulting mixture was poured in ice-water, stirred well and extracted with ethyl acetate. The extract was washed with water , dried and evaporated under reduced pressure. The residue obtained was chromatographed on a column on silica gel to obtain the product as white solid in 55% yield. M.P. 254-2550C and MS (M+ 1) = 437 (MH+, 100%) M.F. = C19H20F4N6O3 Using the above procedure the following compounds were prepared
Figure imgf000135_0002
Example -148
(S)-N- { 3- [3,5-Difluoro-4-(4-2H-tetrazole-2-yl-piperidin- 1 -yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl } -2,2-dichloro-acetamide
Figure imgf000135_0001
To a solution of (S)-5-Aminomethyl-3-[3,5-difluoro-4-(4-2H-tetrazole-2-yl-piperidin-l- yl)-phenyl]-oxazolidin-2-one (1.25 mmol) in dimethyl formamide (10ml), were added successively dichloroacetic acid(1.25 mmol), HOBt (1.25mmol), EDCHCl (1.50mmol) and NMM(1.75mmol). The reaction mixture was stirred for 14h at room temp. The resulting mixture was poured in ice-water, stirred well and extracted with ethyl acetate. The extract was washed with water , dried and evaporated under reduced pressure. The residue obtained was chromatographed on a column on silica gel to obtain the product as white solid in 80% yield.
M.P. 160-162°C and MS (M+l) = 490 (MH+, 100%) M.F. = C18H19Cl2F2N7O3 Example -149
(S)-N-{3-[3-fluoro-4-(4-2H-tetrazol-2-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethylj-carbamic acid ethyl ester
Figure imgf000136_0001
A solution of (S)-5-Aminomethyl-3-[3-fluoro-4-(4-2H-tetrazol-2-yl-piperidin-l-yl)- phenyl]-oxazolidin-2-one (1.25 mmol) in dichloromethane (10ml), containing triethyl amine (3.75 mmol) was cooled to O0C. Ethyl chloroformate (2.0 mmol) was added dropwise. The resulting mixture was stirred for 5h at room temp. The solvent was evaporated under reduced pressure and the residue chromatographed on a column on silica gel to obtain the product as white solid in 70% yield.
M.P. 176-1780C and MS (M+l) = 443 (MH+, 100%) M.F. = C18H22FN7O4
Example -150
(S)-N-{3-[3,5-Difluoro-4-(4-lH-tetrazole-l-yl-piperidin-l-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl }-2,2-difluoro-thioacetamide
Figure imgf000136_0002
To a solution of (S)-N-{3-[3,5-Difluoro-4-(4-lΗ-tetrazole-l-yl-piperidin-l-yl)-phenyl]-2- oxo-oxazolidin-5-ylmethyl}-2,2-difluoro-acetamide (1.25 mmol) in tetrahydrofuran (10ml), was added Lawesson's reagent (4.0 mmol), and the solution was heated under reflux for 1Oh. The solvent was evaporated under reduced pressure and the residue chromatographed on a column on silica gel to obtain the product in 40% yield.
M.P. 156-158°C and MS (M+l) = 456 (MH+, 100%) M.F. = C18H20F2N7O2S. Example -151
(S)-N-{3-[3,5-Difluoro-4-(4-lH-tetrazole-l-yl-piperidin-l-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl } -cyclopropane carboxamide
Figure imgf000137_0001
To a solution of (S)-5-Aminomethyl-3-[3,5-difluoro-4-(4-lΗ-tetrazole-l-yl-piperidin-l- yl)-phenyl]-oxazolidin-2-one (1.25 mmol) in dimethyl formamide (10ml), were added successively cyclopropane carboxylic acid (1.25 mmol), HOBt (1.25mmol), EDCHCl (1.50mmol) and NMM (1.75mmol). The reaction mixture was stirred for 14h at room temp. The resulting mixture was poured in ice-water, stirred well and extracted with ethyl acetate. The extract was washed with water, dried and evaporated under reduced pressure. The residue obtained was chromatographed on a column on silica gel to obtain the product as white solid in 72% yield.
M.P. 162-1640C and MS (M+ 1) = 448 (MH+, 100%) M.F. = C20H23F2N7O3.
Exaniρle-152 and 153
(S)-N-{3-[3,5-Difluoro-4-(4-[l,2,4]triazol-l-yl-piperidin-l-yl)-ρhenyl]-2-oxo- oxazolidin-5-ylmethyl } -propionamide; and
(S)-N-{3-[3,5-Difluoro-4-(4-[l,3,4]triazol-l-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin- 5-ylmethyl } -propionamide;
Figure imgf000137_0002
A mixture of (S)-N-{3-[4-methanesulphonyloxy-piperidin-l-yl)-3,5-difluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-propionarαide (1.12 xnM), 1,2,4-triazole (1.68 niM), and K2CO3 (1.68 mM) in DMF (10 ml) was heated for 22 hrs at 85°C. The resulting mixture was poured into ice-water and stirred for 30 min. The separated solid was purified by column chromatography to obtain two isomeric products in 18% and 22% yields respectively.
Isomer A: M.P. 156-1580C; MS(M+ 1)- 435 ; M.F. C20H24F2N6O3 Isomer B: M.P. 136-1380C; MS(M+ 1)- 435 ; M.F. C19H22F2N6O3
Example -154 and 155
(S)-N7 { 3- [3 , 5-Difluoro-4-(4-2H-tetrazol-2-yl-piperidin- 1 -yl)-phenyl] -2-oxo- oxazolidin-5-ylmethyl}-propionarnide; and (S)-N- { 3-[3,5-Difluoro-4-(4-lH-tetrazol-l-yl-piperidin- l-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-propionamide;
Figure imgf000138_0001
A mixture of (S)-N- { 3- [4-methanesulphonyloxy piperidin-l-yl)-3,5-difluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-propionamide (1.12 mm), tetrazole (1.68 mm), and K2CO3 (1.68 mm) in DMF (10 ml) was heated for 22 hrs at 85 0C. The resulting mixture was poured into ice-water and stirred for 30 min. The separated solid was purified by column chromatography to obtain two isomeric products in 28% and 22% yields respectively. Isomer A: M.P. 190-1920C; MS(M+1)- 436 ; M.F. C19H21F2N7O4 Isomer B: M.P. 158-16O0C; MS(M+!)- 436 ; M.F. C19H21F2N7O4. Example- 156 and 157
(S) N-{3-[3-Fluoro-4-(4-2H-tetrazol-2-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl } -propionamide; and (S) N- { 3-[3-Fluoro-4-(4- lH-tetrazol- 1-yl-piperidin- 1 -yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl } -propionamide;
Figure imgf000139_0001
and
Figure imgf000139_0002
A mixture of (S)-N-{3-[4-methanesulphonyloxy piperidin-l-yl)~3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl} -propionamide (1.12 mM) ,tetrazole (1.68 mM), and K2CO3 (1.68 mM) in DMF (10 ml) was heated for 22 hrs at 850C. The resulting mixture was poured into ice-water and stin-ed for 30 min. The separated solid was purified by column chromatography to obtain two isomeric products in 28% and 22% yields respectively. Isomer A: M.P. 170-1720C; MS(M+1)- 418 ; M.F. C19H22FN7O4 Isomer B: M.P. 156-1600C; MS(M+1)- 418 ; M.F. Ci9H22FN7O4
Example-158 and 159 (S)-N-{3-[3,5-Difluoro-4-(4-[l,2,3]-triazol-2-yl-piperidin-l-yl)-phenyl]-2-oxo- ox azoli din-5 -ylmethyl } -propionamide ; and
(S)-N- { 3- [3 ,5-Difluoro-4-(4-[ 1,2,3] -triazol- 1 -yl-piperidin- l-yl)-phenyl] -2-oxo- oxazolidin-5-ylmethyl}-ρropionamide;
Figure imgf000140_0001
A mixture of (S)-N- { 3- [4-methanesulphonyloxy piperidin-l-yl)-3,5-difluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-propionamide (1.12 mM), [l,2,3]-triazole (1.68 niM), and K2CO3 (1.68 mM) in DMF (10 ml) was heated for 22 hrs at 85°C. The resulting mixture was poured into ice-water and stirred for 30 min. The separated solid was purified by column chromatography to obtain two isomeric products in 18% and 22% yields respectively. Isomer A: M.P. 208-2100C; MS(M-J-I)- 435 ; M.R C20H24F2N6O3 Isomer B: M.P. 182-1840C; MS(MH-I)- 435 ; M.F. C19H22F2N6O3
Example- 160 and 161
(S)-N-{3-[3,5-Difluoro-4-(4-(5-methyl-tetrazol-2-yl)-piperidin-l-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-propionamide; and
(S)-N-{3-[3,5-Difluoro-4-(4-(5-methyl-tetrazol-l-yl)-ρiρeridin-l-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl } -propionamide;
Figure imgf000140_0002
A mixture of (S)-N-{3-[4-methanesulphonyloxy piperidin~l-yl)-3,5-difluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-propionamide (1.12 mM) ,tetrazole (1.68 mM), and K2CO3 (1.68 mM) in DMF (10 ml) was heated for 22 hrs at 850C. The resulting mixture was poured into ice- water and stirred for 30 min. The separated solid was purified by column chromatography to obtain two isomeric products in 16% and 15% yields respectively. Isomer A: M.P. 220-2220C; MS (M+ 1)- 450 ; M.F. C20H25F2N7O3 Isomer B: M.P. 206-2080C; MS(M+1> 450 ; M.F. C20H25F2N7O4.
Example-162-165 cw-(R)-{3-[4-(4-(5-ethoxycarbonyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)- 3- fluorophenyl]-5-(5-ethoxycarbonyl-lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one; and cw-(R)-{3-[4-(4-(5-ethoxycarbonyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluoro- phenyl]-5-(4-ethoxycarbonyl-lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one; and trans-(R)~ { 3-[4-(4-(5-ethoxycarbonyl-lH-[ l,2,3]-triazol- 1 -yl)-piperidin- 1 -yl)-3 -fluorophenyl] -5-(5 -ethoxyc arbonyl - 1 H- [ 1 , 2,3] -triazol- 1 -ylmethyl) } -oxazolidin-2-one ; and trans-(R)-{ 3-[4-(4-(5-ethoxycarbonyl- lH-[ 1 ,2,3]-triazol- 1 -yl)-piperidin-l -yl> 3-fluoro- phenyl]-5-(4-ethoxycarbonyl-lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
Figure imgf000141_0001
To the solution of 5-azidomethyl-3-[4-(4-azido-piperidin-l-yl)-3-fluoro-phenyl]-oxazoli din-2-one (0.5 g, 1.4 mmol) in the toluene (8 ml) was added ethyl propiolate (0.3 ml, 3 mmol) was added and the reaction mixture was heated at 12O0C for 6h. The solvent was removed under reduced pressure and the resulting residue was chromatographed over silica gel using CHC13:MeOH (98:2) as an eluent by gradient method, which has afforded the four isomers. Isomer-1: 25 mg, 7 %, MP. 128-300C and MS (M+ 1) = 559 (MH+, 100%) M.F. = C25H31FN8O6.
Isomer-2: 125 mg, 30 %, MP. 154-56 0C and MS (M+ 1) = 559 (MH+, 100%) M.F. = C25H3IFN8O6.
Isomer-3: 60 mg, 15 %, M.P. 134-36 0C and MS (M+l) = 559 (MH+, 100%) M.F. = C25H31FN8O6.
Isomer-4: 200 mg, 48 %, MP. 216-218 0C and MS (M+l) = 559 (MH+, 100%) M.F. = C25H31FN8O6.
Example- 166 trans-(K)- { 3-[4-(4-(5-hydroxymethyl- lH-[ l,2,3]-triazol- 1 -yl)-piperidin- 1 -yl)- 3-fluoro- phenyl]-5-(4-hydroxymethyl-lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
Figure imgf000142_0001
The isomer-4 was (100 mg, 0.2 mmol ) was taken into ethanol (3 ml) was treated with the sodium borohydride (15 mg, 0.4 mmol)at room temperature. The reaction mixture was stirred for 2h. The reaction was quenched by adding the ice-cold solution of the ammonium chloride and extracted with the ethyl acetate (2 x 10 ml). The combined organic layer was washed with the brine and dried over Na2SO4. Upon removal of the solvent a white solid was obtained. M.P. 190-92 0C and MS (M+l) = 475 (MH+, 100%) M.F. = C21H27FN8O4. Example- 167 /TUBW-(R)- { 3 -[4-(4-(5-hydroxymethyl- lH-[ 1 ,2,3] -triazol- 1 -yl)-ρiρeridin- 1 -yl)- 3-fluoro- phenyl]-5-(5-hydroxymethyl-lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
Figure imgf000143_0001
The isomer-3 was also converted to the alcohol using the same procedure as described above. MP.208-210 0C and MS (M+l) = 475 (MH+, 100%) M.R = C21H27FN8O4.
Example- 168 frαrø-(R)-{3-[4-(4-(5-cyano-lH-[l,2,3]-triazol-l-yl)-piperidm-l-yl)- 3-fluoro-phenyl]-5- (5-cyano-lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
Figure imgf000143_0002
The isomer-3 was reacted with the aqueous ammonia to the ester into the amide and which was further reacted with the trifluoroacetic anhydride at room temperature for overnight. The solvent was removed and the crude mass obtained was purified by the column chromatography over silica gel using CHCl3)MeOH (9.5:0.5) as an eluent to afford the desired compound as a white solid (0.120 mg , 65 %).
M.P. 192-94 0C and MS (M+l) = 463 (MH+, 100%) M.F. = C2iH19FN10O2.
Example- 169 rrβraj-(R)-{3-[4-(4-(5-cyano-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)- 3-fluoro-phenyl]-5- (4-cyano- IH-[1 ,2,3]-triazol- 1-ylmethyl) } -oxazolidin-2-one;
Figure imgf000143_0003
Using the isomer-4 and by the same procedure described as above the desired compound was obtained (90 mg, 60 %)
MP. 220-222 0C and MS (M+l) = 463 (MH+, 100%) M.F. = C21H19FN10O2.
Example- 170
(S)-N-{3-[3,5-Difluoro-4-(4-(4-methyl-5-thioxo-4,5-dihydro-tetrazol-l-yl)-piperidin- 1 -yl)-phenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide;
Figure imgf000144_0001
A mixture of (S)-N-{3-[4-methanesulphonyloxy piperidin-l-yl)-3,5-difluorophenyl]-2- oxo-oxazolidin-5-ylmethyl} -acetamide (1.12 mm) ,5-mercapto-l-fnethyltetrazole (1.68 mm), and K2CO3 (1.68 mm) in DMF (6 ml) was heated for 22 hrs at 850C. The resulting mixture was poured into ice-water mixture , stirred for 30 min. and the separated solid was purified by column chromatography to obtain product in 32% yield. M.P. 182-184°C; MS(M+l)- 467 J M-R Ci9H23F2N7O3S
Example- 171
(S)-N-{3-[3,5-Difluoro-4-(4-(4-methyl-5-thioxo-4,5-dihydro-[l,2,4]triazol-l-yl)- piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000144_0002
A mixture of (S)-N- {3-[4-methanesulphonyloxy piperidin-l-yl)-3,5-difluorophenyl]-2- oxo-oxazolidin-5-ylmethyl} -acetamide (1.12 mm), 4-methyl-4H-[l,3,4]-triazole-3- thiol(1.68 mm), and K2CO3 (1.68 mm) in DMF (6 ml) was heated for 22 hrs at 850C. The resulting mixture was poured into ice-water mixture , stirred for 30 min. and the separated solid was purified by column chromatography to obtain product in 38% yield respectively. M.P. 168-17O0C; MS(M+!)- 466 ; M.F. C20H24F2N6O3S Example- 172
(S)-N-{3-[3-fluoro-4-(4-(4-methyl-5-thioxo-4,5-dihydro-[l,2,4]triazol-l-yl)-piperidin-l- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
Figure imgf000145_0001
A mixture of (S)-N- {3-[4-methanesulphonyloxy piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide (1.12 mmole), 4-methyl 4H-[l,3,4]-triazole-3-thiol (1.68 mmole), and K2CO3 (1.68 mmole) in DMF (6 ml) was heated for 22 hrs at 850C. The resulting mixture was poured into ice-water mixture, stirred for 30 min. and the separated solid was purified by column chromatography to obtain product in 22% yield respectively. M.P. 182-1850C; MS(M+1)- 448 ; M.F. C20H25FN6O3S
Example-173
(S)-N- {3-[4-(4-(isoxazol-3-yloxymethyl)-piperidin- l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000145_0002
To the stirred solution of (S)-N- {-3- [3-Fluoro-4-(4-hydroxymethyl-piperidin- 1-yl)- phenyl]-2-oxo-oxazolidin-5-ylmethyl} -acetamide (1.5 g, 4.1 mmol) in THF was added 3- hydroxy isoxazole (0.38 g, 4,52 mmol) and triphenylphospine (1.396 g, 5.33 mmol) and the resulting solution was stirred under nitrogen at rt for 10 minutes. DIAD (0.99 g , 4.92 mmoles) was added and stirred at an ambient temperature for 3h. After completion, the reaction was quenched with 100 ml water & extracted with ethyl acetate (3 x 50 ml). The combined organic layers were washed with brine, dried (Na2SO4) and concentrated to give crude compound. Purification by column chromatography eluting with CHCl3: CH3OH (98:2) afforded the pure compound in 80 % yield. M.P. 163-1650C and MS (M+ 1) = 433 (MH+, 100%) M.F. = C21H25FN4O5. Example- 174
(S)-N-{3-[4-(4-(l,4-dioxa-8-azaspiro[4.5]dec-8-yl-)-3-fluorophenyl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000146_0001
A solution of triphenylphosphine (440 mg, 1.6 mmol) in dimethoxyethane and tetrahydrofuran mixture (8:2, 40 ml) was stirred at room temperature under inert atmosphere, to it was added palladium acetate (90 mg, 0.4 mmol) and stirred for 30min. (l,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl)-boronic acid (3.54 gm, 12.6 mmol) was added and stirred for 30min. Then water (190 μl, 10.4 mmol) was added and stirring continued, after 30min powdered potassium carbonate (3.6 gm, 26 mmol) and (S)-N-3- {4-iodo-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (3.92 gm, 10.4 mmol) was added under stirring. Reaction mixture was then heated to reflux for 14 hr. and title compound was obtained by purifying the crude compound on silica gel column chromatography in 72% yield. MS (M+l) = 488 (MH+, 100%) for M.F. = C25H27F2N3O5.
Similarly, following compounds were synthesized.
Figure imgf000146_0002
Figure imgf000147_0001
Example- 186 (S)-N-{3-[4-(6-(Thiomoφholin-l-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl } -acetamide ;
Figure imgf000148_0001
A solution of triphenylphosphine (220 mg, 0.8 mmol) in dimethoxyethane and tetrahydrofuran mixture (8:2, 20 ml) was stirred at room temperature under inert atmosphere, to it was added palladium acetate (45 mg, 0.2 mmol) and stirred for 30min. (2-Thiomorpholiri-l-yl-pyridin-5-yl)-boronic acid (1.41 gm, 6.3 mmol) was added and stirred for 30min. Then water (94 μl, 5.2 mmol) was added and stirring continued, after 30min powdered potassium carbonate (1.8 gm, 13 mmol) and (S)-N-3-{4-iodo-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl} -acetamide (1.96 gm, 5.2 mmol) was added under stirring. Reaction mixture was then heated to reflux for 14 hr. and title compound was obtained by purifying the crude compound on silica gel column chromatography in 72% yield. MS (M+l) = 431 (MH+, 100%) for M.F. = C21H23FN4O3S.
Similarly, following compounds were synthesized.
Figure imgf000148_0002
Figure imgf000149_0001
Figure imgf000150_0002
Ex.ample-205
(S)-N-{3-[4-(6-(S-Oxo thiomoφholin-l-yl)- pyridyl-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin~5-ylmethyl}-acetamide;
Figure imgf000150_0001
The title compound was prepared by reacting (S)-N-{3-[4-(6-(thiomorpholin-l-yl)- pyridin-3-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (1.25 gm, 2.9 mmol) with sodium metaperiodate (0.68 gm, 3.2 mmol) in methanol water mixture (8:2, 15 ml) at 35°C for 4 hours and by purifying the crude compound on silica gel column chromatography in 76% yield. MS (M+ 1) = 447 (MH+, 100%) for M.F. =
C21H23FN4O4S.
Similarly, following compounds were synthesize.
Figure imgf000151_0001
Figure imgf000152_0002
Example-219
(S)-N-{3-[4-(2-(S,S-Dioxo-thiomorpholin-l-yl)- pyridyl-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
Figure imgf000152_0001
The title compound was prepared by reacting (S)-N-{3-[4-(2-(thiomorpholin-l-yl)- pyridin-5-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide (1.25 gm, 2.9 mmol) with sodium metaperiodate (1.37 gm, 6.4 mmol) in methanol water mixture (8:2, 15 ml) at a temperature 70 0C for 6 hours and by purifying the crude compound on silica gel column chromatography in 87% yield. MS (M+ 1) = 463 (MH+, 100%) for M.F. = C2IH23FN4O5S.
Similarly, following compounds were synthesized
Figure imgf000153_0001
Figure imgf000154_0001
Figure imgf000155_0002
Example-239
(S)-N-{3-{4-{6-(4-Oxopiperidin-l-yl-pyridin-3-yl)-3-fluorophenyl}-2-oxo-oxazolidin-5- yl methyl }-acetamide;
Figure imgf000155_0001
(S)-N -{3-{4 -(2-(l,4-Dioxa-8-azaspiro [4.5] dec-8-yl)-pyridin-5-yl)-3-fluorophenyl} -2- oxo-oxazolidin -5-yl methyl }-acetamide (469 mg, 100 mmol), p-toluene sulphonic acid (380 mg, 200 mmol) in acetone: water mixture (6:4) 10 ml, was refluxed for 5 hrs. The reaction mixture was concentrated under vacuum and neutralized with sodium bicarbonate. Obtained precipitate was filtered and purified on silica column to afford the title compound in 81 % yield. Ms (M+l) = 427 (MH+, 100 %), M. F. = C22H23FN4O4.
Similarly, following compounds were synthesized.
Figure imgf000155_0003
Figure imgf000156_0001
Example-242
(S)-N-{ 3-[4 -(6-(4-Hydroxy-piperidin- l-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin -5-yl methyl }-acetamide
Figure imgf000156_0002
(S)-N- {3-{4-{2-(4-Oxopiperidin-l-yl-pyridm-5-yl)-3-fluorophenyl}-2-oxo-oxazolidin-5- yl methyl }-acetamide ( 636 mg, 150 mmol), was treated with sodium borohydride ( 66 mg , 177 mmol ) in 15 ml methanol at 5 0C and stirred for 1 hr at room temperature. The reaction mixture was concentrated under vacuum and treated with water, extracted with ethyl acetate. Organic layer separated, dried over sodium bicarbonate and evaporated to give title compound in 87 % yield. Ms (M+ 1) = 429 (MH+, 100 %), M. F. = C22H25FN4O4. Similarly, following compounds were synthesized.
Figure imgf000156_0003
Example-245
(S)-N-{3-[4 -(6-(4- rnethanesulfonyloxy piperidin-l-yl)-pyridin-3-yl)-3- fluorophenyl]-2-oxo-oxazolidin -5-yl methyl }-acetamide
Figure imgf000157_0001
(S)-N-[3-{ 4-hydroxypiperidin- l-yl)-pyridin-3-yl]-3-fluoro-phenyl }-2-oxa-oxazolidin-5-yl]- acetamide (213 mg, 50 mmol) in 10 ml dichloromethane was treated with triethyl amine (175 /xl, 125 mrnol) and methanesulphonyl chloride (48 μl, 60 mmol) for 1 hr. The reaction mixture was washed with 10 ml water. Organic layer was separated dried over sodium sulfate and evaporated under vacuum to afford title compound in 91 % yield. Ms (M+l) = 509 (MH+, 100 %), M. F. = C22H25FN4O7S.
Similarly, following compounds were synthesized.
Figure imgf000157_0002
Example-248 (S)-N-{3-{4 - [4-(l-oxa-6-aza-spiro[2.5]oct-6-yl) -3-fluorophenyl]-3-fluorophenyl} -2- oxo-oxazolidin -5-yl methyl }-acetamide;
Figure imgf000158_0001
Sodium hydride (0.03 gm, 1.25 mmol) was added to stirred dimethyl sulphoxide 10 ml at room temperature, trimethylsulphoxonium iodide (0.33 gm, 1.5 mmol) was added to it after 10 min, Suspension became clear after 30 min of stirring. Then added (S)-N-{3-{4-{2-(4-Oxopiperidin-l-yl-3-fluorophenyl)-3-fluorophenyl}-2-oxo-oxazolidin -5-yl methyl }-acetamide (0.44 gm, 1 mmol) and stirred for 1 hr. at room temperature. Quenched by using water, extracted with ethyl acetate and organic layer separated, dried and evaporated to give title compound in 88% yield. Ms (M+ 1) = 490 (MH+, 100 %), M. F. = C25H29F2N3O5
Example-249
(S)-N-{3-[4-(4-(4,4-dimethoxypiperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000158_0002
(S)-N-{3-{4-{2-(4-Oxopiperidin-l-yl-3-fluorophenyl)-3-fluorophenyl}-2-oxo-oxazolidin -5-yl methyl }-acetamide (0.44 gm, 1 mmol) was dissolved in methanol 10 ml and p- toluene sulphonic acid (0.34 gm, 2 mmol). Trimethyl orthoformate (0.21 gm, 2 mmol) was added to it and stirred for 12 hr. at room temperature. Methanol evaporated up to dryness and reaction mixture neutralized by aqueous sodium bicarbonate, extracted with ethyl acetate and organic layer separated, dried and evaporated to give title compound in 68% yield. Ms (M+l) = 458 (MH+, 100 %), M. F. = C24H25F2N3O4
Example-250
(S)-N-{ 3-[4-(4-(4-Cyanomethylidene piperidin-l-yl)-3-fluorophenyl)-3-fluoro phenyl]-2- oxo-oxazolidin-5-ylmethyl } -acetamide;
Figure imgf000159_0001
(S)-N-{3-{4-{2-(4-Oxopiperidin-l-yl-3-fluorophenyl)-3-fluorophenyl}-2-oxo-oxazolidin -5-yl methyl }-acetamide (0.44 gm, 1 mmol) was dissolved in tetrahydrofuran (15 ml), to it was added triethyl amine (0.27 ml, 2 mmol), lithium bromide (0.11 gm, 1.2 mmol) and then diethylcyanomethyl phosphonate (0.22 ml, 1.2 mmol). The reaction mixture was heated at 80 0C for 12 hr. Solvent removed on rota evaporator and reaction mixture was treated with water. Extracted with ethyl acetate, organic layer separated, dried and evaporated to give title compound in 72% yield Ms (M+ 1) = 467 (MH+, 100 %), M. F. = C25H24F2N4O3.
Similarly, following compounds were synthesized.
Figure imgf000159_0002
Examρle-253
(S)-N- { 3- [4-(4-cyanomethyl-piperidin- 1 -yl)-3 -fluorophenyl } -3-fluorophenyl] -2-oxo- oxazolidin-5-ylmethyl } -acetamide
Figure imgf000159_0003
(S)-N-{3-[4-(4-(4-Cyanomethylidene ρiperidin-l-yl)-3-fluorophenyl)-3-fluoro phenyl]-2- oxo-oxazolidin-5-ylmethyl}-acetamide (0.47 gm, 1 mmol) was dissolved in methanol 25 ml to it was added 40 mg 10% palladium on carbon and under 60 PSI hydrogen pressure reaction was put on Parr shaker for 12 hr. After completion catalyst was filter through celite, solvent evaporated to give title compound in 94% yield. Ms (M+l ) = 469 (MH+, IOO %), M. F. = C25H26F2N4O3.
Example-254
(S)-N-{3-[4-(4-(4-cyanomethyl-3,4-dehydropiperidin-l-yl)-3-fluorophenyl)-3- fl uorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide
Figure imgf000160_0001
(S)-N-{3-{4-{'2-(4-Oxopiperidin-l-yl-3-fluorophenyl)-3-fluorophenyl}-2-oxo-oxazol idin-5-yl methyl} -acetamide (0.44 gm, 1 mmol) was suspended in toluene 15 ml, to it was added ammonium acetate (38 mg, 0.5 mmol), and cyanoacetic acid (94 mg, 1.1 mmol), The reaction mixture was heated at 110 0C for 12 hr. Solvent removed on rota evaporator and reaction mixture as such was put on silica column to give pure title compound in 66% yield
Ms (M+l) = 467 (MH+, 100 %), M. F. = C25H24F2N4O3.
Example-255
(S)-N-{3-[4-(4-(4-(iH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000160_0002
(S)-N-{3-[4-(4-(4-methansulfonyloxypiperidin-l-yl)-3-fluorophenyl)-3-fluoro phenyl]-2- oxo-oxazolidin-5-ylmethyl} -acetamide (0.53 gm, 1 mmol) was suspended in dimethylformamide 15 ml, and potassium carbonate (0.28 gm, 2 mmol), at room temperature. The reaction mixture was heated at 75 0C for 12 hr. Reaction mixture was filtered solvent removed on rota evaporator and treated with water, extracted with ethyl acetate organic layer separated and purified on silica column to give pure title compound in 54% yield. Ms (M+ 1) = 497 (MH+, 100 %), M. F. = C25H26F2N6O3.
Similarly, following compounds were synthesized.
Figure imgf000161_0002
Example-257
(S)-N-{3-[4-(4-benzyloxycarbonylpiperazin-l-yl-3-fluorophenyl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000161_0001
(S)-N-{3-[4-(Piperazin-l-yl-3-fluorophenyl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethylj-acetamide (0.43 gm, 1 mmol) was suspended in acetone: water mixture (8:2) 15 ml, potassium carbonate (0.28 gm, 2 mmol), at room temperature and then 2- benzyloxyacetyl chloride ( 0.24 ml, 1.4 mmol) was added to it. The reaction mixture was stirred at 35 0C for 12 hr. Reaction mixture was filtered, solvent removed on rota evaporator and treated with water, extracted with ethyl acetate organic layer separated and purified on silica column to give pure title compound in 78 % yield Ms (M+l) = 565 (MH+, 100 %), M. F. = C30H30F2N4O5. Similarly, following compounds were synthesized.
Figure imgf000162_0002
Example-260
(S)-N-{3-[4-(4-(4-(2-nitrofuran-5-yl-methyl)-piperazin-l-yl)-3-fluorophenyl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide;
Figure imgf000162_0001
(S)-N-{ 3-[4-(Piperazin-l-yl-3-fluorophenyl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl} -acetamide (0.43 gm, 1 mmol) was dissolved in dichloromethane 15 ml, 2- nitro furan aldehyde (0.28 gm, 2 mmol) was then added and stirred at room temperature for 12 hr and then sodium triacetoxyborohydride ( 0.24 ml, 1.4 mmol) was added to it at 0-5 0C. The reaction mixture was stirred at 30 0C for 3 hr. solvent removed on rota evaporator and treated with water, extracted with ethyl acetate organic layer separated and purified on silica column to give pure title compound in 66 % yield Ms (M+l) = 556 (MH+, 100 %), M. F. = C27H27F2N5O6. Similarly, following compounds were synthesized.
Figure imgf000163_0002
Example-262
(S)-N-{3-[4-(4-(4-hydroxy-4-hydroxymethylpiperidin-l-yl)-3-fluorophenyl)-3 - fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000163_0001
The title compound was prepared by treating (S)-N-{3-[4-(4-(l-Oxa-6-aza-spiro[2.5]oct- 6-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo-oxazolidin-5-yl methyl }-acetamide (1.03 gm, 2.1 mmol) in 0.5 N hydrochloric acid (5 ml) at a temperature 800C for 2 hours and by purifying the crude compound by silica gel column chromatography in 46% yield.
MS (M+l) = 476 (MH+, 100%) for M.F."= C24H27F2N3O5
Similarly, following compounds were synthesized.
Figure imgf000163_0003
Example-264
(S)-N- { 3-[4-(6-(S-Oxo-S-imino-thiomorpholin-4-yl)-pyridyl-3-yl)-3-fluorophenyl- 1-yl]-
2-oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000164_0001
(S)- N- {3-4-{2-(S-Oxo thiomorpholin-4-yl) -pyridyl-5-yl-3-fluorophenyl}-]} -2-oxo- oxazolidin -5-yl methyl }-acetamide (0.44 gm, 1 mmol) was dissolved in polyphosphoric acid 5 ml at room temperature, sodium azide (0.1 gm, 1.5 mmol) was then added and stirred at 60 0C for 12 hr. Cooled to room temperature, treated with water and neutralized with sodium bicarbonate, extracted with chloroform. Organic layer separated, solvent removed on rota evaporator and purified on silica column to give pure title compound in 56 % yield. Ms (M+l) = 462 (MH+, 100 %), M. F. = C2IH24FN5O4S. Similarly, following compounds were synthesized.
Figure imgf000164_0003
Example-266
(S)-N-{3-[4-(6-(S-Oxo-S-(N-methylϊmino)-thiomorpholin-4-yl)-pyridyl-3-yl)-3- fluorophenyl-l-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000164_0002
(S)- N- {3-4-{2-(S-Oxo-l-iminothiomoφholin-4-yl) -pyridyl-5-yl-3-fluorophenyl-l- yl- }-] } -2-oxo-oxazolidin -5-yl methyl }-acetamide (0.46 gm, 1 mmol) was dissolved in formic acid 5 ml at room temperature, formaldehyde (0.15 ml, 5 mmol) was then added and stirred at 80 0C for 12 hr. Cooled to room temperature, treated with water extracted with ethyl acetate. Organic layer separated, solvent removed on rota evaporator and purified on silica column to give pure title compound in 74 % yield Ms (M+l) = 476 (MH+, IOO %), M. F. = C22H26FN5O4S Example-267
(S)-N-{3-[4-(6-(S-Oxo-S-(N-acetylimino)-thiomorpholin-4-yl)-pyridyl-3-yl)-3- fluorophenyl - 1 -yl] -2-oxo-oxazolidin-5 -ylmethyl } -acetarαide ;
Figure imgf000165_0001
(S)- N- {3-4-{2-(S-Oxo-l-iminothiomoφholin-4-yl) -pyridyl-S-yl-S-fluorophenyl-l- yl- }-]} -2-oxo-oxazolidin -5-yl methyl }-acetamide (0.46 gm, 1 mmol) was dissolved in dichloromethane 15 ml, triethyl amine (0.34 ml, 2.5 mmol) was then added and cooled to 0 0C, then added acetyl chloride (88 μl, 1.1 mmol) and stirred at room temperature for 1 hr. Treated with water extracted with ethyl acetate. Organic layer separated, solvent removed on rota evaporator and purified on silica column to give pure title compound in 74 % yield Ms (M+l) = 504 (MH+, 100 %), M. F. = C23H26FN5O5S.
Example-268 (S)-N-{3-[4-(6-(S-Oxo-S-(l-chloroethylurido)-thiomorρholin-4-yl)-pyridyl-3-yl)-3- fluorophenyl-l-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
Figure imgf000165_0002
(S)- N- {3-4-{2-(S-Oxo-l-iminothiomorpholin-4-yl) -pyridyl-S-yl-S-fluorophenyl-l- yl- }-] } -2-oxo-oxazolidin -5-yl methyl }-acetamide (0.46 gm, 1 mmol) was dissolved dichloromethane 15 ml, triethyl amine (0.34 ml, 2.5 mmol) was then added and cooled to 0 0C, then added 1-chloroethylisocynate (126 mg, 1.2 mmol) and stirred at room temperature for 1 hr. at room temperature, treated with diethyl ether solid separated, filtered and purified on silica column to give pure title compound in 66 % yield Ms (M+l) = 567 (MH+, 100 %), M. F. = C24H28ClFN6O5S. Example-269
(R)-Phosphoric acid mono {3-[4-(6-(S,S-dioxo-thiomorpholin-4-yl)-pyridin-3-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } ester;
Figure imgf000166_0001
To a stirred solution of (S)- N-{3-{4-{2-(S,S-Dioxo thiomorpholin-4-yl) -pyridin-5-yl}- 3-fluorophenyl]} -2-oxo-oxazolidin -5-yl methyl} -alcohol (0.84 gm, 2 mmol) and di-tert- butyl N, N-diisopropylphosphoramidite (1.2 gm, 3 mmol) in anhydrous dichloromethane 40 ml was added IH- Tetrazole (0.48 gm, 7 mmol). After 1 hr of stirring mixture was cooled to 0 0C and 0.3 ml of 30 % hydrogen peroxide was added. The mixture was stirred at room temperature for 1 hr, diluted with dichloromethane 80 ml and washed with 10% sodium metabisulfide and saturated sodium bicarbonate and water. Organic layer was separated concentrated to 1/3 volume and to it was added trifluoroacetic acid 3 ml. Stirred for 3.5 hr and evaporated up to dryness. Purification on silica column gave pure title product in 52% yield. Ms (M+ 1) = 502 (MH+, 100 %), M. F. = Ci9H21FN3O8PS.
Similarly, following compounds were synthesized.
Figure imgf000166_0002
Figure imgf000167_0001
Example-276
(2S,5R)-2-Amino-propionic acid 3-{4-[6-(S,S-dioxo-thiomoφholin-4-yl)-pyridin-3-yl]- 3-fluoro-phenyl}-2-oxo-oxazolidin-5-ylmethyl ester methanesulfonic acid salt;
Figure imgf000167_0002
To a stirred solution of Boc alanine (0.35 gm, 1.85 mmol) in anhydrous dichloromethane 40 ml was added N, N-dicyclohexylcarbodiimide (0.48 gm, 7 mmol) and (S)- N-{3-{4- (2-(S,S-Dioxo thiomorpholin-4-yl) -pyridin-5-yl}-3-fluorophenyl]} -2-oxo-oxazolidin - 5-yl methyl }-alcohol (0.4 gm, 0.95 mmol) at
- 5 0C. After 1 hr of stirring mixture was cooled to 0 0C and (65 mg, 0.5 mmol) N, N- dimethylpyridine was added. The mixture was stirred at 0 0C for 2 hr, diluted with dichloromethane 40 ml and washed with water. Organic layer was separated, dried and evaporated up to dryness. 25 ml acetone and (150 μl, 1.6 mmol) methanesulphonic acid was added and heated to 65 0C for 12 hr, Solid separated was filtered and washed with diethyl ether to yield title compound in 80% yield.
Ms (M+l) = 516 (MH+, IOO %), M. F. = C23H26FN3O6S.
Similarly, following compounds were synthesized.
Figure imgf000168_0001
Example-278
(2S,5R)-Acetic acid 3-{4-[6-(S,S-dioxo-thiomorpholin-4-yl)-pyridin-3-yl]-3-fluoro- phenyl }-2-oxo-oxazolidin-5-ylmethyl ester;
Figure imgf000168_0002
To a stirred solution of (S)- N-{3-{4-{2-(S,S-Dioxo thiomorpholin-4-yl) -pyridin-5-yl}- 3-fluorophenyl]} -2-oxo-oxazolidin -5-yl methyl} -alcohol (0.2 gm, 0.48 mmol) and pyridine (80 μl, 1 mmol) in anhydrous dichloromethane 20 ml was added acetic anhydride (58 μl, 0.56 mmol) and (29 mg, 0.5 mmol) N, N-dimethylpyridine was added at 0 0C. The mixture was stirred at room temperature for 12 hr, diluted with dichloromethane 40 ml and washed with water. Organic layer was separated and evaporated up to dryness. Purification on silica column gave pure title product in 92% yield. Ms (M+l) = 464 (MH+, 100 %), M. F. = C21H22FN3O6S. Similarly, following compounds were synthesized.
Figure imgf000169_0002
Example-280
(5S)- { 3-[2-Fluoro- 1,1' -biphenyl-3 '-methoxy-4-yl]-2-oxo-oxazolidin-5yl-methyl } - acetamide;
Figure imgf000169_0001
N-[3-(3-Fluoro-4-iodo-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide (1.322 mmol) and tetrakis(triphenylphosphine)palladiurn (0.05g) were added to a r. b. flask containing tetrabutylammonium bromide (1.5g) and the contents were stirred and heated to 12O0C. 3-Methoxyphenylboronic acid (1.45 mmol) and aq. potassium carbonate (0.35g potassium carbonate dissolved in 1.5 ml water) were added to the r.b. flask and the reaction mixture was stirred for about 3 hours, till the TLC showed completion of the reaction. Water (50 ml) was added to the reaction mixture and the contents were extracted with ethyl acetate (25 ml x 2). The organic layer was dried over anhy. sodium sulfate and evaporated under vacuum to obtain a crude compound, which was purified by flash silica gel column chromatography to get the title compound in 34% yield. M.P. = 98-1000C, M.F. = Ci9H19FN2O4, M+l = 359.
Using the procedure described for the above compound the title compound was prepared.
Figure imgf000170_0003
Example-283
(5S)-{3-[(3,5-Difluoro-4-[6-(4-thiomoφholin-l,l-dioxide-4-yl)-3-pyridinyl]phenyl]-2- oxo-oxazolidin-5yl-methyl } -acetamide;
Figure imgf000170_0001
N-{3-[3,5-Difluoro-4-(6-thiomorpholin-4-yl-pyridin-3-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl }-acetamide (0.446 mmol) was dissolved in aq. methanol (1:1, 5 ml) and sodium periodate (1.33 mmol) was added at R. T. The reaction mixture was stirred for about 1 hour, till the TLC showed completion of the reaction. Methanol was evaporated under vacuum and the solid was filtered to obtain the crude compound. It was purified by flash silica gel column chromatography to get the title compound in 40% yield. • M.P. = 146-148°C; M. F. = C21H22F2N4O5S; M+l = 481.
Example-284
(5S)-N-[3-(3'-Chloromethyl-2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-ylmethyl]- acetamide;
Figure imgf000170_0002
To the solution of (5S)-{3-[(2-fluoro-l,r-biphenyl-3'-yl)methanol]-2-oxo-oxazolidin- 5yl -methyl} -acetamide (1.8 mmol) in dichloromethane (25 ml) was added triethyl amine (5 mmol) and the contents were stirred at R. T. Methanesulfonic acid (3 mmol) was added drop-wise to the solution at R. T. and the reaction mixture was stirred for about 3 hours, till the TLC showed disappearance of the starting material. The reaction mixture was evaporated under vacuum and water (25 ml) was added to the residue. The crude product thus obtained was filtered, washed with water and dried under vacuum. The crude product was purified by flash silica gel column chromatography to get the title compound in 60% yield. MP. = 128-13O0C; M. F. = C19Hi8ClFN2O3; M+l = 377.
Example-285
(5S)-N-[3-(2-Fluoro-3'-fluoromethyl-biphenyl-4-yl)-2-oxo-oxazolidin-5-ylmethyl]- acetamide;
Figure imgf000171_0001
The solution of (5S)-{3-[(2-fluoro-l,l'-biphenyl-3'-yl)methanol]-2-oxo-oxazolidin-5yl- methyl} -acetamide (2.23 mmol) in dichloromethane (250 ml) was cooled to 50C and (diethylamino)sulfur trifluoride (DAST, 2.23 mmol) was added to the above solution. The contents were stiiτed at 50C for about 4 hours, till the TLC showed disappearance of the starting material. The reaction mixture was evaporated under vacuum and water (50 ml) was added to the residue. The crude .product thus obtained was filtered, washed with water and dried under vacuum. The crude product was purified by flash silica gel column chromatography to get the title compound in 25% yield. M.P. = 120-1220C; M. F. = Ci9H18F2N2O3; M+l = 361.
Example-286
(5S)-N-[3-(2-Fluoro-3'-azidomethyl-biphenyl-4-yl)-2-oxo-oxazolidin-5-ylmethyl]- acetamide;
Figure imgf000171_0002
(5S)-7V-[3-(2-Fluoro-3'-chloromethyl-biρhenyl-4-yl)-2-ox.o-oxazolidin-5-ylmethyl]- acetamide (2.7 mmol) was dissolved in NiV-DMF (30 ml) and sodium azide (8.1 mmol) was added to the above solution. The contents were stiiτed at 700C for about 6 hours, till the TLC showed disappearance of the starting material. The reaction mixture was poured in water (100 ml), the precipitated product was filtered and suck dried to obtain the title compound. M. F. = C19Hi8FN5O3; M+l = 384.
Example-287
(5S)-N-[3-(3'-Aminomethyl-2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-ylmethyl]- acetamide;
Figure imgf000172_0001
(5S)-N-[3-(2-Fluoro-3'-azidomethyl-biphenyl-4-yl)-2-oxo-oxazolidin-5-ylmethyl]- acetamide (2.61 mmol), Palladium on carbon (Pd/C, 100 mg) and methanol (30 ml) were charged in a r. b. flask and the contents were stirred under hydrogen atmosphere (rubber balloon) at RT. After about 5 hours, the TLC showed completion of the reaction. The Pd/C was filtered on celite bed and the bed was washed with methanol (50 ml). The combined filtrate was evaporated under vacuum to obtain a crude product, which was purified by flash silica gel column chromatography to get the title compound in 68% yield. M.P. = 1700C; M.F. = C19H20FN3O3, M+l = 358.
Examρle-288
(5S)-2-({4'-[5-(Acetylammo-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-biphenyl-3- ylmethyl }-amino)-acetamide;
Figure imgf000172_0002
To the solution of (5S)-N-[3-(3'-aminomethyl-2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin- 5-ylmethyl]-acetamide (1.12 mmol) in methanol (10 ml) and dichloroniethane (10 ml), was added Hunig's base (1.12 mmol) and the contents were heated to 8O0C. Bromoacetamide (1.12 mmol) was charged to the above solution and the reaction mixture was stirred at 8O0C for about 7 hours, till the TLC showed completion of the reaction. The solvents were removed under vacuum and water (20 ml) was added to the residue to obtain a crude product. The crude product was purified by flash silica gel column chromatography to get the title compound in 32.3% yield. M. F. = C21H23FN4O4, M+l = 415.
Example-289
(5S)-2-({4'-[5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-biphenyl-3- ylmethyl } -carbamoylmethyl-amino)-acetamide
Figure imgf000173_0001
To the solution of (5S)-N-[3-(3'-aminomethyl-2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin- 5-ylmethyl]-acetamide (1.12 mmol) in methanol (10 ml) and dichloromethane (10 ml), was added Hunig's base (4.12 mmol) and the contents were heated to 8O0C. Bromoacetamide (4.12 mmol) was charged to the above solution and the reaction mixture was stirred at 800C for about 7 hours, till the TLC showed completion of the. reaction. The solvents were removed under vacuum and water (20 ml) was added to the residue to obtain a crude product. The crude product was purified by flash silica gel column chromatography to get the title compound in 11% yield. M.P. = 2130C, M. F. = C22H26F N5O5, M+l = 472.

Claims

We claim
1. An oxazolidinone compound of Formula I.
Figure imgf000174_0001
Formula I wherein Q is
Figure imgf000174_0002
X and Y may be same or different, represent, CH, CF, N;
X' and Y' may be same or different, represent,
CH, CF, N, C-OCH3, C-CH2-Ra", wherein Ra is hydrogen, amino, halogen, hydroxyl, azido, carboxamido, NHCH2CONH2, N(CH2C0NH2)2;
R2 and R2' may be same or different, represent, hydrogen, methyl, hydroxyl, C1-C6 alkoxy or halogen;
R4 is selected from the group, comprising a) 0-R1, b) NRbRc; wherein Rb is selected from hydrogen, C1-Cg alkylcarbonyl; Rc is selected from hydrogen, C(O)OCH2OC(O)Rd or CH(CH3)OC(O)Re; wherein Rd is hydrogen, C1-C6 alkyl, substituted C1-C6 alkyl with substitutents selected from amino or Ci-C6 alkylamido Re is selected from hydrogen, Ci-C6 alkyl, substituted Ci-C6 alkyl; c) formamide; d) carbamate; e) thiocarbamate; f) urea; g) Ci-Ce alkylamido; h) CpCό haloalkylamido; i) Ci-Cβ thioalkylamido; j) substituted Ci-C6 thioalkylamido, wherein the alkyl group is substituted with halo; k) unsubstituted or substituted heteroaryl, wherein substituents of the heteroaryl are selected from the group comprising Ci-C6 alkyl, nitro, cyano, hydroxyl, halo, amino, Ci-C6 alkylcarbonyl, C1-Cg alkoxycarbonyl, carboxy; wherein Ri is selected from the group comprising hydrogen, Ci-C6 alkylsulfonyl, Ci-C6 alkylcarbonyl, -P(O)(OM)2, wherein M is hydrogen, methyl, ethyl, t-butyl, phenyl or an alkali metal ion such as Li, Na, K; or Ri is an amino acid residue derived from one of the 20 naturally occurring amino acids viz. alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine, attached to the oxygen via carbonyl of the amino acid to form a ester linkage;
When Q is
Figure imgf000175_0001
wherein n is 0, 1 or 2;
W represents 3-7 membered heterocyclyl bearing one or more heteroatom selected from N, O, S, optionally substituted with one or more substitutents selected from the group comprising Ci-C6 alkyl, Ci-C6 alkylcarbonyl, C1-C6 alkoxycarbonyl, carboxamide, cyano, hydroxyl, amino, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl or heteroaryl bearing one or more heteroatom selected from N, O S, optionally substituted with one or more substitutents selected from the group comprising i. substituted or unsubstituted C1-C6 alkyl with substituents selected from the group hydroxyl, halo, nitro, cyano, aryl or heteroaryl; ii. substituted or unsubstituted C2-C6 alkenyl with substituents selected from the group hydroxyl, halo, nitro, cyano, aryl or heteroaryl; „1 C1-C6 alkylc arbonyl ;
IV . C1-C6 alkoxycarbonyl; V. C1-C6 alkoxycarbonylalkyl; vi. Cχ-C6 alkylcarbonylalkyl;
C1-C6 haloalkyl; formyl; carboxy; carboxamide; cyano; amino; nitro; hydroxyl; halo; morpholinocarbonylalkyl; xvii. hydroxyiminoalkyl ; alkylcarbonylaminoalkyl ; alkoxyiminoalkyl ; ar alkyl oxyiminoalkyl ; hydroiminoaminoalkyl ; aryl, substituted aryl, with substituents selected from Ci-C6 alkyl, nitro, cyano, hydroxyl, halo, amino, heterocyclyl; substituted or unsubstituted heteroaryl, with substituents selected from Ci-C6 alkyl, nitro, cyano, hydroxyl, halo, amino, heterocyclyl; substituted or unsubstituted heterocyclyl, with substituents selected from Q- C6 alkyl, C]-C6 alkylcarbonyl, aralkyl, nitro, cyano, hydroxyl, halo, amino; xxv. Ci-C6 alkylthio; xxvi. C1-C6 alkylsulfanylalkyl; xxvϋ. Ci-C6 aralkylsulfanyl; xxviϋ. C1-C6 alkylsulfonylmethyl; xxix. Ci-C6 alkylsulfonyloxy;
XXX. NRbRc; xxxi. -(C1-C6 alkyl)-NRr(Ci-C6 alkyl)-NRbRc; wherein Rf is hydrogen, Cj-C6 alkyl, substituted C1-C6 alkyl with substitutents selected from amino or C1-C6 alkylamido; or
W is heteroaryloxy group optionally substituted with one or more substitutents such as Ci-C6 alkyl, C2-C6 alkenyl, Ci-C6 alkylcarbonyl, Ci-C6 alkoxycarbonyl, formyl, carboxy, carboxamide, cyano, amino, hydroxyiminoalkyl, alkoxyiminoalkyl, aralkyloxyiminoalkyl, hydroxyiminoaminoalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl, substituted heterocyclyl; OR
when Q is
Figure imgf000177_0001
X' and Y' are as defined above;
T is hydrogen or
Figure imgf000177_0002
wherein
R2 and R2* are as defined above; "a" is optional double bond;
R3 and R3' may be same or different, represent, hydrogen, methyl, hydroxyl, C1-C6 alkoxy or halogen; with the proviso that when T is hydrogen, R4 is not acetamido;
Zrepresents group selected from CH, NH, O, S, CH2, C(R6)R6', C=O, NR7, C=C(R8)R8-, SO, SO2, S=NH, S=NC(O)CH3, S=NC(O)NHCH3, S(O)=NH, S(O)=NCH3, S(O)NC(O)CH3, S(O)=NC(O)NHCH3, S(O)=NC(O)NHCH2CH2Cl, with proviso that when X is CH, Y is CF, one of X' or Y' or both X' , Y' are N, then Z is not NH.
wherein R6 and R6' may be same or different, represent, hydrogen, hydroxyl, amino, azido, Cj-C6 alkoxy, C1-C6 alkylcarbonyloxy, C1-C6 alkylsulfonyloxy, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, Ci-C6 alkyl optionally substituted with one or more substituent selected from the group comprising azido, cyano, carboxamido, hydroxyl, C1-C6 alkyloxy, Ci-C6 alkylcarbonyloxy, Ci-C6 alkylcarbonyl or C2-CO alkenyl optionally substituted with one or more azido, cyano, carboxamido or hydroxyl; or
R6 and Rβ' are combined together to provide 3-7 member heterocyclyl bearing one or more heteroatom selected from N, O, S optionally substituted with substituent selected from group comprising Ci-C6 alkyl, C2-C6 alkenyl, C1-C6 alkylcarbonyl, Ci-C6 alkoxycarbonyl, formyl, carboxy, carboxamide, cyano, amino, hydroxyiminoalkyl, alkoxyiminoalkyl, aralkyloxyiminoalkyl, hydroxyiminoaminoalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl, substituted heterocyclyl; R7 represents hydrogen, cyano, aralkyl, CO-OCH2Ph, Ci-C6-alkylcarbonyl, C1-C6 alkyl optionally substituted with one or more azido, cyano, heteroaryl, substituted heteroaryl, carboxamido or hydroxyl;
Rg, Rs- may be same or different, represent, hydrogen, C1-C6 alkyl, C2-C6 alkenyl, cyano, amino, CpC6 alkylcarbonyl, C1-C6 alkoxycarbonyl, cyano, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl, substituted heterocyclyl;
and isomers, polymorphs, N-oxides thereof or pharmaceutical acceptable salts thereof.
2. The compound of claim 1 , wherein, X, Y, R4 are as defined in claim 1 and Q is
Figure imgf000179_0001
wherein n, R2, Rr, W, have the definitions as provided in claim 1.
3. The compound of claim 2, wherein n is 0 or 1.
4. The compound of claim 2, wherein R2" and R2> are each independently . hydrogen, methyl, hydroxyl, halogen.
5. The compound of claim 4, wherein halogen is F.
6. The compound of claim 2, wherein W is heteroaryl or substituted heteroaryl, wherein substituents are as defined in claim 1.
7. The compound of claim 6, wherein heteroaryl is [l,2,3]-triazol, [l,2,4]-triazol, pyrrol, pyrazol, tetrazol, imidazol, [l,3,4]-oxadiazol, [l,2,4]-thiadiazol, [l,3,4]-thiadiazol, oxazol, isoxazol, thiazol, benzotriazol.
8. The compound of claim 6, wherein heteroaryl is [l,2,3]-triazol, [l,2,4]-triazol, pyrazol, tetrazol, [l,2,4]-thiadiazol, [l,3,4]-thiadiazol.
9. The compound of claim 6, wherein heteroaryl is [l,2,3]-triazol, tetrazol.
10. The compound of claim 2, wherein n is 0 or 1;
R2, Rr each and independently is hydrogen, hydroxyl, fluorine; W is [l,2,3]-triazol or tetrazol; R4 is as defined in claim 1.
11. The compound of claim 6, wherein the substituents of the heteroaryl are selected from the group comprising methyl, cyano, amino, ethoxycarbonyl, fluoro, difluoromethyl, formyl, [l,3]-dioxolan, hydroxymethyl, hydroxyethyl, carboxamido, carboxy, acetyl, methyl-oxJranyl, (E/Z)-2-cyano- vinyl, hydroxyimino-methyl, 1-methoxyimino-ethyl, 1- methoxyimino-methyl, 1-benzyloxyimino-methyl, hydroxyiminoamino-methyl, 4-N,N- dimethylaminoethylaminomethyl, phenyl, 4-nitrophenyl, 4-pyridinyl, 3-pyridinyl, morpholin-4-yl, diethylamino, piperazin-1-yl, methylsulfanylmethyl, methylsulfonylmethyl, benzylsulfanyl, thiophen-2-yl-methyl, moφholinocarbonylmethyl, 4-methylpiperazin-l-yl, 4-acetyl-piperazin-l-yl, 4- cyanopiperazin-1-yl, 4-benzylpiperazin-l-yl, ethoxycarbonylmethyl, acetylaminomethyl.
12. The compound of claim 6, wherein substituted heteroaryl is selected from the group comprising 3-ethoxycarbonyl-imidazol, fluoro-4-(lH-[l,2,3]-triazol, 4-difluoromethyl- lH-[l,2,3]-triazol, 4-formyl-lH-[l,2,3]-triazol, 4-[l,3]-dioxolan-2-yl-lH-[l,2,3]-triazol, 4-ethoxycarbonyl- IH- [ 1 ,2,3 ]-triazol, 4-hydroxymethyl- IH- [ 1 ,2,3] -triazol, 4-cyano- IH- [l,2,3]-triazol, 4-carboxamido-lH-[l,2,3]-triazol, 4-hydroxycarbonyl-lH-[l,2,3]-triazol, ^acetyl-H-tl^^J-triazol^-Cl-hydroxyethyD-lH-tl^^l-triazol^-Cmethyl-oxiranyl)- lΗ-[l,2,3]-triazol, 4-(2-hydroxyethyl)-lH-[l,2,3]-triazol, 4-((E/Z)-2-cyano-vinyl)-lH- [l,2,3]-triazol, 4-(hydroxyimino-methyl)-lH-[l,2,3]-triazol, 4-(l-methoxyimino-ethyl)- lH-[l,2,3]-triazol, 4-(l-methoxyimino-methyl)-lH-[l,2,3]-triazol, 4-(l-benzyloxyimino- methyl)-lH-[l,2,3]-triazol, 4-(hydroxyiminoamino-methyl)-[l,2,3]-triazol, 4- benzotriazol, 4-N,N-dimethylaminoethylaminomethyl)- IH-[1, 2,3]-triazol, 1-methyl-lΗ- tetrazol, 2-methyl-2H-tetrazol, 5-methyl-tetrazol, 5-phenyl-tetrazol, 5-(4-nitrophenyl)-tetrazol, 5-(4-pyridinyl)-tetrazol, 5-(3-pyridinyl)-tetrazol, 5-(morpholin-4-yl)-tetrazol, 5-amino-tetrazol, 5-(diethylamino)-tetrazol, 5-(piperazin-l-yl)-tetrazol, 5-methylsulfanylmethyl-tetrazol, 5-methylsulfonylmethyl- ' tetrazol, 5-benzylsulfanyl-tetrazol, 5-(thiophen-2-yl-methyl)-tetrazol, 5- (morpholinocarbonylmethyl)-tetrazol, 5-(4-methylpiperazin-l-yl)-tetrazol, 5-(4-acetyl- piperazin-l-yl)-tetrazol, 5-(4-cyanopiperazin-l-yl)-tetrazol, 5-(4-benzylpiperazin-l-yl)- tetrazol, 5-ethoxycarbonylmethyl-tetrazol, 5-hydroxyethyl-tetrazol, 5-acetylaminomethyl- tetrazol, 5-methyl-[l,2,4]-oxadiazol, 5-phenyl-[l,2,4]-oxadiazol, 5-pyridin-3-yl-[l,2,4]- oxadiazol, 5-methyl-[l,3,4]-oxadiazol, 5-phenyl-[l,3,4]-oxadiazol, 5-amino-2H-[ 1,3,4] - thiadiazol, 5-amino-2#-[l ,2,4]-thiadiazol.
13. The compound of claim 6, wherein substituents of the heteroaryl are selected from the group comprising methyl, cyano, amino, fluoro, difluoromethyl, formyl, hydroxyl methyl, carboxamide, acetyl, 1-methoxyimino-methyl, 4-pyridinyl, 3-pyridinyl, diethylamino, methylsulfonylrαethyl.
14. The compound of claim 2, wherein X and Y are each independently CH, or CF.
15. The compound of claim 2, wherein at least one of X and Y is CF.
16. The compound of claim 2, wherein R4 is C1-C6 alkylamido, C1-C6 haloalkylamido, Ci-Cβ thioalkylamido, substituted C1-C6 thioalkylamido, wherein the alkyl group is substituted with halo; carbamate, thiocarbamate, urea, unsubstituted or substituted heteroaryl, wherein substituents of the heteroaryl are selected from the group comprising Ci-C6 alkyl, nitro, cyano, hydroxyl, halo, amino, Cj-C6 alkylcarbonyl, C1-C6 alkoxycarbonyl, carboxy.
17. The compound of claim 2, wherein R4 is acetamide, difluoroacetamide, thioacetamide, difluoroacetamide, carbamate, thiocarbamate, urea, [l,2,3]-triazol, [1,2,4]- triazol.
18. The compound of claim 2, wherein R4 is acetamide, carbamate, [l,2,3]-triazol.
19. The compound of claim 10, wherein n, R2, R2 1, W is as defined in claim 10, R4 is acetamide, carbamate, [l,2,3]-triazol; X and Y are each independently CH, or CF.
20. The compound of claim 1, wherein X, Y, R4 are as defined in claim 1; and Q is
Figure imgf000182_0001
wherein X', Y' and T have the definition as provided in claim 1.
21. The compound of claim 20, wherein X' and Y' are each independently CH, CF, N, C-CH3.
22. The compound of claim 20, wherein X' and Y' are each independently CH, CF, N, C-CH3; X, Y, R4 are as defined in claim 1;
T is hydrogen or
Figure imgf000182_0002
wherein R2, R2-, R3, R3-, Z, n, have definition as provided in claim 1, with proviso that when T is hydrogen, R4 is not acetamido.
23. The compound of claim 22, wherein Z is selected from the group comprising CH, NH, O, S, CH2, C(R6)R6' , C=O, NR7, C=C(R8)R8., SO, SO2, S=NH, S=NC(O)CH3, S=NC(O)NHCH3, S(O)=NH, S(O)=NCH3, S(O)NC(O)CH3, S(O)=NC(O)NHCH3, S(O)=NC(O)NHCH2CH2Cl, with proviso that when X is CH, Y is CF, one of X' or Y' or both X', Y' are N, then Z is not NH.
24. The compound of claim 22, wherein Z is selected from the group S, SO, SO2; X' and Y' are each independently CH, CF, N, C-CH3;
X, Y, are each independently CH or CF; R4 is as defined in claim 1; R2, R2', R3, R3', are each independently selected from hydrogen, methyl, hydroxyl, fluorine.
25. The compound of claim 22, wherein R4 is acetamido, [l,2,3]-triazol, methyl carbamate, t-butyl carbamate, ORi wherein Ri is hydrogen, P(O)(OM)2, wherein M is hydrogen, Na, methyl, ethyl, t-butyl, phenyl; or R1 is an amino acid residue derived from one of the 20 naturally occurring amino acids viz. alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine, attached to the oxygen via carbonyl of amino acid to form an ester linkage.
26. The compound of claim 25, wherein amino acid is L-alanine and L-valine.
27. The compound of claim 22, wherein at least one of the X, Y is CF and at least one of X', Y' is CF.
28. The compound of claim 22, wherein at least one of the X, Y is CF and at least one of
X', Y' is N.
29. The compound of claim 22, wherein X, is CH, Y is CF, X' is N and Y' is C-CH3.
30. The compound of claim 24, wherein Z, X, Y, X', Y', R2, R2-, R3, R3- are as defined in claim 24, R4 is selected from the group comprising acetamido, [l,2,3]-triazol, methyl carbamate, t-butyl carbamate, ORi, wherein Ri is as defined in claim 25;
31. A compound or a pharmaceutically acceptable salt thereof which is
(S)-N-{ 3-[4-(4-(2-Cyanoaziridin- l-yl)-piperidin- l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-
5-ylniethyl }-acetamide;
(S)-N-{3-[4-(4-pyriOl-l-yl-piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl }-acetamide; (S)-N-{3-[3,5-Difluoro-4-(4-pyrrol-l-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl } - acetami de ;
(S)-N-{3-[4-(4-(iH-imidazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl } -acetami de ;
(S)-N-{3-[4-(4-(lH-[l,23]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(2H-[l,2,3]-triazol-2-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide; (S)-N- { 3- [4-(4-(2H- [ 1 ,2,3]-triazol-2-yl)-piperidin- 1 -yl)-3 ,5 -difluorophenylI-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(lH-[l,2,3]-triazol-l-yl)-3-fluoropiperidin-l-yl)-3,5-difluorophenyl]-2- oxo-oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(2H-[l,2,3]-triazol-2-yl)-3-fluoropiperidin-l-yl)-3,5-difluorophenyl]-2- bxo-oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(lH-[l,2,3]-triazol-l-yl)-3-fluoropiperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl }-acetamide; (S)-N-{3-[4-(4-(2H-[l,2,3]-triazol-2-yl)-3-fluoropiperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5 -ylmethyl } -acetamide; (S)-N-{3-[4-(4-(7H-[l,2,4]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide; (S)-N-{ 3-[4-(4-([l,2,3,4]-tetrazol-5-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{ 3-[4-(4-([l,2,3,4]-tetrazol-5-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide; (S)-N-{ 3-[4-(4-(lH-[l,2,3,4]-tetrazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{ 3-[4-(4-(2H-[l,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{ 3-[4-(4-(lΗ-[l,2,3,4]-tetrazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(2H-[l,2,3,4]-tetrazol-2-yl)-piρeridin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(lH-[l,2,3,4]-tetrazol-l-yl)-3-hydroxypiperidin-l-yl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl} -acetamide and isomer thereof; (S)-N-{3-[4-(4-(lH-[l,2,3,4]-tetrazol-l-yl)-3-hydroxypiperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetarnide;
(S)-N-{3-[4-(4-(lH-[l,2,3,4]-tetrazol-l-yl)-3-fluoroρiρeridin-l-yl)-3,5-difluoroρhenyl]- 2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(4-formyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl }-acetamide;
(S)-N-{3-[4-(4-(4-formyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2- oxo-oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(4-formyl-lH-[l,2,3]-triazol-l-yl)-3-fluoropiperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; (R)-{3-[4-(4-(4-formyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]- 5-(lH- [ 1 ,2,3]-triazol- 1-ylmethyl) } -oxazolidin-2-one;
(S)-N-{3-[4-(4-(4-difluoromethyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(4-difluoromethyl-iH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3,5- difluoiOphenyl]-2-oxo-oxazolidin-5-ylmethyl }-acetamide; (S)-N-{3-[4-(4-(4-[l,3]-Dioxolan-2-yl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-5-(luf-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
(S)-N-{3-[4-(4-(4-ethoκycarbonyl-lH-[l,2,3]-triazol-l-yl)-methyl-piperidin-l-yl)-3- fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; (S)-N-{3-[4-(4-(5-ethoxycarbonyl-lH-[l,2,3]-triazol-l-yl)-methyl-piperidin-l-yl)-3- fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(4-ethoxycarbonyl-lH-[l,2,3]-triazol-l-yl)-3-fluoropiperidin-l-yl)-3- fluorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(4-ethoxycarbonyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3,5- difluorophenyl] -2-oxo-oxazolidin-5-ylmethyl } -acetamide;
(R)-{3-[4-(4-(4-ethoxycarbonyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-
5-( lH-[ l,2,3]-triazol-l-ylmethyl) }-oxazolidin-2-one;
(R)-{3-[4-(4-(4-ethoxycarbonyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3,5- difluorophenyl] -5-(1H-[1 ,2,3]-triazol- 1 -ylmethyl) } -oxazolidin-2-one; (S)-N-{3-[4-(4-(4-hydroxymethyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(5-hydroxymethyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N- { 3- [4-(4-(4-hydroxymethyl-lH- [ 1 ,2,3]-triazol- l-yl)-3-fluoropiperidin- l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(4-hydroxymethyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3,5- di fluorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide;
(R)-{3-[4-(4-(4-hydroxymethyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-
5-(lH-[l,2,3]-triazol-l-ylmethyl) }-oxazolidin-2-one; (R)-{3-[4-(4-(4-hydroxymethyl-lH-[l,2,3]-triazol-l-yl)-ρiperidin-l-yl)-3,5- difluorophenyl]-5-(lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one; (S)-N-{3-[4-(4-((4-hydroxymethyl)-[l,2,3]-triazol-l-yl-methyl)-piperidin-l-yl)-3-fluoro- phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(4-cyano-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl }-acetamide; (S)-N-{ 3-[4-(4-(4-carboxamido-l#-[l ,2,3]-triazol- l-yl)-piperidin- l-yl)-3-fluorophenyl]-
2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(R)-{ 3-[4-(4-(4-carboxamido-l#-[l ,2,3]-triazol- l-yl)-piperidin- l-yl)-3-fluorophenyl]-5-
(lH-[l,2,3]-triazol-l-ylmethyl) }-oxazolidin-2-one; (S)-N-{ 3-[4-(4-(4-carboxamido-lH-[l,2,3]-txiazol-l-yl)-methyl-piperidin-l-yl)-3-fluoro- phenyl] -2-oxo-oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(5-carboxamido-m-[l,2,3],-triazol-l-yl)-methyl-ρiperidin-l-yl)-3-fluoro- phenyl] -2-oxo-oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(4-hydroxycarbonyl-lH-[l,2,3]-triazol-l-yl)-methyl-piρeridin-l-yl)-3- fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide ;
(S )-N- { 3- [4-(4-(5 -hydroxycarbonyl- lH-[ 1 ,2,3]-triazol- 1 -yl)-methyl-piperidin- 1 -yl)-3- fluoro-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{ 3-[4-(4-(4-acetyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide; (S)-N-{3-[4-(4-(4-acetyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2- oκo-oxazolidin-5-ylmethyl } -acetamide;
(R)-{3-[4-(4-(4-acetyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-5-(lH-
[1 ,2,3]-triazol- 1-ylmethyl) }-oxazolidin-2-one;
(S)-N-{3-[4-(4-(4-acetyl-lH-[l,2,3]-trizol-l-ylmethyl)-lH-[l,2,3]-triazol-l-yl)-piperidin- l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(4-(l-hydroxyethyl)-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{ 3- [4-(4-(4-(l -hydroxyethyl)- lH-[ 1 ,2,3]-triazol- 1 -yl)-piperidin- l-yl)-3,5- di fluorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide; (R)-{3-[4-(4-(4-(2-hydroxyethyl)-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl] -5 -( IH- [ 1 ,2 ,3] -tri azol- 1 -ylmethyl) } -oxazolidin-2-one;
(S)-N- { 3- [4-(4-(4-(2-methyl-oxiranyl)-lH- [1 ,2,3]-triazol- l-yl)-piperidin- l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; (R)- { 3 -[4-(4-(4-(2-methyl-oxiranyl)- lH-[ 1 ,2,3]-triazol- l-yl)-piperidin- l-yl)-3- fluorophenyl]-5-(lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one; (S)-N-{3-[4-(4-((4-((E/Z)-2-cyano-vinyl)-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(4-hydroxyimino-methyl)-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl] -2-oxo-oκazolidin-5 -ylmethyl } -acetamide; (S)-N-{3-[4-(4-(l-methoxyimino-ethyl)-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3,5- difluorophenyl] -2-oxo-oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(4-(l-niethoxyimino-ethyl)-lH-[l,2,3]-triazol-l-yl)-piperidm-l-yl)-3- fluorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide;
(R)-{3-[4-(4-(4-(l-methoxyimino-ethyl)-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-5-(lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
(R)-{3-[4-(4-(4-(l-methoxyimino-ethyl)-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3,5- ' difluorophenyl]-5-(lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
(S)-N-{3-[4-(4-(l-methoxyimino-methyl)-lH-[l,2,3]-triazol-l-yl)-piρeridin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; (S)-N-{3-[4-(4-(l-methoxyiraino-methyl)-lH-[l,2,3]-triazol-l-yl)-ρiperidin-l-yl)-3,5- difluorophenyl] -2-oxo-oxazolidin-5-ylmethyl }-acetamide;
(S)-N-{ 3-[4-(4-(l-benzyloxyimino-methyl)-lH-[l,2,3]-triazol-l-yl)-piρeridin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl }-acetamide;
(S)-N-{3-[4-(4-(4-hydroxyiminoamino-methyl)-[l,2,3]-triazol-l-yl)-piperidm-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(4-N,N-dimethylaminoethylaminomethyl)-lH-[l,2,3]-triazol-l-yl)- piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{ 3-[4-(4-(2Η-benzotriazol-2-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide; (S)-N- { 3- [4-(4-( lH-benzotriazol- 1 -yl)-piperidin- 1 -yl)-3 ,5 -difluorophenyl] -2-oxo- oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-Benzotriazol-2-yl-piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl } -acetamide;
(S)-N-{3-[4-(4-Benzotriazol-l-yl-piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl} -acetamide; (S)-N-{3-[4-(4-(4-(lH-[l,2,3,4]-tetrazol-l-ylmethyl)-lH-[l,2,3]-triazol-l-yl)-piperidin-l- yl)-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetarnide;
(S)-N-{3-[4-(4-(2H-[l,2,3,4]-tetrazol-2-ylmethyl)-[l,2,3]-triazol-l-yl)-ρiperidin-l-yl)-3- fluorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide; (S)-N-{3-[4-(4-(lH-imidazol-l-ylmethyl)-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-ox.azolidin-5-ylmethyl}-acetamide;
(R)-{3-[4-(4-(lH-[l,2)3]-triazol-l-yl)-3-fluoropiρeridin-l-yl)-3-fluorophenyl]-5-(lH-
[1, 2,3] -triazol-1 -ylmethyl) }-ox.azolidin-2-one;
(R)-{3-[4-(4-(lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-5-(lH-[l,2,3]- triazol-1 -ylmethyl) }-oxazolidin-2-one;
(R)-{3-[4-(4-(lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]-5-(lH-[l,2,3]- triazo]-l-ylmethyl)}-oxazolidin-2-one;
(R)-{3-[4-(4-(lH-[l,2,3]-triazol-l-yl)-3-fluoropiperidin-l-yl)-3,5-difluorophenyl]-5-
( IH- [ 1 ,2,3 ] -triazol- 1 -ylmethyl) } -oxazolidin-2-one ; (S)-N-{3-[4-(4-([l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl } -thioacetamide;
(S)-N-{3-[4-(4-(5-methyl-2Η-[l,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-3-fluorophenyl]-2- ox.o-oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(5-methyl-lH-[l,2,3,4]-tetrazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]- 2-oxo-oxazolidin-5-ylmethyl} -acetamide;
(S)-N-{3-[4-(4-(5-methyl-lH-[l,2,3,4]-tetrazol-l-yl)-ρiρeridin-l-yl)-3,5- di fluorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(5-methyl-2H-[l,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-3,5- di fluorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide; (S)-N- { 3- [4-(4-(2-methyl-2H-tetrazol-5-yl)-piperidin- l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5 -ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(l-methyl-lH-tetrazol-5-yl)-piperidin-l-yl)-3-fluorophenyl]-2-pxo- oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(2-methyl-2H-tetrazol-5-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oχazolidin-5-ylmethyl }-acetamide; (S)-N-{3-[4-(4-(l-methyl-lH-tetrazol-5-yl)-piperidin-l-yl)-3,5-difluoroρhenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
(R)-{3-[4-(4-(2-methyl-2Η-tetrazol-5-yl)-piperidin-l-yl)-3-fluorophenyl]-5-(lH-[l,2,3]- triazol-lylmethyl)-oxazolidin-2-one; (R)-{3-[4-(4-(l-methyl-lH-tetrazol-5-yl)-piperidin-l-yl)-3-fluorophenyl]-5-(lH-[l,2,3]- triazol- 1 -ylmethyl) }-oxazolidin-2-one;
(S)-N- { 3-[4-(4-(l -methyl)- lH-tetrazol-5-ylmethyl-piperidin- 1 -yl)-3 ,5-difluoro-phenyl] -
2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(2-methyl)-2H-tetrazol-5-ylmethyl-ρiperidin-l-yl)-3,5-difluoro-phenyl]- 2-oxo-oxazolidin-5-ylmethyl }-acetamide;
(S)-N-{3-[4-(4-(l-methyl-lH-tetrazol-5-ylmethyl)-piperidin-l-yl)-3-fluoro-phenyl]-2- oxo-oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(2-methyl-2Η-tetrazol-5-ylmethyl)-piperidin-l-yl)-3-fluoro-phenyl]-2- oxo-oxazolidin-5-ylmethyl } -acetamide; (S)-N-{3-[4-(4-(5-methylsulfanylmethyl-2H-[l,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{ 3- [4-(4-(5-methylsulfanylmethyl- lH-[ 1 ,2,3,4]-tetrazol- 1 -yl)-piperidin- 1 -yl)-3- fluorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(5-methylsulfanylmethyl-2H-[l,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5 -ylmethyl} -acetamide;
(S)-N-{3-[4-(4-(5-methylsulfanylmethyl-lH-[l,2,3,4]-tetrazol-l-yl)-piperidin-l-yl)-3,5- fluoiOphenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(5-benzylsulfanyl-iΗ-[l,2,3,4]-tetrazol-l-yl)-piperidin-l-yl)-3,5- difluorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide; (S)-N-{3-[4-(4-(5-(benzylsulfanyl)-2H-[l,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-3,5- difluorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(5-(benzylsulfanyl)-2H-[l,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylrαethyl}-acetamide;
(S)-N-{3-[4-(4-(5-(benzylsulfanyl)-2H-[l,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylniethyl }-acetamide; (S)-N-{3-[4-(4-(5-methylsulfonylmethyl-lH-[l,2,3,4]-tetrazol-l-yl)-piperidin-l-yl)-3,5- difluorophenyl] -2-oxo-oxazolidin-5-ylπiethyl } -acetamide;
(S)-N-{3-[4-(4-(5-methylsulfonylmethyl-lH-[l,2,3,4]-tetrazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; (S)-N-{3-[4-(4-(5-(thiophen-2-yl-methyl)-lH-[l,2,3,4]-tetrazol-l-yl)-piperidin-l-yl)-3- fluorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(5-(thiophen-2-yl-methyl)-lH-[l,2,3,4]-tetrazol-l-yl)-ρiperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(5-(thiophen-2-yl-methyl)-lH-[l,2,3,4]-tetrazol-l-yl)-ρiρeridin-l-yl)-3,5- difluorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide;
(S)-N-{ 3-[4-(4-(5-(thiophen-2-yl-methyl)-2H-[l,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-3,5- difluorophenyJ]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(5-(morpholinocarbonylmethyl)-lH-[l,2,3,4]-tetrazol-l-yl)-piperidin-l- yl)-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; (S)-N-{3-[4-(4-(5-(morpholinocarbonylmethyl)-lH-[l,2,3,4]-tetrazol-l-yl)-piperidin-l- yl)-3 ,5-difluorophenyl] -2-oxo-ox.azolidin-5-ylmethyl }-acetamide;
(S)-N-{ 3-[4-(4-(5-(morpholin-4-yl)-2H-[l,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(5-(morpholin-4-yl)-2H-_[l,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(5-phenyl-2H-[l,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-3,5-difluorophenyl]-
2-oxo-oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(5-phenyl-2H-[l,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-acetamide; (S)-N-{ 3-[4-(4-(5-(4-nitrophenyl)-2H-[l ,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl }-acetamide;
(S)-N-{3-[4-(4-(5-(4-nitrophenyl)-2H-[l,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(5-(4-pyridinyl)-lH-[l,2,3,4]-tetrazol-l-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl }-acetamide; (S)-N-{3-[4-(4-(5-(3-pyridinyl)-2H-[l,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-3- fluoiOphenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(5-(4-ρyridinyl)-lH-[l,2,3,4]-tetrazol-l-yl)-piperidin-l-yl)-3,5- difluorophenyl] -2-oxo-oxazolidin-5-ylmethyl } -acetamide; (S)-N-{3-[4-(4-(5-(3-ρyridinyl)-2H-[l,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-3,5- difluorophenyl] -2-oxo~oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(5-amino-2H-[l,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl} -acetamide;
(S)-N-{3-[4-(4-(5-amino-2H-[l,2,3,4]-tetrazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]- 2-oxo-oxazolidin-5-ylmethyl }-acetamide;
(S)-N-{3-[4-(4-(5-(diethylamino)-2/ϊ-[l,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-3,5- difluorophenyl] -2-oxo-oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(5-(piperazin-l-yl)-2Η-[l,2,3,4],-tetrazol-2-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; (S)-N-{ 3-[4-(4-(5-(piperazin-l-yl)-2H-[l ,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-3,5- difluorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide;
(S)-N-{ 3-[4-(4-(5-(4-methylpiperazin-l-yl)-2H-[l,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(5-(4-methylpiperazin-l-yl)-2H-[l,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)- 3,5-difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl }-acetamide;
(S)-N-{ 3-[4-(4-(5-(4-acetyl-ρiperazin-l-yl)-2H-[l,2,3,4]-tetrazol-2-yl)-piρeridm-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{ 3-[4-(4-(5-(4-acetyl-piperazin-l-yl)-2H-[l,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-
3,5-difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; (S)-N-{ 3-[4-(4-(5-(4-cyanopiperazin-l-yl)-2H-[l ,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-3- fluorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide ;
(S)-N-{3-[4-(4-(5-(4-cyanopiperazm-l-yl)-2H-[l,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-
3,5-difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(5-(4-benzylpiperazin-l-yl)-2Η-[l,2,3,4]-tetrazol-2-yl)-piρeridin-l-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl }-acetamide; (S)-N-{3-[4-(4-(5-(4-benzylpiperazm-l-yl)-2H-[l,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-
3,5-difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N- { 3-[4-(4- lH-tetrazol-5-ylmethyl-piperidin- l-yl)-3-fluoro-phenyl]-2-oxo- oxazolidin-5-ylmethyl }-acetamide; (S)-N-{3-[4-(4-lH-tetrazol-5-ylmethyl-piρeridin-l-yl)-3,5-difluoroρhenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-([l,2,3]-triazol-l-yl-methyl)-piρeridin-l-yl)-3-fluoro-phenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
(R)-{3-[4-(4-(lH-[l,2,3,4]-tetrazol-l-yl)-piρeridin-l-yl)-3-fluorophenyl]-5-(lH-[l,2,3]- triazol-l-ylmethyl)}-oxazolidin-2-one;
(R)-{3-[4-(4-(2H-[l,2,3,4]-tetrazol-2-yl)-ρiperidin-l-yl)-3-fluorophenyl]-5-(lH-[l,2,3]- triazol-l-ylme.thyl)}-oxazolidin-2-one;
(S)-{3-[4-(4-([l,2,3,4]-tetrazol-5-yl)-piperidin-l-yl)-3-fluorophenyl]-5-(lH-[l,2,3]- tiiazol- 1-ylmethyl) } -oxazolidin-2-one; (S)-N-{ 3-[4-(4-(5-methyl-[l ,2,4]-oxadiazol-3-yl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(5-methyl-[l,2,4]-oxadiazol-3-ylmethyl)-piperidin-l-yl)-3-fluoro- phenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide;
(S)-N-{ 3-[4-(4-(5-methyl-[l,2,4]-oxadiazol-3-ylmethyl)-piperidin-l-yl)-3,5-difluoro- ρhenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(5-phenyl-[l,2,4]-oxadiazol-3-ylmethyl)-piperidin-l-yl)-3-fluoro-phenyl]-
2-oxo-oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(5-phenyl-[l,2,4]-oxadiazol-3-ylmethyl)-piperidin-l-yl)-3,5-difluoro- phenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide; (S)-N-{3-[4-(4-((5-pyridin-3-yl)-[l,2,4]-oxadiazol-3-ylmethyl)-piperidin-l-yl)-3-fluoro- phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(5-methyl-[l,3,4]-oxadiazol-2-ylmethyl)-piperidin-l-yl)-3-fluoro- phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S )-N- { 3 - [4-(4-(5 -phenyl- [ 1 ,3 ,4] -oxadiazol-2-ylmethyl)-ρiperidin- 1 -yl)-3-fluoro-phenyl] - 2-oxo-oxazolidin-5-ylmethyl }-acetamide; (S)-N-{ 3-[4-(4-(5-Amino-2#-[ l,3,4]-thiadiazol-2-yl)-piperidin- l-yl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(5-Amino-[l,3,4]-thiadiazol-2-yl)-piρeridin-l-yl)-3,5-difluoro-phenyl]-2- oxo-oxazolidin-5-ylmethyl}-acetamide; (S)-N-{3-[4-(4-(5-Amino-[l,3,4]-thiadiazol-2-ylmethyl)-piperidin-l-yl)-3,5-difluoro- phenyl]-2-oxo-oxazolidin-5~ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(3-ethoxycarbonyl-imidazol-l-yl)-methyl-piperidin-l-yl)-3-fluoro- phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[3,5-Difluoro-4-(4-2H-tetrazol-2-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin- 5-ylmethyl }-carbamic acid methyl ester;
(S)-N-{3-[3,5-Difluoro-4-(4-lH-tetrazol-l-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-
5-ylmethyl}-carbamic acid methyl ester;
(S)-N-{3-[3,5-Difluoro-4-(4-[l,2,3]-triazol-l-yl-ρiperidin-l-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-carbamic acid methyl ester; (S)-N-{ 3-[3-fluoro-4-(4-2H-tetrazol-2-yl-piperidin- l-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethylj-carbamic acid methyl ester;
(S)-N-{3-[3-fluoro-4-(4-iH-tetrazol-l-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethylj-carbamic acid methyl ester;
(S)-N-{3-[4-(4-2H-[l,2,3]-triazol-2-yl-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-carbamic acid methyl ester;
(S)-N-{3-[3,5-Difluoro-4-(4-[l,2,3]triazol-2-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-
5-ylmethyl}-2,2-difluoro-acetamide;
(S)-N-{3-[3,5-Difluoro-4-(4-[l,2,3]-triazol-l-yl-piperidin-l-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl } -2,2-difluoro-acetamide; (S)-N-{3-[3,5-Difluoro-4-(4-[l,2,3,4]-tetrazol-2-yl-piperidin-l-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-2,2-difluoro-acetamide;
(S)-N- { 3- [3 ,5-Difluoro-4-(4-[ 1 ,2,3 ,4]-triazol- 1 -yl-piperidin- 1 -yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-2,2-difluoro-acetamide;
(S)-N-{3-[3,5-Difluoro-4-(4-2Η-tetrazole-2-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin- 5-ylmethyl }-2,2-dichloro-acetamide; (S)-N-{3-[3-fluoro-4-(4-2H-tetrazol-2-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethylj-carbamic acid ethyl ester;
(S)-N- { 3-[3 ,5 -Difluoro-4-(4- lH-tetrazole- 1 -yl-piperidin- l-yl)-phenyl] -2-oxo-oxazolidin-
5-ylmethyl}-2,2-difluoro-thioacetamide; (S) -N- { 3- [3 ,5 -Difluoro-4- (4- lH-tetrazole- 1 -yl-piperidin- 1 -yl)-phenyl] -2-oxo-oxazolidin-
5-ylmethyl } -cyclopropane carboxamide;
(S)-N-{3-[3,5-Difluoro-4-(4-[l,2,3]-triazol-l-yl-piperidin-l-yl)-phenyl]-2-oxo- ox.azolidin-5-ylrnethyl}-propionamide;
(S)-N- { 3- [3 ,5-Difluoro-4-(4- [ 1 ,2,3] -triazol-2-yl-piperidin- 1 -yl)-phenyl]-2-oxo- oxazolidin-5-ylrnethyl}-propionarnide;
(S)-N-{3-[3,5-Difluoro-4-(4-2H-tetrazol-2-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-
5-ylmethyl }-propionamide;
(S)-N- { 3- [3,5-Difluoro-4-(4- lH-tetrazol- 1-yl-piperidin- l-yl)-phenyl] -2-oxo-oxazolidin-
5-ylmethyl }-propionamide; (S) N- { 3-[3-Fluoro-4-(4-2H-tetrazol-2-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl } -propionamide;
(S) N-{3-[3-Fluoro-4-(4-lH-tetrazol-l-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl } -propionamide;
(S)-N-{3-[3,5-Difluoro-4-(4-[l,2,3]triazρl-2-yl-piperidin-l-yl)-phenyl]-2-oxo- oxazolidin-5 -ylmethyl } -propionamide ;
(S)-N-{3-[3,5-Difluoro-4-(4-[l,2,3]-triazol-l-yl-piperidin-l-yl)-phenyl]-2-oxo- oxazolidin-5 -ylmethyl } -propionamide;
(S)-N- { 3- [3 ,5-Difluoro-4-(4-(5-methyl-tetrazol-2-yl)-piperidin- l-yl)-phenyl]-2-oxo- oxazolidin-5 -ylmethyl } -propionamide ; (S)-N- { 3- [3 ,5-Difluoro-4-(4-(5-methyl-tetrazol- l-yl)-ρiρeridin- 1 -yl)-phenyl] -2-oxo- oxazolidin-5-ylmethyl}-piOpionamide;
(S)-N-{3-[3,5-Difluoro-4-(4-(4-methyl-5-thioxo-4,5-dihydro-tetrazol-l-yl)-piperidin-l- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N- { 3-[3 ,5-Difluoro-4-(4-(4-methyl-5-thioxo-4,5-dihydro-[l ,2,4]triazol- 1 -yl)- piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; (S)-N-{3-[3-fluoro-4-(4-(4-methyl-5-thioxo-4,5-dihydro-[l,2,4]triazol-l-yl)-piperidin-l- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(isoxazol-3-yloxymethyl)-piperidin-l-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide; (S)-N-{3-[4-(4-([l,2,3]-triazol-l-yl)-methyl-piperidin-l-yl)-3-fluoro-phenyl]-5-(isoxazol-
3-yloxymethyl) } -oxazolidin-2-one;
(R)-{3-[4-(4-((4-hydroxymethyl)-[l,2,3]-txiazol-l-yl)-methyl-piperidin-l-yl)-3-fluoro- phenyl]- 5-(isoxazol-3-yloxymethyl) } -oxazolidin-2-one; cw-(R)-{3-[4-(4-(5-ethoxycarbonyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3- fluorophenyl] -5 -(5 -ethoxycarbonyl- IH-[1, 2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one; cw-(R)-{3-[4-(4-(5-ethoxycarbonyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluoro- phenyl] -5-(4-ethoxycarbonyl- IH- [ 1 ,2,3]-triazol- 1 -ylmethyl) } -oxazolidin-2-one; fran5'-(R)-{3-[4-(4-(5-ethoxycarbonyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluoro- phenyll-S-CS-ethoxycarbonyl-lH-Cl^^l-triazol-l-ylmethy^J-oxazolidin^-one; frarø-(R)-{3-[4-(4-(5-ethoxycarbonyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluoro- phenyl]-5-(4-ethoxycarbonyl-lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one; trαrø-(R)-{3-[4-(4-(5-hydroxymethyl-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluoro- phenyl]-5-(4-hydroxymethyl-lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one; trα«5'-(R)-{3-[4-(4-(5-hydroxymethyl-lΗ-[l,2,3]-triazol-l-yl)-ρiperidin-l-yl)-3-fluoro- phenyl]-5-(5-hydroxymethyl-lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one;
?rα«5'-(R)-{3-[4-(4-(5-cyano-lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluoro-phenyl]-5-
(5-cyano-lH-[l,2,3]-triazol-l-ylmethyl)}-oxazolidin-2-one; trans-(R)- { 3- [4-(4-(5 -cyano- lH-[ 1 ,2,3] -triazol- 1 -yl)-piperidin- 1 -yl)-3-fluoro-phenyl] -5-
(4-cy ano- 1 H- [ 1 ,2 , 3] -tri azol- 1 -ylmethyl) } -oxazolidin-2-one ; (3R,5S)-N-{3-[4-(Fluoro-4-(lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3-fluoro-phenyl]-2- ox.o-oxazolidin-5-ylmethyl } -acetamide;
(R)- { 3- [4-(4-(5 -ethoxycarbonylmethyl^H- [ 1 ,2,3 ,4] -tetrazol-2-yl)-piperidin- l-yl)-3 ,5- difluorophenyl] -5-(1H-[1 ,2,3]-triazol- 1-ylmethyl) } -oxazolidin-2-one;
(S)-N-{3-[4-(4-(5-hydroxyethyl-2H-[l,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl }-acetamide; (S)-N-{3-[4-(4-(5-acetylaminomethyl-2F-[l,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-3,5- difluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(R)-{ 3-(4-phenyl-3-fluorophenyl)-5-iH-l ,2,3-triazol-l-ylmethyl }-oxazolidin-2-one;
(R)-{3-(4-phenyl-3-fluorophenyl)-5-iH-l,2,4-triazol-l-ylmethyl}-oxazolidin-2-one; (R)-{ 3-(4-phenyl-3-fluorophenyl)-5-iH-l ,2,3-triazol-2-ylmethyl }-oxazolidin-2-one;
(R)-{3-[4-(4-(piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl }-methanesulfonate;
(S)-N-{3-[4-(4-(piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl }-acetamide; (S)-{3-[4-(4-(piperidin- l-yl)-3-fluorophenyl)-3-fluorophenyl]-5-imidazol-l-ylmethyl }- ox.azolidin-2-one;
(R)-{3-[4-(4-(piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-5-iH-l,2,3-triazol-l- ylmethyl }-oxazolidin-2-one;
(R)-{3-[4-(4-(piperidin-l-yl)-3-fluoroρhenyl)-3-fluorophenyl]-5-iH-l,2,3-triazol-2- ylmethyl}-oxazolidin-2-one;
(R)-{3-[4-(4-(piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-5-iH-l,2,3,4-tetrazol-l- ylmethyl }-oxazolidin-2-one;
(S)-N-{3-[4-(4-(4,4-dimethoxypiperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide; (R)-{ 3-[4-(4-(l ,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -methanesulf onate;
(S)-N-{3-[4-(4-(l,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-fluoroρhenyl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(6-(l,4-dioxa-8-azaspiro[4.5]dec-8-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl }-acetamide;
(R)-{3-[4-(4-(4-oxo-piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl } -methanesulf onate;
(S)-N-{3-[4-(4-(4-oxo-piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo- oχazolidin-5-ylmethyl}-acetamide; (R)-{3-[4-(4-(4-hydroxy-piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-methanesulfonate; (S)-N- { 3-[4-(4-(4-hydroxy-piperidin- l-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(6-(4-hydroxy-ρiperidin-l-yl)-ρyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide; (R)-{3-[4-(4-(4-methanesulfonyloxy-piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-methanesulfonate;
(S)-N-{3-[4-(4-(4-methanesulfonyloxy-piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-
2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(6-(4-niethanesulfonyloxy-piperidin-l-yl)-pyridin-3-yl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl } -acetamide ;
(S)-N-{3-[4-(4-(4-cyanomethylidene-piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-acetamide;
(R)-{3-[4-(4-(4-cyanomethylidene-piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-5-
(IH- 1 ,2,3-triazol- l-yl)-methyl } -oxazolidin-2-one; (R)-{ 3-[4-(4-(4-cyanomethylidene-piperidin-l-yl)-3-fluorophenyl)-3-fluorophenyl]- 5-
(Hϊ-tetrazol- l-yl)methyl } -oxazolidin-2-one;
(S)-N-{3-[4-(4-(4-cyanomethyl-3,4-dehydropiperidin-l-yl)-3-fluorophenyl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(4-cyanomethyl-piperidin-l-yl)-3-fluoroρhenyl)-3-fluorophenyl]-2-6xo- oxazolidin-5 -ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(4-hydroxy-4-hydroxymethyl-piperidin-l-yl)-3-fluorophenyl)-3- fluorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide ;
(S)-N-{3-[4-(4-(4-azidomethyl-4-hydroxy-piperidin-l-yl)-3-fluorophenyl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } -acetamide; (S)-N-{3-[4-(4-(4-(iH-l,2,3-triazol-l-yl)-piperidin-l-yl)-3-fluorophenyl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide and isomer thereof;
(S)-N-{3-[4-(4-(4-(iH-l,2,3,4-tetrazol-l-yl)-piperidin-l-yl)-3-fluorophenyl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide and isomer thereof;
(S)-N-{3-[4-(6-(4-Oxopiperidin-l-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5- ylmethyl} -acetamide; (S)-N-{3-[4-(6-(4-Hydrox:y-4-methoxymethylpiperidin-l-yl)-pyridin-3-yl)-3- fluorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } -acetamide;
(S)-N-{3-[4-(6-(4-Hydroxy-4-acetylox.ymethylpiperidin-l-yl)-pyridin-3-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; (R)-{3-[4-(4-(ρiρerazin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-5-iH-l,2,3-triazol-l- ylmethyl } -oxazolidin-2-one;
(^-{S-^-C^Cpiperazin-l-yO-S-fluoropheny^-S-fluorophenylJ-S-iH-l^^^-tetrazol-l- ylmethyl } -ox.azolidin-2-one;
(R)-{3-[4-(4-(piperazin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl }-methanesulfonate hydrochloride;
(^-{S-^-C^Cpiperazin-l-yO-S-fluoropheny^-S-fluorophenylJ-S-Cl^^-triazol-l- yl)methyl }-oxazolidin-2-one hydrochloride;
(S)-{3-[4-(4-(4-hydroxymethylcarbonyl-piperazin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-
2-oxo-oxazolidin-5-ylmethyl}-acetamide; (R)- { 3-[4-(4-(4-(2-niti-ofuran-5-yl-methyl)-piperazin- l-yl)-3-fluorophenyl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-methanesulfonate;
(S)-N-{3-[4-(4-(4-(2-nitrofuran-5-yl-methyl)-piperazin-l-yl)-3-fluorophenyl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl }-acetamide;
(R)-{3-[4-(4-(4-benzyloxycarbonyl-piperazin-l-yl)-3-fluorophenyl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-methanesulfonate;
(S)-{3-[4-(4-benzyloxycarbonyl-piperazin-l-yl-3-fluorophenyl)-3-fluorophenyl]-5-iH- l,2,3-triazol-l-ylmethyl}-oxazolidin-2-one;
(S)-N-{3-[4-(4-benzyloxycarbonyl-piperazin-l-yl-3-fluorophenyl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl } -acetamide; (S)-N-{3-[4-(4-(l-oxa-6-azasρiro[2.5]oct-6-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(4-(morpholin-l-yl)-phenyl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(thiomoφholin-4-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo-oxazolidin- 5-ylmethyl}-acetamide; (S)-N-{3-[4-(6-(thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo-oxa2olidin-5- ylmethyl }-methanesulfonate;
(S)-N-{3-[4-(6-(thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl }-acetamide; (R)-{ 3-[4-(6-(Thiomoφholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo-oxazolidin -5- ylmethyl }-methansulphonate;
(S)-N-{3-[4-(6-(Thiomoφholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl }-formamide;
(S)-N-{3-[4-(6-(Thiomoφholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl }-propionamide;
(S)-{3-[4-(6-(thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethylj-carbamic acid methyl ester;
(S)-{3-[4-(6-thiomorpholin-4-yl-pyridin-3-yl)-3-fluorophenyl]-5-l,2,3-triazol-l- ylmethyl } -oxazolidin-2-one; (S)-N-{3-[6-(6-(Thiomoφholin-4-yl)-pyridin-3-yl)-pyridin-3-yl]-2-oxo-oxazolidin-5- ylmethyl } -acetamide;
(S)-N-{ 3-[6-(4-(Thiomoφholin-4-yl)-3-fluorophenyl)-pyridin-3-yl]-2-oxo-oxazolidin-5- ylmethyl } -acetamide;
(S)-N-{3-[4-(6-(Thiomoφholin-4-yl)-pyridin-3-yl)-phenyl]-2-oxo-oxazolidin-5-yl methyl } -acetamide;
(S)-N- { 3- [4-(2-(Thiomoφholin-4-yl)-pyrimidin-5-yl)-3-fluorophenyl]-2-oxo-oxazolidin-
5-ylmethyl}-carbamic acid methyl ester;
(S)-N-{3-[4-(2-(Thiomoφholin-4-yl)-pyrimidin-5-yl)-3-fluorophenyl]-5- hydroxymethyl }-oxazolidin-2-one; (S)-N-{3-[4-(2-(Thiomoipholin-4-yl)-pyrimidin-5-yl)-3-fluorophenyl]-2-oxo-oxazolidin-
5-ylmethyl } -acetamide;
(S)-N-{3-[4-(2-(Thiomorρholin-4-yl)-pyrimidin-5-yl)-3-fluorophenyl]-5-l,2,3-triazol-l- ylmethyl}-oxazolidin-2-one;
(S)-N-{3-[4-(6-(Thiomorpholin-4-yl)-3-methylpyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl }-carbamic acid methyl ester; (S)-N-{3-[4-(6-(Thiomoφholin-4-yl)-3-methylρyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl }-acetamide;
(S)-N-{3-[4-(6-(Thiomorpholin-4-yl)-3-methylpyridin-3-yl)-3-fluorophenyl]-5- hydroxymethyl } -oxazolidin-2-one; (S)-N-{3-[4-(6-(Thiomoφholin-4-yl)-3-methylpyridin-3-yl)-3-fluoroρhenyl]-5-l,2,3- triazol-1 -ylmethyl } -oxazolidin-2-one;
(S)-N-{3-[4-(2-(S-Oxo-thiomorpholin-4-yl)-pyrimidin-5-yl)-3-fluorophenyl]-5- hydroxymethyl } -oxazolidin-2-one;
(S)-N-{3-[4-(4-(S-oxo-thiomoφholin-4-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[6-[6-(S-ox.o-thiomorpholin-4-yl)-pyridin-3-yl]-pyridin-3-yl]-2-oxo-oxazolidin-
5-ylmethyl }-acetamide;
(S)-N-{3-[4-(6-(S-oxo-thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5 -ylmethyl } -acetamide; (R)-{3-[4-(6-(S-Oxo-thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -methansulphonate;
(S)-N-{ 3-[4-(6-(S-OxO- thiomorpholin-4-yl)-pyridin-3-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl }-acetamide;
(S)-N-{3-[4-(2-(S-Oxo-thiomorpholin-4-yl)-pyrimidin-5-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl }-carbamic acid methyl ester;
(S)-N-{3-[4-(2-(S-Oxo-thiomorpholin-4-yl)-pyrimidin-5-ylr)-3-fluorophenyl]-2-oxo- oxazolidin-5-yl methyl}- acetamide;
(S)-N-{3-[4-(2-(S-Oxo-thiomorpholin-4-yl)-pyrimidin-5-yl)-3-fluoroρhenyl]-5-l,2,3- triazol- 1 -ylmethyl } -oxazolidin-2-one; (S)-N-{3-[4-(6-(S-Oxo-thiomorpholin-4-yl)-pyrimidin-5-yl)-3-fluorophenyl]-5- hydroxymethyl}-oxazolidin-2-one;
(S)-N-{3-[4-(6-(S-Oxo-thiomorpholin-4-yl)-3-methylpyridin-3-yl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-carbamic acid methyl ester;
(S)-N-{3-[4-(6-(S-Oxo-thiomorpholin-4-yl)-3-methylpyridin-3-yl)-3-fluorophenyl]-5- 1,2,3-triazol-l-ylmethyl} -oxazolidin-2-one; (S)-N-{3-[4-(6-(S-Oxo-thiomorpholin-4-yl)-3-methylpyridin-3-yl)-3-fluorophenyl]-5- hydroxymethyl } -oxazolidin-2-one;
(S)-N-{3-[4-(6-(S-Oxo-thiomorpholin-4-yl)-3-methylpyridin-3-yl)-3-fluorophenyl]-2- oxo-oxazolidin-5-ylmethyl}-acetamide; (S)-N- {3-[4-(6-(S-ox.o-3-fluoro-thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl] -2- oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(6-(S,S-dioxo-thiomoφholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(6-(S,S-dioxo-thiomoφholin-4-yl)-pyridin-3-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(6-(S,S-dioxo-3-methyl-thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-
2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N- { 3-[4-(4-(S ,S-dioxo-thiomoφholin-4-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo- oxazolidin-5 -ylmethyl } -acetamide; (S)-N-13-[6-[6-(S ,S-dioxo-thiomoφholin-4-yl)-pyridin-3-yl]-pyridin-3-yl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[6-(4-(S,S-dioxo-thiomoφholin-4-yl)-3-fluorophenyl)-pyridin-3-yl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
(R)-3-{4-[6-(S,S-dioxo-thiomoφholin-4-yl)-pyridin-3-yl]-3-fluorophenyl}-5- hydroxymethyl-oxazolidin-2-one ;
(2S,5R)-2-Amino-propionic acid 3-{4-[6-(S,S-dioxo-thiomorpholin-4-yl)-pyridin-3-yl]-
3-fluoro-phenyl }-2-oxo-oxazolidin-5-ylmethyl ester;
(2S,5R)-2-Amino-propionic acid 3-{4-[6-(S,S-dioxo-thiomoφholin-4-yl)-pyrid in-3-yl]-
3-fluoro-phenyl}-2-oxo-oxazolidin-5-ylmethyl ester methanesulfonic acid salt; (2S,5R)-2-Amino-3-methyl-butyric acid 3-{4-[6-(S,S-dioxo-thiomorpholin-4-yl)-pyridin-
3-yl] -3-fluoro-ρhenyl } -2-oxo-oxazolidin-5-ylmethyl ester;
(2S, 5 R)-2-Amino-3 -methyl-butyric acid 3-{4-[6-(S,S-dioxo-thiomoφholin-4-yl)-pyridin-
3-yl]-3-fluoro-phenyl}-2-oxo-oxazolidin-5-ylmethyl ester methane sulfonic acid salt;
(R)-Acetic acid 3-{4-[6-(S,S-dioxo-thiomorpholin-4-yl)-pyridin-3-yl]-3-fluoro-phenyl}- 2-oxo-oxazolidin-5-ylmethyl ester; (S)-N-{3-[4-(6-(S,S-Dioxo-thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmemyl}-forrnamide;
(R)-{3-[4-(6-(S,S-Dioxo-thiomoφholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -methansulphonate; (S)-N- { 3-[4-(6-(S ,S-Dioxo-thiomoφholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -propionamide;
(S)-N-{3-[4-(6-(S,S-Dioxo-thiomoφholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-carbamic acid methyl ester;
N-Acetyl-(R)-N-{3-4-{2-(S,S-Dioxo-thiomoφholin-4-yl)-pyridyl-5-yl-3-fluoroρhenyl-l- yl-] } -2-oxo-oxazolidin-5-yl methyl } -aminocarbonyl-oxymethyl acetate;
(S)-N- { 3-[4-(6-(S ,S-Dioxo-thiomoφholin-4-yl)-pyridin-3-yl)-3-fluoroρhenyl]-5- 1 ,2,3- triazol- 1-ylmethyl }-oxazolidin-2-one;
(S)-N-{3-[4-(6-(S,S-Dioxo-thiomoφholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -urea; (S)-N-{3-[4-(6-(S,S-Dioxo-thiomoφholin-4-yl)-pyridin-3-yl)-phenyl]-2-oxo-oxazolidin-
5-ylmethyl }-acetamide;
(S)-N-{3-[6-(6-(S,S-Dioxo-thioniθφholin-4-yl)-pyridin-3-yl)-pyridin-3-yl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(2-(S,S-Dioxo-thiomoφholin-4-yl)-pyrimidin-5-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethylJ-carbamic acid methyl ester;
(S)-N-{3-[4-(2-(S,S-Dioxo-thiomoφholin-4-yl)-pyrimidin-5-yl)-3-fluorophenyl]-5- hydroxymethyl}-oxazolidin-2-one;
(S)-N-{3-[4-(2-(S,S-Dioxo-thiomoφholin-4-yl)-pyrimidin-5-yl)-3-fluorophenyl]-2-oxo- ox. azolidin-5 -ylmethyl } -acetamide; (S)-N-{3-[4-(2-(S,S-Dioxo-thiomorpholin-4-yl)-pyrimidin-5-yl)-3-fluorophenyl]-5-l,2,3- triazol- 1-ylmethyl }-oxazolidin-2-one;
(S)-N-{3-[4-(6-(S,S-Dioxo-thiomorpholin-4-yl)-3-methylpyridin-3-yl)-3-fluorophenyl]-
2-oxo-oxazolidin-5-ylmethyl}-carbamic acid methyl ester;
(S)-N-{3-[4-(6-(S,S-Dioxo-thiomorpholin-4-yl)-3-methylpyridin-3-yl)-3-fluorophenyl]- 5-hydroxymethyl }-oxazolidin-2-one; (S)-N-{3-[4-(6-(S,S-Dioxo-thiomorpholin-4-yl)-3-methylρyridin-3-yl)-3-fluorophenyl]-
2-oxo-oxazolidin-5 -ylmethyl }-acetamide;
(S)-N-{3-[4-(6-(S,S-Dioxo-thiomoφholin-4-yl)-3-methylpyridin-3-yl)-3-fluorophenyl]-
5-1 ,2,3-triazol- 1 -ylmethyl }-oxazolidin-2-one; (S)-N-{3-[4-(6-(S,S-Dioxo-3-methyl-thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-
2-oxo-oxazolidin-5-ylmethyl}-difluoroacetamide;
(S)-N-{3-[4-(6-(S-Oxo-S-(N-methylimino)-thiomoφholin-4-yl)-pyridyl-3-yl)-3- fluorophenyl- 1 -yl] -2-oxo-oxazolidin-5-ylmethyl } -acetamide ;
(S)-N- { 3-[4-(6-(S-Oxo-S-(N-methylimino)-thiomorpholin-4-yl)-pyridin-3-yl)-phenyl] -2- oxo-oxazolidin-5-ylmethyl }-acetamide;
(S)-N-{3-[4-(6-(S-Oxo-S-(N-acetylimino)-thiomorpholin-4-yl)-ρyridyl-3-yl)-3- fluorophenyl- 1-yl] -2-oxo-oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(6-(S-Oxo-S-(l-chloroethylurido)-thiomorpholin-4-yl)-pyridyl-3-yl)-3- fluorophenyl-l-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide; (S)-N-{3-[4-(6-(S-Oxo-S-imino-thiomoφholin-4-yl)-pyridyl-3-yl)-3-fluorophenyl-l-yl]-
2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[4-(6-(l,4-Dioxa-8-azaspiro[4.5]dec-8-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin -5 -ylmethyl} -acetamide;
(S)-N-{3-[4-(6-(S-Oxo-3,3-dichloro-thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]- 2-oxo-oxazolidin-5-ylmethyl } -acetamide;
(R)-Phosphoric acid { 3- [4-(6-(S ,S-dioxo-thiomorpholin-4-yl)-pyridin-3-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5 -ylmethyl} ester disodium salt;
Phosphoric acid mono (R)- N-{3-{4-{2-(thiomorpholin-4-yl) -pyrimidin-5-yl}-3- fluorophenyl] } -2-oxo-oxazolidin -5-yl methyl} ester; Phosphoric acid mono (R)- N-{3-{4-{2-(S-oxo-thiomorpholin-4-yl)-pyrimidin-5-yl}-3- fluorophenyl] } -2-oxo-oxazolidin -5-yl methyl} ester;
Phosphoric acid mono (R)- N-{3-{4-{2-(S,S-dioxo-thiomorpholin-4-yl) -pyrimidin-5- yl}-3-fluorophenyl]} -2-oxo-oxazolidin -5-yl methyl} -ester;
(R)-Phosphoric acid mono {3-[4-(6-(S,S-dioxo-thiomorpholin-4-yl)-pyridin-3-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylrnethyl} ester; Phosphoric acid mono (R)-N-{3-{4-{2-(S,S-Dioxo thiomorpholin-4-yl) -pyrimidin-5-yl}-
3 -fluorophenyl] } -2-oxo-oxazolidin -5-yl methyl} -ester disodium salt;
(R)-Phosphoric acid mono {3-[4-(6-(thiomorpholin-4-yl)-3-methylpyridin-3-yl)-3- fluorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } ester; (R)-Phosphoric acid mono {3-[4-(6-(S-oxo-thiomorpholin-4-yl)-3-methylpyridin-3-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl} ester;
(R)-Phosphoric acid mono {3-[4-(6-(S,S-dioxo-thiomoφholin-4-yl)-3-methylpyridin-3- yl)-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl } ester;
(R)-Phosphoric acid mono {3-[4-(6-(S-oxo-thiomorpholin-4-yl)-3-methylpyridin-3-yl)-3- fluorophenyl] -2-oxo-oxazolidin-5 -ylmethyl } ester disodium salt;
(5S)-N-[3-(3'-Chloromethyl-2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-ylmethyl]- acetamide;
(5S)-7V-[3-(2-Fluoro-3'-fluoromethyl-biphenyl-4-yl)-2-oxo-oxazolidin-5-ylmethyl]- acetamide; (5S)-N- [3-(2-Fluoro-3'-azidomethyl-biphenyl-4-yl)-2-oxo-oxazolidin-5-ylmethyl]- acetamide; >
(5S)-N-[3-(3'-Aminomethyl-2-fluoro-biphenyl-4-yl)-2-oxo-oxazolidin-5-ylmethyl]- acetamide;
(5S)-2-({4'-[5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-biphenyl-3- ylmethyl }-amino)-acetamide;
(5S)-2-({4'-[5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2'-fluoro-biphenyl-3- ylmethyl } -carbarαoylmethyl-amino)-acetamide;
(5S)-N-{3-[4-(4-Azido-piperidin-l-yl)-3,5-difluoro-phenyl]-2-oxo-oxazolidin-5- ylmethyl } -acetamide; (5 S)- { 3 -[2-Fluoro- 1,1' -biphenyl-3 ' -methoxy-4-yl]-2-oxo-oxazolidin-5yl-methyl } - acetamide;
(5 S)- { 3-[(2-Fluoro- 1,1' -biphenyl-3 ' -yl)methanol]-2-oxo-oxazolidin-5yl-methyl }- acetamide;
(5S)-{3-[(3,5-Difluoro-4-[6-(4-thiomorpholin-l,l-dioxide-4-yl)-3-pyridinyl]phenyl]-2- oxo-oxazolidin-5yl-methyl } -acetamide;
32. A compound or a pharmaceutically acceptable salt thereof which is (S)-N-{3-[4-(4-(lH-[l,2,3,4]-tetrazol-l-yl)-ρiperidin-l-yl)-3-fluorophenyl]-2-oxo- ox.azolidin-5-ylmethyl } -acetamide; (S)-N-{3-[4-(4-(2H-[l,2,3,4]-tetrazol-2-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(4-(lH-[l,2,3,4]-tetrazol-l-yl)-piρeridin-l-yl)-3,5-difluorophenyl]-2-oxo- oxazolidin-5 -ylmethyl } -acetamide
(S)-N-{3-[4-(4-(lH-[l,2,3]-triazol-l-yl)-piperidin-l-yl)-3,5-difluorophenyl]-2-oxo- ox.azolidin-5-ylmethyl } -acetamide; (S)-N-{3-[3,5-difluoro-4-(4-2Η-tetrazol-2-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl } -propionamide;
(S)-N-{3-[3,5-difluoro-4-(4-lH-tetrazol-l-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethyl } -propionamide;
(S)-N- { 3- [4-(4- (2H-benzotriazol-2-yl)-piperidin- l-yl)-3 ,5-difluorophenyl] -2-oxo- oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[3,5-difluoiO-4-(4-[l,2,3]-triazol-l-yl-piperidin-l-yl)-phenyl]-2-oxo- oxazolidin-5-ylmethyl}-carbamic acid methyl ester;
(S)-N-{3-[3-fluoro-4-(4-2H-tetrazol-2-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethylj-carbamic acid methyl ester; (S)-N-{3-[3-fluoro-4-(4-7H-tetrazol-l-yl-piperidin-l-yl)-phenyl]-2-oxo-oxazolidin-5- ylmethylj-carbamic acid methyl ester;
(S)-N-{3-[3,5-difluoro-4-(4-(4-methyl-5-thioxo-4,5-dihydro-tetrazol-l-yl)-piperidin-l- yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
(S)-N-{3-[3,5-difluoro-4-(4-[l,2,3]-triazol-l-yl-piperidin-l-yl)-ρhenyl]-2-oxo- oxazolidin-5-ylmethyl }-2,2-difluoro-acetamide;
33. A compound or a pharmaceutically acceptable salt thereof which is (S)-N-{3-[4-(4-(thiomoφholin-4-yl)-3-fluoroρhenyl)-3-fluorophenyl]-2-oxo-oxazolidin- 5-ylmethyl } -acetamide ; (S)-N-{3-[4-(4-(S-oxo-thiomorpholin-4-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo- oxazolidin-5 -ylmethyl }-acetamide; (S)-N-{3-[4-(4-(S,S-dioxo-thiomorρholin-4-yl)-3-fluorophenyl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(6-(thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl }-acetamide; (S)-N-{3-[4-(6-(S-oxo-thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{3-[4-(6-(S,S-dioxo-thiomoφholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl } -acetamide;
(S)-N-{ 3-[4-(6-(S,S-dioxo-3-methyl-thiomoφholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]- 2-oxo-oxazolidin-5-ylmethyl }-acetamide;
(R)-3-{4-[6-(S,S-Dioxo-thiomoφholin-4-yl)-pyridin-3-yl]-3-fluorophenyl}-5- hydroxymethyl-oxazolidin-2-one;
(R)-Phosphoric acid mono {3-[4-(6-(S,S-dioxo-thiomoφholin-4-yl)-pyridin-3-yl)-3- fluoiOphenyl]-2-oxo-oxazolidin-5-ylmethyl } ester; (R)-Phosphoric acid {3-[4-(6-(S,S-dioxo-thiomorpholin-4-yl)-pyridin-3-yl)-3- fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl} ester disodium salt;
(2S,5R)-2- Amino-propionic acid 3-{4-[6-(S,S-dioxo-thiomorpholin-4-yl)-pyridin-3-yl]-
3-fluoro-phenyl }-2-oxo-oxazolidin-5-ylmethyl ester;
(2S,5R)-2-Amino-propionic acid 3-{4-[6-(S,S-dioxo-thiomorpholin-4-yl)-pyridin-3-yl]- 3-fluoro-phenyl }-2-oxo-oxazolidin-5-ylmethyl ester methanesulphonic acid salt;
(2S,5R)-2-Amino-3-methyl-butyric acid 3-{4-[6-(S,S-dioxo-thiomorpholin-4-yl)-pyridin-
3-yl] -3-fluoro-phenyl } -2-oxo-oxazolidin-5-ylmethyl ester;
(2S,5R)-2-Amino-3-methyl-butyric acid 3-{4-[6-(S,S-dioxo-thiomoφholin-4-yl)-pyridin-
3-yl] -3-fluoro-phenyl }-2-oxo-oxazolidin-5-ylmethyl ester methanesulphonic acid salt; (2S,5R)-Acetic acid 3-{4-[6-(S,S-dioxo-thiomoφholin-4-yl)-pyridin-3-yl]-3-fluoro- phenyl }-2-oxo-oxazolidin-5-ylmethyl ester;
(S)-N-{3-[4-(6-(Thiomorpholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5- ylmethyl } -formamide;
(S)-N-{3-[4-(6-(S,S-Dioxo-thiomorρholin-4-yl)-pyridin-3-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl }-formamide; (S)- {3 -[4-(6-(thiomorpholin-4-yl)-pyridin-3-yl)-3 -fluorophenyl] -2-oxo-oxazolidin-5- ylmethyl }-carbamic acid methyl ester;
(S)-N-{3-[4-(2-(S,S-Dioxo-thiomoφholin-4-yl)-pyridin-5-yl)-3-fluorophenyl]-2-oxo- oxazolidin-5-ylmethyl}-carbamic acid methyl ester; (S)-N-{3-[4-(2-(S,S-Dioxo-thiomoφholin-4-yl)-3-methylpyridin-5-yl)-3-fluorophenyl]-
2-oxo-oxazolidin-5-ylinethyl}-carbamic acid methyl ester;
(S)-N-{3-[4-(2-(S,S-Dioxo-thiomorpholin-4-yl)-3-methylpyridin-5-yl)-3-fluoiOphenyl]-
5-hydroxymethyl}-ox.azolidin-2-one;
(R)-Phosphoric acid mono {3-[4-(2-(S,S-dioxo-thiomorpholin-4-yl)-3-methylpyridin-5- yl)-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl} ester;
(R)-Phosphoric acid mono {3-[4-(2-(S-oxo-thiomorρholin-4-yl)-3-methylpyridin-5-yl)-3- fluorøphenyl]-2-oxo-oxazolidin-5-ylmethyl} ester disodium salt; (S)-N-{ 3-[4-(2-(S,S-Dioxo-thiomorpholin-4-yl)-3-methylpyridin-5-yl)-3-fluorophenyl]-
2-oxo-oxazolidin-5-ylmethyl}-acetamide; (S)-N-{3-[4-(2-(S,S-Dioxo-thiomoφholin-4-yl)-3-methylpyridin-5-yl)-3-fluorophenyl]-
5-1 ,2,3-triazol-l-ylmethyl }-oxazolidin-2-one;
34. Pharmaceutical composition comprising a compound according to claim 1 and an excipient, diluent, solvent or a carrier.
35. Pharmaceutical composition comprising a compound according to claim 31 and an excipient, diluent, solvent or a carrier.
36. Pharmaceutical composition comprising a compound according to claim 32 and an excipient, diluent, solvent or a carrier.
37. Pharmaceutical composition comprising a compound according to claim 33 and an excipient, diluent, solvent or a carrier.
38. A method for treating a disease caused by a microbial infection in a human or animal comprising administering an effective amount of a compound according to claim 1, to the human or animal in need thereof.
39. A method for treating a disease caused by a microbial infection in a human or animal comprising administering an effective amount of a compound according to claim 31, to the human or animal in need thereof.
40. A method for treating a disease caused by a microbial infection in a human or animal comprising administering a pharmaceutical composition according to claim 32, to the human or animal in need thereof.
41. A method for treating a disease caused by a microbial infection in a human or animal comprising administering a pharmaceutical composition according to claim 33, to the human or animal in need thereof.
42. A method for preventing a disease caused by a microbial infection in a human or animal comprising administering an effective amount of a compound according to claim 1, to the human or animal at risk of being infected.
43. A method for preventing a disease caused by a microbial infection in a human or animal comprising administering an effective amount of a compound according to claim 31, to the human or animal at risk of being infected.
44. A method for preventing a disease caused by a microbial infection in a human or animal comprising administering a pharmaceutical composition according to claim 32, to the human or animal at risk of being infected.
45. A method for preventing a disease caused by a microbial infection in a human or animal comprising administering a pharmaceutical composition according to claim 33, to the human or animal at risk of being infected.
46. The animal in claim 38-45 is selected from mammal, fish, bird.
47. The microbial infection in claims 38-45 are central nervous system infections, external ear infections, infections of the middle ear, such as acute otitis media, infections of the cranial sinuses, eye infections, infections of the oral cavity, such as infections of the teeth, gums and mucosa, upper respiratory tract infections, lower respiratory tract infections, genitourinary infections, gastrointestinal infections, gynecological infections, mastitis, septicemia, bone and joint infections, skin and skin structure infections, bacterial endocarditis, burns, antibacterial prophylaxis of surgery, and antibacterial prophylaxis in immunosuppressed patients, such as patients receiving cancer chemotherapy, or organ transplant patients, osteomyelitis, endocarditis and diabetic foot.
48. The method of preparation of a compound according to claim 1.
PCT/IN2006/000208 2005-06-20 2006-06-19 Oxazolidinones bearing antimicrobial activity composition and methods of preparation WO2007023507A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/922,239 US20090018123A1 (en) 2005-06-20 2006-06-19 Oxazolidinones Bearing Antimicrobial Activity Composition and Methods of Preparation
EP06821680A EP1912980A2 (en) 2005-06-20 2006-06-19 Oxazolidinones bearing antimicrobial activity composition and methods of preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN723MU2005 2005-06-20
IN723/MUM/2005 2005-06-20

Publications (2)

Publication Number Publication Date
WO2007023507A2 true WO2007023507A2 (en) 2007-03-01
WO2007023507A3 WO2007023507A3 (en) 2007-07-12

Family

ID=37684775

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2006/000208 WO2007023507A2 (en) 2005-06-20 2006-06-19 Oxazolidinones bearing antimicrobial activity composition and methods of preparation

Country Status (3)

Country Link
US (1) US20090018123A1 (en)
EP (1) EP1912980A2 (en)
WO (1) WO2007023507A2 (en)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009014910A3 (en) * 2007-07-19 2009-04-02 Metabolex Inc N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders
EP2072513A1 (en) 2007-12-17 2009-06-24 Ferrer Internacional, S.A. A cyano piperidinyl-phenil-oxazolidinone and use thereof
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2010042887A2 (en) * 2008-10-10 2010-04-15 Trius Therapeutics Methods for preparing oxazolidinones and compositions containing them
US8124623B2 (en) 2006-11-10 2012-02-28 Actelion Pharmaceuticals Ltd. 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials
JP2012523384A (en) * 2009-04-13 2012-10-04 グラクソ グループ リミテッド (Pyrazol-3-yl) -1,3,4-thiadiazol-2-amine and (pyrazol-3-yl) -1,3,4-thiazol-2-amine compounds
EP2519508A2 (en) * 2009-12-31 2012-11-07 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2012160034A1 (en) 2011-05-24 2012-11-29 Bayer Intellectual Property Gmbh 4-aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group
US8410127B2 (en) 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
US8426389B2 (en) 2009-02-03 2013-04-23 Trius Therapeutics, Inc. Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
US8580767B2 (en) 2009-05-28 2013-11-12 Trius Therapeutics, Inc. Oxazolidinone containing dimer compounds, compositions and methods to make and use
WO2013182070A1 (en) * 2012-06-08 2013-12-12 四川贝力克生物技术有限责任公司 Drug for preventing or treating mycobacterial diseases
CN103476772A (en) * 2011-03-30 2013-12-25 乐高化工生物科学株式会社 Novel oxazolidinone derivative and medical composition containing same
US9163043B2 (en) 2003-12-18 2015-10-20 Dong-A St Co., Ltd. Oxazolidinone derivatives
US9241924B2 (en) 2010-06-23 2016-01-26 Cymabay Therapeutics, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2017146246A1 (en) * 2016-02-26 2017-08-31 大塚製薬株式会社 Piperidine derivative
CN108135887A (en) * 2015-10-22 2018-06-08 默沙东公司 Oxazolidinone compounds and its application method as antiseptic
US10087171B2 (en) 2016-12-19 2018-10-02 Actelion Pharmaceuticals Ltd Crystalline forms of cadazolid
US10292983B2 (en) 2016-08-03 2019-05-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
WO2020021468A1 (en) * 2018-07-25 2020-01-30 Cadila Healthcare Limited Substituted oxazolidinones for the treatment of mammalian infections
EP3600297A4 (en) * 2017-03-20 2020-12-16 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents
EP3914587A4 (en) * 2019-01-18 2022-11-23 Merck Sharp & Dohme LLC Oxazolidinone compounds and methods of use thereof as antibacterial agents
RU2798336C2 (en) * 2018-07-25 2023-06-21 Зидус Лайфсайенсиз Лимитед New compounds for the treatment of mammalian infections

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2018792B1 (en) * 2006-05-09 2015-09-16 Wockhardt Limited Substituted piperidino phenyloxazolidinones
CA2664572C (en) * 2006-09-25 2015-06-16 Wockhardt Research Centre Substituted piperidinophenyl oxazolidinones
US9041730B2 (en) 2010-02-12 2015-05-26 Dexcom, Inc. Receivers for analyzing and displaying sensor data
WO2013123320A1 (en) * 2012-02-15 2013-08-22 University Of Rochester Methods, pharmaceutical compositions, therapeutic systems, and compounds for treating b cell malignancies

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995025106A1 (en) * 1994-03-15 1995-09-21 Pharmacia & Upjohn Company Oxazolidinone derivatives and pharmaceutical compositions containing them
US5736545A (en) * 1996-02-26 1998-04-07 Pharmacia & Upjohn Company Azolyl piperazinyl phenyl oxazolidinone antimicrobials
WO2001094342A1 (en) * 2000-06-05 2001-12-13 Dong A Pharm. Co., Ltd. Novel oxazolidinone derivatives and a process for the preparation thereof
WO2004009587A1 (en) * 2002-07-22 2004-01-29 Orchid Chemicals & Pharmaceuticals Ltd Oxazolidinone derivatives as antibacterial agents
WO2004014392A1 (en) * 2002-07-29 2004-02-19 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
WO2004048350A2 (en) * 2002-11-28 2004-06-10 Astrazeneca Ab Oxazolidinones as antibacterial agents
WO2004056819A1 (en) * 2002-12-19 2004-07-08 Astrazeneca Ab Oxazolidinone derivatives as antibacterial agents
WO2004089944A1 (en) * 2003-04-07 2004-10-21 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
WO2005005398A2 (en) * 2003-07-02 2005-01-20 Merck & Co., Inc. Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642238B2 (en) * 2000-02-10 2003-11-04 Pharmacia And Upjohn Company Oxazolidinone thioamides with piperazine amide substituents

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995025106A1 (en) * 1994-03-15 1995-09-21 Pharmacia & Upjohn Company Oxazolidinone derivatives and pharmaceutical compositions containing them
US5736545A (en) * 1996-02-26 1998-04-07 Pharmacia & Upjohn Company Azolyl piperazinyl phenyl oxazolidinone antimicrobials
WO2001094342A1 (en) * 2000-06-05 2001-12-13 Dong A Pharm. Co., Ltd. Novel oxazolidinone derivatives and a process for the preparation thereof
WO2004009587A1 (en) * 2002-07-22 2004-01-29 Orchid Chemicals & Pharmaceuticals Ltd Oxazolidinone derivatives as antibacterial agents
WO2004014392A1 (en) * 2002-07-29 2004-02-19 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
WO2004048350A2 (en) * 2002-11-28 2004-06-10 Astrazeneca Ab Oxazolidinones as antibacterial agents
WO2004056819A1 (en) * 2002-12-19 2004-07-08 Astrazeneca Ab Oxazolidinone derivatives as antibacterial agents
WO2004089944A1 (en) * 2003-04-07 2004-10-21 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
WO2005005398A2 (en) * 2003-07-02 2005-01-20 Merck & Co., Inc. Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof

Cited By (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9163043B2 (en) 2003-12-18 2015-10-20 Dong-A St Co., Ltd. Oxazolidinone derivatives
US8124623B2 (en) 2006-11-10 2012-02-28 Actelion Pharmaceuticals Ltd. 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials
US9737537B2 (en) 2006-12-28 2017-08-22 Cymabay Therapeutics, Inc. Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US8227495B2 (en) 2006-12-28 2012-07-24 Metabolex Inc. 2,4-disubsituted thiazoles and pharmaceutical compositions thereof
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US8921350B2 (en) 2006-12-28 2014-12-30 Cymabay Therapeutics, Inc. Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US8975258B2 (en) 2006-12-28 2015-03-10 Cymabay Therapeutics, Inc. Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US9925189B2 (en) 2006-12-28 2018-03-27 Cymabay Therapeutics, Inc. Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US8288384B2 (en) 2006-12-28 2012-10-16 Metabolex, Inc. Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US8846675B2 (en) 2007-07-19 2014-09-30 Cymabay Therapeutics, Inc. N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US8183381B2 (en) 2007-07-19 2012-05-22 Metabolex Inc. N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
WO2009014910A3 (en) * 2007-07-19 2009-04-02 Metabolex Inc N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders
WO2009077484A2 (en) * 2007-12-17 2009-06-25 Ferrer Internacional, S.A. A cyano piperidinyl-phenil-oxazolidinone and use thereof.
WO2009077484A3 (en) * 2007-12-17 2009-10-01 Ferrer Internacional, S.A. A cyano piperidinyl-phenil-oxazolidinone and use thereof.
EP2072513A1 (en) 2007-12-17 2009-06-24 Ferrer Internacional, S.A. A cyano piperidinyl-phenil-oxazolidinone and use thereof
JP2012505252A (en) * 2008-10-10 2012-03-01 トリウス セラピューティクス Methods of preparing oxazolidinones and compositions containing them
RU2659792C1 (en) * 2008-10-10 2018-07-04 Мерк Шарп Энд Домэ Корп. Oxazolidinones and the method of their cleaning
US9328087B2 (en) 2008-10-10 2016-05-03 Merck Sharp & Dohme Corp. Methods for preparing oxazolidinones and compositions containing them
RU2556234C2 (en) * 2008-10-10 2015-07-10 Траюс Терапьютикс Methods of producing oxazolidinones and compositions containing same
WO2010042887A3 (en) * 2008-10-10 2010-06-24 Trius Therapeutics Methods for preparing oxazolidinones and compositions containing them
US8604209B2 (en) 2008-10-10 2013-12-10 Trius Therapeutics, Inc. Methods for preparing oxazolidinones and compositions containing them
WO2010042887A2 (en) * 2008-10-10 2010-04-15 Trius Therapeutics Methods for preparing oxazolidinones and compositions containing them
US10065947B1 (en) 2009-02-03 2018-09-04 Merck Sharp & Dohme Corp. Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
US10442829B2 (en) 2009-02-03 2019-10-15 Merck Sharp & Dohme Corp. Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
US9624250B2 (en) 2009-02-03 2017-04-18 Merck Sharp & Dohme Corp. Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
US8426389B2 (en) 2009-02-03 2013-04-23 Trius Therapeutics, Inc. Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
US9988406B2 (en) 2009-02-03 2018-06-05 Merck Sharp & Dohme Corp. Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
JP2012523384A (en) * 2009-04-13 2012-10-04 グラクソ グループ リミテッド (Pyrazol-3-yl) -1,3,4-thiadiazol-2-amine and (pyrazol-3-yl) -1,3,4-thiazol-2-amine compounds
US8580767B2 (en) 2009-05-28 2013-11-12 Trius Therapeutics, Inc. Oxazolidinone containing dimer compounds, compositions and methods to make and use
US9150567B2 (en) 2009-10-01 2015-10-06 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
US8815886B2 (en) 2009-10-01 2014-08-26 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
US8410127B2 (en) 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
JP2013516418A (en) * 2009-12-31 2013-05-13 ヴィアメット ファーマスーティカルズ，インコーポレイテッド Metalloenzyme inhibitory compounds
EP2519508A4 (en) * 2009-12-31 2013-05-29 Viamet Pharmaceuticals Inc Metalloenzyme inhibitor compounds
AU2010339508B2 (en) * 2009-12-31 2016-02-04 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US8987315B2 (en) 2009-12-31 2015-03-24 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EP2519508A2 (en) * 2009-12-31 2012-11-07 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US9241924B2 (en) 2010-06-23 2016-01-26 Cymabay Therapeutics, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US10098843B2 (en) 2010-06-23 2018-10-16 Cymabay Therapeutics, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
CN103476772B (en) * 2011-03-30 2016-03-30 乐高化工生物科学株式会社 Oxazolidinone derivative and comprise the pharmaceutical composition of Gai oxazolidinone derivative
RU2617408C2 (en) * 2011-03-30 2017-04-25 Легокем Байосайенсез, Инк. New oxazolidinone derivative and pharmaceutical composition that includes it
EP3372598A1 (en) * 2011-03-30 2018-09-12 LegoChem Biosciences, Inc. Novel oxazolidinone derivative and pharmaceutical composition including the same
EP2692727A4 (en) * 2011-03-30 2014-10-15 Legochem Biosciences Inc Novel oxazolidinone derivative and medical composition containing same
CN103476772A (en) * 2011-03-30 2013-12-25 乐高化工生物科学株式会社 Novel oxazolidinone derivative and medical composition containing same
EP2692727A2 (en) * 2011-03-30 2014-02-05 LegoChem Biosciences, Inc. Novel oxazolidinone derivative and medical composition containing same
WO2012160034A1 (en) 2011-05-24 2012-11-29 Bayer Intellectual Property Gmbh 4-aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group
US9669034B2 (en) 2011-05-24 2017-06-06 Bayer Intellectual Property Gmbh 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group
US9962389B2 (en) 2011-05-24 2018-05-08 Bayer Intellectual Property Gmbh 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group
WO2013182070A1 (en) * 2012-06-08 2013-12-12 四川贝力克生物技术有限责任公司 Drug for preventing or treating mycobacterial diseases
CN104364240A (en) * 2012-06-08 2015-02-18 四川贝力克生物技术有限责任公司 Drug for preventing or treating mycobacterial diseases
EP3364968A4 (en) * 2015-10-22 2019-05-01 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents
CN108135887B (en) * 2015-10-22 2021-07-30 默沙东公司 Oxazolidinone compounds and methods of use as antibacterial agents
US10947205B2 (en) 2015-10-22 2021-03-16 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents
CN108135887A (en) * 2015-10-22 2018-06-08 默沙东公司 Oxazolidinone compounds and its application method as antiseptic
JPWO2017146246A1 (en) * 2016-02-26 2018-12-20 大塚製薬株式会社 Piperidine derivatives
WO2017146246A1 (en) * 2016-02-26 2017-08-31 大塚製薬株式会社 Piperidine derivative
US10851079B2 (en) 2016-02-26 2020-12-01 Otsuka Pharmaceutical Co., Ltd. Piperidine derivative
CN108884044A (en) * 2016-02-26 2018-11-23 大塚制药株式会社 Piperidine derivative
CN108884044B (en) * 2016-02-26 2023-01-31 大塚制药株式会社 Piperidine derivatives
US10292983B2 (en) 2016-08-03 2019-05-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
US10087171B2 (en) 2016-12-19 2018-10-02 Actelion Pharmaceuticals Ltd Crystalline forms of cadazolid
EP3600297A4 (en) * 2017-03-20 2020-12-16 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents
WO2020021468A1 (en) * 2018-07-25 2020-01-30 Cadila Healthcare Limited Substituted oxazolidinones for the treatment of mammalian infections
RU2798336C2 (en) * 2018-07-25 2023-06-21 Зидус Лайфсайенсиз Лимитед New compounds for the treatment of mammalian infections
US12109203B2 (en) 2018-07-25 2024-10-08 Zydus Lifesciences Limited Substituted oxazolidinones for the treatment of mammalian infections
EP3914587A4 (en) * 2019-01-18 2022-11-23 Merck Sharp & Dohme LLC Oxazolidinone compounds and methods of use thereof as antibacterial agents

Also Published As

Publication number Publication date
EP1912980A2 (en) 2008-04-23
WO2007023507A3 (en) 2007-07-12
US20090018123A1 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
EP1912980A2 (en) Oxazolidinones bearing antimicrobial activity composition and methods of preparation
US12012466B2 (en) Peptide macrocycles against Acinetobacter baumannii
KR100340365B1 (en) Oxazolidinone derivatives and pharmaceutical compositions containing them
US10301305B2 (en) Heteroaromatic derivatives and their use as pharmaceuticals
ES2220759T5 (en) DERIVATIVES OF OXAZOLIDINONES WITH ANTIBIOTIC ACTIVITY.
US6919329B2 (en) N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives
WO2007037534A9 (en) 2-heteroaryl-substituted indole derivative
US20070015801A1 (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives
US20120157434A1 (en) Antimicrobial heterocyclic compounds for treatment of bacterial infections
US20120065170A1 (en) Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections
MXPA06013539A (en) 3-[4-(6-{4, 5-dihydroisoxazol -3-yl} pyridin-3-yl)- 3-phenyl]-5 -(1h-1, 2, 3-triazol -1-ylmethyl)-1, 3-oxazolidin- 2-ones as antibacterial agents.
MXPA06013540A (en) 3- (4- (2-dihydroisoxazol-3-ylpyridin-5-yl) phenyl) -5-triazol-1-ylmethyloxazolidin-2-one derivaives as mao inhibitors for the treatment of bacterial infections.
CA2737299C (en) Novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone and pharmaceutical compositions thereof
JP2008500317A (en) 3-'4- {6-substituted alkanoyl) pyridin-3-yl} -3-phenyl-5- (1H-1,2,3-triazol-1-ylmethyl) -1,3-oxazolidine- as antibacterial agent 2-on
US6875784B2 (en) Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives
JP2004196678A (en) Pyrazole-based derivative
US20240158370A1 (en) CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS
KR20110088737A (en) Novel oxazolidinone derivatives with cyclic amidrazone and pharmaceutical compositions thereof
CN117715892A (en) Quaternary ammonium cation substituted compounds for the treatment of bacterial infections
AU2010277601B2 (en) Dihydrobenzoindazoles
WO2005082900A2 (en) Oxazolidinone amidoximes as antibacterial agents
CA2589250A1 (en) Diazepine oxazolidinones as antibacterial agents
US20040014746A1 (en) Antimicrobial thiadiazinone derivatives and their application for treatment of bacterial infections
KR20120081579A (en) Novel oxazolidinone derivatives with cyclic amidrazone and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2006821680

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006821680

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11922239

Country of ref document: US